<html lang="en" class="pb-page js" data-request-id="94d6d44785b61aed-SJC"><head data-pb-dropzone="head"><style type="text/css" nonce="94d6d44785b61aed-SJC">@font-face {font-family: "Source Sans Pro";src: url(https://consent.trustarc.com/get?name=SourceSansPro-Regular.ttf) format("truetype"),url(https://consent.trustarc.com/get?name=SourceSansPro-Regular.woff) format("woff"),url(https://consent.trustarc.com/get?name=SourceSansPro-Regular.otf) format("opentype"),url(https://consent.trustarc.com/get?name=SourceSansPro-Regular.eot) format("embedded-opentype");}.truste_cursor_pointer {cursor: pointer;}.truste_border_none {border: none;}.truste_accessible_link {font-family: "Source Sans Pro", sans-serif;color: #1D4ED8;font-size: 14px;font-weight: 600;text-decoration: underline;}.truste_accessible_link:hover {color: #1D4ED8;text-decoration: none !important;}.truste_accessible_link:focus-visible {outline: none;border-radius: 4px;box-shadow: 0 0 0 1px #FFFFFF, 0 0 0 4px #3699F1;}</style><script src="https://ssl-cdn.janraincapture.com/widget_data/flow.js:7h8bznq6j7bvyvzqcrwvyp8dfb:en-US:20240514181256512029:standard" type="text/javascript"></script><script src="https://cssjs.nejm.org/akamai/capture:login" type="text/javascript"></script><script src="https://ssl-widget-cdn.rpxnow.com/translations/login/en-US" type="text/javascript"></script><script type="text/javascript" id="janrainAuthWidget" src="https://cssjs.nejm.org/akamai/mms-prod.js"></script><script type="text/javascript" src="https://www.nejm.org/Ok_qD_yoJmhWtkSjKrdv7dhGgD1ZbxySJ0EAJijn95hUTtEb5UF8A-9mC5Yv70e4TyWNFm84h2Ct_NNXffBneQ=="></script>
            

<meta charset="UTF-8">






    
        
            
        
    
        
            
        
    
        
            
        
    
        
            
        
    
        
    
        
    
        
            
                
                
<title>Albuterol–Budesonide Fixed-Dose Combination Rescue Inhaler for Asthma | New England Journal of Medicine</title>





                
            
        
    







    
        
            
        
    
        
            
        
    
        
            
                
                



                
            
        
    
        
            
        
    
        
    
        
    
        
            
        
    











    








    

    
    

    
    
    
    
        
            
                <link rel="stylesheet" type="text/css" href="/wro/1125813~article-metrics.css">
            
            
            
        
    

    
    
        
            <link rel="icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_nejm_1-994b0160d1eb33dc79517ef0295aab1b.ico" type="image/x-icon">
        
        
            <link rel="icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_16-4aa032aa775940f725817b7ff42f0e2c.png" type="image/png" sizes="16x16">
        
        
            <link rel="icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_32-0a94fa44823476ffa0bb15bdb320fb34.png" type="image/png" sizes="32x32">
        
        
            <link rel="apple-touch-icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_152-d6c3522864a8e483996b7e9c132c901a.png" sizes="152x152">
        
        
            <link rel="apple-touch-icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_180-f2538afc53a365d4cd3f10ab73c56aad.png" sizes="180x180">
        
        
            <link rel="apple-touch-icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_167-8e888012bbdd31a00c3e54bc5b8ca5b6.png" sizes="167x167">
        
    

    
    
            <link rel="stylesheet" href="/products/mms-nextgen/mms/releasedAssets/css/build-5b89b331018866a4a965.css" media="all">
        <link rel="stylesheet" href="/products/mms-nextgen/mms/releasedAssets/css/print-5b89b331018866a4a965.css" media="print">
           <link rel="stylesheet" href="/products/mms-nextgen/mms/releasedAssets/css/build-article-5b89b331018866a4a965.css" media="all" id="article-style-sheet">
    
        <script nonce="94d6d44785b61aed-SJC">
        try {
            document.documentElement.classList.add('js');
        } catch (e) {
        }
    </script>
     
    

















    
        
            
                
                
                
                    
                    <!-- TrustArc Scripts -->
<script async="async" src="https://consent.trustarc.com/notice?domain=nejm.com&amp;c=teconsent&amp;js=nj&amp;noticeType=bb&amp;gtm=1&amp;text=true&amp;pcookie" crossorigin="" id="truste_0.3666580260595097"></script>
<script src="https://consent.trustarc.com/autoblockasset/core.min.js?domain=nejm.com"></script>
<script src="https://consent.trustarc.com/autoblockoptout?domain=nejm.com"></script>
<!-- /TrustArc Scripts -->
<!-- BlueConic Scripts -->
<script src="https://bc.nejm.org/script.js"></script>
    <!-- /BlueConic Scripts -->
<!-- Printing Meta Tags -->
    <meta name="topics" content="Asthma (Allergy/Immunology)|Clinical Medicine General|Outpatient-Based Clinical Medicine|Pediatrics General|Asthma (Pulmonary/Critical Care)|Adolescent Medicine">
<meta name="articleCategory" content="Research">
<meta name="articleType" content="Original Article">
<meta name="Specialties" content="Allergy/Immunology|Pulmonary/Critical Care|Clinical Medicine|Pediatrics"><script type="text/javascript">var mmsData = {"access":{"isFreeCountry":"n"},"ad":{"category":"article"},"imageChallenge":{"id":null},"article":{"doi":"10.1056/NEJMoa2203163","title":"Albuterol–Budesonide Fixed-Dose Combination Rescue Inhaler for Asthma","category":"Research","type":"Original Article","topics":"Asthma (Allergy/Immunology)|Clinical Medicine General|Outpatient-Based Clinical Medicine|Pediatrics General|Asthma (Pulmonary/Critical Care)|Adolescent Medicine","specialties":"Allergy/Immunology|Pulmonary/Critical Care|Clinical Medicine|Pediatrics","seriesTitle":"","viewType":"Full","age":"2Years-1990","issueDate":"2022-06-02T00:00Z","isFree":"y","broadTopics":"","perspectiveTopics":"","granularTopics":"","methodologicalArea":"","isOnlineFirst":"n","isCurrentIssue":"n","metaTags":"\u003cmeta name\u003d\"topics\" content\u003d\"Asthma (Allergy/Immunology)|Clinical Medicine General|Outpatient-Based Clinical Medicine|Pediatrics General|Asthma (Pulmonary/Critical Care)|Adolescent Medicine\"/\u003e\n\u003cmeta name\u003d\"articleCategory\" content\u003d\"Research\"/\u003e\n\u003cmeta name\u003d\"articleType\" content\u003d\"Original Article\"/\u003e\n\u003cmeta name\u003d\"Specialties\" content\u003d\"Allergy/Immunology|Pulmonary/Critical Care|Clinical Medicine|Pediatrics\"/\u003e"},"page":{"activity":"showFullText","url":"www.nejm.org/doi/full/10.1056/NEJMoa2203163","viewType":"desktop","journal":"NEJM"},"user":{"ucid":null,"audienceSegment":null,"specialtyGroupCode":null,"meterCountRemaining":null,"totalMeterCount":null},"object":[{"type":"Quick Take","title":"Albuterol–Budesonide Rescue Inhaler in Asthma","doi":"10.1056/NEJMdo006554","issueDate":"2022-06-02T00:00Z","age":"6Months-1990","isFree":"n","topics":"Asthma (Allergy/Immunology)|Clinical Medicine General|Outpatient-Based Clinical Medicine|Pediatrics General|Asthma (Pulmonary/Critical Care)|Adolescent Medicine","viewType":"Full","specialties":"Allergy/Immunology|Pulmonary/Critical Care|Clinical Medicine|Pediatrics"},{"type":"Research Summary","title":"Albuterol–Budesonide Fixed-Dose Combination Rescue Inhaler for Asthma","doi":"10.1056/NEJMdo006555","issueDate":"2022-06-02T00:00Z","age":"6Months-1990","isFree":"n","topics":"Asthma (Allergy/Immunology)|Clinical Medicine General|Outpatient-Based Clinical Medicine|Pediatrics General|Asthma (Pulmonary/Critical Care)|Adolescent Medicine","viewType":"Full","specialties":"Allergy/Immunology|Pulmonary/Critical Care|Clinical Medicine|Pediatrics"}]};</script>
    <script type="text/javascript">var mmsDataAdd = {"user":{"customerType":"null","accessInstitutionID":"null"}};</script>
    <!-- Prehiding snippet for Adobe Target with asynchronous Launch deployment -->
    <!-- placeholder id=null, description=Adobe-Target-Prehiding-Snippet --><!--
  Adobe Target - Prehiding Snippet
  v2.0.0
-->
<script nonce="94d6d44785b61aed-SJC">
function tgtNoFlicker(e,n,t,o,i,c,l,r){function d(){return n.getElementsByTagName("head")[0]}function a(e,t){if(e){var o=n.getElementById(t);o&&e.removeChild(o)}}function f(e,o){!function(e,t,o){if(e){var i=n.createElement("style");i.id=t,i.innerHTML=o,e.appendChild(i)}}(d(),t,e),setTimeout(function(){a(d(),t)},o)}var m;n.location.href.indexOf(c)>-1?f(l,r):f(o,i),n.location.href.indexOf("mboxDisable")>-1?(a(d(),t),console.log("[TARGET] - Disabled, removing prehiding style")):(m=function(e){e&&(a(d(),t),console.log("[TARGET] - Blocked, removing prehiding style"))},fetch("//cdn.tt.omtrdc.net/cdn/target-vec.js",{method:"HEAD",mode:"no-cors"}).then(e=>m(!1)).catch(e=>m(!0)))}

tgtNoFlicker(window, document, 'at-body-style', 'div[data-location-name="Anonymous Module"], div[data-location-name="Anonymous Banner"], main > div.page-body > div > div > div > div.col-md-2-3.o-col.o-col--primary > div[class*="u-hide"], main > div.page-body > div > div > div > div.col-md-1-3.o-col.o-col--secondary > aside, header > h1#mainContent, a.m-article__link[href*="/10.1056/NEJMoa2116747"] > span.m-article__blurb > p, li.g-nejm-group__user-tool-secondary {opacity: 0 !important}', 3000);

tgtNoFlicker(window, document, 'at-mbox-style', '.N-ad-global-top-right, #N-ad-myNEJM-contextual-top, .N-ad-recentArticles, #N-ad-article-rightRail-1, #N-ad-siteWide-rightRail-1, #N-ad-imageChallenge-rightRail-2 {opacity: 0 !important}', 3000);
</script><!-- /Prehiding snippet for Adobe Target with asynchronous Launch deployment -->
    <!-- Launch Header Embed Code -->
    <script src="//assets.adobedtm.com/launch-ENcd6450fae3ae4870becbe6a2b01ab2e1.min.js" async="" type="ta-blocked" data-ta-blocked="1"></script>
    <!-- /Launch Header Embed Code -->

                    
                
            
        
    
        
            
                
                
                
                    
                    <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/"><meta name="citation_journal_title" content="New England Journal of Medicine"><meta name="dc.Title" content="Albuterol–Budesonide Fixed-Dose Combination Rescue Inhaler for Asthma"><meta name="dc.Creator" content="Alberto Papi"><meta name="dc.Creator" content="Bradley E. Chipps"><meta name="dc.Creator" content="Richard Beasley"><meta name="dc.Creator" content="Reynold A. Panettieri, Jr."><meta name="dc.Creator" content="Elliot Israel"><meta name="dc.Creator" content="Mark Cooper"><meta name="dc.Creator" content="Lynn Dunsire"><meta name="dc.Creator" content="Allison Jeynes-Ellis"><meta name="dc.Creator" content="Eva Johnsson"><meta name="dc.Creator" content="Robert Rees"><meta name="dc.Creator" content="Christy Cappelletti"><meta name="dc.Creator" content="Frank C. Albers"><meta name="dc.Description" content="As asthma symptoms worsen, patients typically rely on short-acting β2-agonist (SABA) rescue therapy, but SABAs do not address worsening inflammation, which leaves patients at risk for severe asthma..."><meta name="Description" content="As asthma symptoms worsen, patients typically rely on short-acting β2-agonist (SABA) rescue therapy, but SABAs do not address worsening inflammation, which leaves patients at risk for severe asthma..."><meta name="dc.Publisher" content="Massachusetts Medical Society"><meta name="dc.Date" scheme="WTN8601" content="2022-06-02"><meta name="dc.Type" content="research-article"><meta name="dc.Format" content="text/HTML"><meta name="dc.Identifier" scheme="doi" content="10.1056/NEJMoa2203163"><meta name="dc.Identifier" scheme="publisher-id" content="NJ202206023862205"><meta name="dc.Language" content="EN"><meta name="dc.Relation" content="10.1056/NEJMe2205717"><meta name="dc.Coverage" content="world"><meta name="dc.Rights" content="Copyright © 2022 Massachusetts Medical Society. All rights reserved.">




<link rel="meta" type="application/atom+xml" href="https://doi.org/10.1056%2FNEJMoa2203163">
<link rel="meta" type="application/rdf+json" href="https://doi.org/10.1056%2FNEJMoa2203163">
<link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1056%2FNEJMoa2203163">


                    
                
            
        
    
        
            
                
                
                
                
                
            
        
    
        
            
                
                
                
                    
                    





<meta name="robots" content="noarchive">





    





    
    
        
        <meta name="twitter:title" content="Albuterol–Budesonide Fixed-Dose Combination Rescue Inhaler for Asthma | NEJM">
        <meta property="og:title" content="Albuterol–Budesonide Fixed-Dose Combination Rescue Inhaler for Asthma | NEJM">
    


    <meta property="og:type" content="article">


    
    
        <meta property="og:url" content="https://www.nejm.org/doi/full/10.1056/NEJMoa2203163">
    
    


    
    
        <meta property="og:image" content="https://www.nejm.org/cms/asset/064d7417-8268-4305-aba1-5cd26a8cace9/nejmoa2203163_f0.jpg">
        <meta name="twitter:image" content="https://www.nejm.org/cms/asset/064d7417-8268-4305-aba1-5cd26a8cace9/nejmoa2203163_f0.jpg">
    



    <meta property="og:site_name" content="The New England Journal of Medicine">


    
    
        
        <meta property="og:description" content="As asthma symptoms worsen, patients typically rely on short-acting β2-agonist (SABA)
rescue therapy, but SABAs do not address worsening inflammation, which leaves patients
at risk for severe asthma...">
        <meta name="twitter:description" content="As asthma symptoms worsen, patients typically rely on short-acting β2-agonist (SABA)
rescue therapy, but SABAs do not address worsening inflammation, which leaves patients
at risk for severe asthma...">
    


    
    
        <meta property="og:image:width" content="2640">
    


    
    
        <meta property="og:image:height" content="3416">
    


    <meta name="twitter:card" content="summary">


    <meta name="twitter:site" content="@NEJM">


<meta name="viewport" content="width=device-width,initial-scale=1"><meta name="publication_doi" content="10.1056/NEJMoa2203163">


    















                    
                
            
        
    
        
    
        
    
        
            
                
                
                
                
                
            
        
    




<meta name="format-detection" content="telephone=no">

<meta http-equiv="X-UA-Compatible" content="IE=edge">
    




    
        
        
        <link rel="canonical" href="https://www.nejm.org/doi/full/10.1056/NEJMoa2203163">
    
    







<meta name="pbContext" content=";requestedJournal:journal:nejm;page:string:Article/Chapter View;issue:issue:doi\:10.1056/nejm_2022.386.issue-22;ctype:string:Journal Content;wgroup:string:MMS NextGen Website Group;pageGroup:string:Publication Pages;subPage:string:Full Text;website:website:mms-site;article:article:doi\:10.1056/NEJMoa2203163;journal:journal:nejms">
        <script id="altmetric-embed-js" src="https://d1bxh8uas1mnw7.cloudfront.net/assets/altmetric_badges-288192a491f0ad9cc434f05ea175659426f5ab0cfd6befb3f3592f96bb90b0d1.js"></script><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-933-8e181dff8b36ea01dc4c.css"><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-34-6ea546d794fb7a1cea52.css"><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-743-ddd329e1530654ec0846.css"><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-305-9eee37798fdfe5196307.css"><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-388-bb098c62445f518c0b46.css"><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-556-8e58ca05fb5497e541ef.css"><script charset="utf-8" src="https://www.nejm.org/products/mms-nextgen/mms/releasedAssets/js/0-dfd243c732a07d3608f6.js"></script><script charset="utf-8" src="https://www.nejm.org/products/mms-nextgen/mms/releasedAssets/js/7-10d355ba95f7ec1fddf2.js"></script><script charset="utf-8" src="https://www.nejm.org/products/mms-nextgen/mms/releasedAssets/js/11-04bf2a0da30146b4a5d0.js"></script><script src="https://static.addtoany.com/menu/modules/core.pt5ow5lr.js" type="module"></script><link rel="preconnect" href="https://use.typekit.net"><link rel="stylesheet" href="https://quilt-cdn.janrain.com/HEAD/providers.css" type="text/css"><style type="text/css">.a2a_hide{display:none}.a2a_logo_color{background-color:#0166ff}.a2a_menu,.a2a_menu *{-moz-box-sizing:content-box;-webkit-box-sizing:content-box;box-sizing:content-box;float:none;margin:0;padding:0;position:static;height:auto;width:auto}.a2a_menu{border-radius:6px;display:none;direction:ltr;background:#FFF;font:16px sans-serif-light,HelveticaNeue-Light,"Helvetica Neue Light","Helvetica Neue",Arial,Helvetica,"Liberation Sans",sans-serif;color:#000;line-height:12px;border:1px solid #CCC;vertical-align:baseline;overflow:hidden}.a2a_mini{min-width:200px;position:absolute;width:300px;z-index:9999997}.a2a_overlay{display:none;background:#616c7deb;backdrop-filter:blur(4px);-webkit-backdrop-filter:blur(4px);position:fixed;top:0;right:0;left:0;bottom:0;z-index:9999998;-webkit-tap-highlight-color:transparent;transition:opacity .14s,backdrop-filter .14s}.a2a_full{background:#FFF;border:1px solid #FFF;box-shadow:#2a2a2a1a 0 0 20px 10px;height:auto;height:calc(320px);top:15%;left:50%;margin-left:-320px;position:fixed;text-align:center;width:640px;z-index:9999999;transition:transform .14s,opacity .14s}.a2a_full_footer,.a2a_full_header,.a2a_full_services{border:0;margin:0;padding:12px;box-sizing:border-box}.a2a_full_header{padding-bottom:8px}.a2a_full_services{height:280px;overflow-y:scroll;padding:0 12px;-webkit-overflow-scrolling:touch}.a2a_full_services .a2a_i{display:inline-block;float:none;width:181px;width:calc(33.334% - 18px)}div.a2a_full_footer{font-size:12px;text-align:center;padding:8px 14px}div.a2a_full_footer a,div.a2a_full_footer a:visited{display:inline;font-size:12px;line-height:14px;padding:8px 14px}div.a2a_full_footer a:focus,div.a2a_full_footer a:hover{background:0 0;border:0;color:#0166FF}div.a2a_full_footer a span.a2a_s_a2a,div.a2a_full_footer a span.a2a_w_a2a{background-size:14px;border-radius:3px;display:inline-block;height:14px;line-height:14px;margin:0 3px 0 0;vertical-align:top;width:14px}.a2a_modal{height:0;left:50%;margin-left:-320px;position:fixed;text-align:center;top:15%;width:640px;z-index:9999999;transition:transform .14s,opacity .14s;-webkit-tap-highlight-color:transparent}.a2a_modal_body{background:0 0;border:0;font:24px sans-serif-light,HelveticaNeue-Light,"Helvetica Neue Light","Helvetica Neue",Arial,Helvetica,"Liberation Sans",sans-serif;position:relative;height:auto;width:auto}.a2a_thanks{color:#fff;height:auto;margin-top:20px;width:auto}.a2a_thanks>div:first-child{margin:0 0 40px 0}.a2a_thanks div *{height:inherit}#a2a_copy_link{background:#FFF;border:1px solid #FFF;cursor:pointer;margin-top:15%}label.a2a_s_link#a2a_copy_link_icon,label.a2a_w_link#a2a_copy_link_icon{background-size:48px;border-radius:0;display:inline-block;height:48px;left:0;line-height:48px;margin:0 3px 0 0;position:absolute;vertical-align:top;width:48px}#a2a_modal input#a2a_copy_link_text{background-color:transparent;border:0;color:#2A2A2A;cursor:pointer;font:inherit;height:48px;left:62px;max-width:initial;min-height:auto;padding:0;position:relative;width:564px;width:calc(100% - 76px)}#a2a_copy_link_copied{background-color:#0166ff;color:#fff;display:none;font:inherit;font-size:16px;margin-top:1px;padding:3px 8px}@media (forced-colors:active){.a2a_color_buttons a,.a2a_svg{forced-color-adjust:none}}@media (prefers-color-scheme:dark){.a2a_menu a,.a2a_menu a.a2a_i,.a2a_menu a.a2a_i:visited,.a2a_menu a.a2a_more,i.a2a_i{border-color:#2a2a2a!important;color:#fff!important}.a2a_menu a.a2a_i:active,.a2a_menu a.a2a_i:focus,.a2a_menu a.a2a_i:hover,.a2a_menu a.a2a_more:active,.a2a_menu a.a2a_more:focus,.a2a_menu a.a2a_more:hover,.a2a_menu_find_container{border-color:#444!important;background-color:#444!important}.a2a_menu:not(.a2a_thanks){background-color:#2a2a2a;border-color:#2a2a2a}.a2a_menu_find{color:#fff!important}.a2a_menu label.a2a_s_find svg{background-color:transparent!important}.a2a_menu label.a2a_s_find svg path{fill:#fff!important}.a2a_full{box-shadow:#00000066 0 0 20px 10px}.a2a_overlay{background-color:#373737eb}}@media print{.a2a_floating_style,.a2a_menu,.a2a_overlay{visibility:hidden}}@keyframes a2aFadeIn{from{opacity:0}to{opacity:1}}.a2a_starting{opacity:0}.a2a_starting.a2a_full,.a2a_starting.a2a_modal{transform:scale(.8)}@media (max-width:639px){.a2a_full{border-radius:0;top:15%;left:0;margin-left:auto;width:100%}.a2a_modal{left:0;margin-left:10px;width:calc(100% - 20px)}}@media (min-width:318px) and (max-width:437px){.a2a_full .a2a_full_services .a2a_i{width:calc(50% - 18px)}}@media (max-width:317px){.a2a_full .a2a_full_services .a2a_i{width:calc(100% - 18px)}}@media (max-height:436px){.a2a_full{bottom:40px;height:auto;top:40px}}@media (max-height:550px){.a2a_modal{top:30px}}@media (max-height:360px){.a2a_modal{top:20px}.a2a_thanks>div:first-child{margin-bottom:20px}}.a2a_menu a{color:#0166FF;text-decoration:none;font:16px sans-serif-light,HelveticaNeue-Light,"Helvetica Neue Light","Helvetica Neue",Arial,Helvetica,"Liberation Sans",sans-serif;line-height:14px;height:auto;width:auto;outline:0}.a2a_menu a.a2a_i:visited,.a2a_menu a.a2a_more{color:#0166FF}.a2a_menu a.a2a_i:active,.a2a_menu a.a2a_i:focus,.a2a_menu a.a2a_i:hover,.a2a_menu a.a2a_more:active,.a2a_menu a.a2a_more:focus,.a2a_menu a.a2a_more:hover{color:#2A2A2A;border-color:#EEE;border-style:solid;background-color:#EEE;text-decoration:none}.a2a_menu label.a2a_s_find{background-size:24px;height:24px;left:8px;pointer-events:auto;position:absolute;top:7px;width:24px}.a2a_menu label.a2a_s_find svg{background-color:#FFF}.a2a_menu label.a2a_s_find svg path{fill:#CCC}#a2a_menu_container{display:inline-block}.a2a_menu_find_container{border:1px solid #CCC;border-radius:6px;padding:2px 24px 2px 0;position:relative;text-align:left}.a2a_cols_container .a2a_col1{overflow-x:hidden;overflow-y:auto;-webkit-overflow-scrolling:touch}#a2a_modal input,#a2a_modal input[type=text],.a2a_menu input,.a2a_menu input[type=text]{display:block;background-image:none;box-shadow:none;line-height:100%;margin:0;outline:0;overflow:hidden;padding:0;-moz-box-shadow:none;-webkit-box-shadow:none;-webkit-appearance:none}#a2afeed_find_container input,#a2afeed_find_container input[type=text],#a2apage_find_container input,#a2apage_find_container input[type=text]{background-color:transparent;border:0;box-sizing:content-box;color:#2A2A2A;float:none;font:inherit;font-size:16px;height:28px;line-height:20px;left:38px;outline:0;margin:0;max-width:initial;min-height:initial;padding:2px 0;position:relative;width:99%}.a2a_clear{clear:both}.a2a_svg{background-repeat:no-repeat;display:block;overflow:hidden;height:32px;line-height:32px;padding:0;pointer-events:none;width:32px}.a2a_svg svg{background-repeat:no-repeat;background-position:50% 50%;border:none;display:block;left:0;margin:0 auto;overflow:hidden;padding:0;position:relative;top:0;width:auto;height:auto}a.a2a_i,i.a2a_i{display:block;float:left;border:1px solid #FFF;line-height:24px;padding:6px 8px;text-align:left;white-space:nowrap;overflow:hidden;text-overflow:ellipsis;width:132px}a.a2a_i span,a.a2a_more span{display:inline-block;overflow:hidden;vertical-align:top}a.a2a_i .a2a_svg{margin:0 6px 0 0}a.a2a_i .a2a_svg,a.a2a_more .a2a_svg{background-size:24px;height:24px;line-height:24px;width:24px}a.a2a_sss:hover{border-left:1px solid #CCC}a.a2a_more{border-bottom:1px solid #FFF;border-left:0;border-right:0;line-height:24px;margin:6px 0 0;padding:6px;-webkit-touch-callout:none}a.a2a_more span{height:24px;margin:0 6px 0 0}.a2a_kit .a2a_svg{background-repeat:repeat}.a2a_default_style a:empty,.a2a_flex_style a:empty,.a2a_floating_style a:empty,.a2a_overlay_style a:empty{display:none}.a2a_color_buttons a,.a2a_floating_style a{text-decoration:none}.a2a_default_style:not(.a2a_flex_style) a{float:left;line-height:16px;padding:0 2px}.a2a_default_style a:hover .a2a_svg,.a2a_floating_style a:hover .a2a_svg,.a2a_overlay_style a:hover .a2a_svg svg{opacity:.7}.a2a_overlay_style.a2a_default_style a:hover .a2a_svg{opacity:1}.a2a_default_style .a2a_count,.a2a_default_style .a2a_svg,.a2a_floating_style .a2a_svg,.a2a_menu .a2a_svg,.a2a_vertical_style .a2a_count,.a2a_vertical_style .a2a_svg{border-radius:4px}.a2a_default_style .a2a_counter img,.a2a_default_style .a2a_dd,.a2a_default_style .a2a_svg{float:left}.a2a_default_style .a2a_img_text{margin-right:4px}.a2a_default_style .a2a_divider{border-left:1px solid #000;display:inline;float:left;height:16px;line-height:16px;margin:0 5px}.a2a_kit a{cursor:pointer;transition:none}.a2a_floating_style{background-color:#fff;border-radius:6px;position:fixed;z-index:9999995}.a2a_overlay_style{z-index:2147483647}.a2a_floating_style,.a2a_overlay_style{animation:a2aFadeIn .2s ease-in;padding:4px}.a2a_vertical_style:not(.a2a_flex_style) a{clear:left;display:block;overflow:hidden;padding:4px}.a2a_floating_style.a2a_default_style{bottom:0}.a2a_floating_style.a2a_default_style a,.a2a_overlay_style.a2a_default_style a{padding:4px}.a2a_count{background-color:#fff;border:1px solid #ccc;box-sizing:border-box;color:#2a2a2a;display:block;float:left;font:12px Arial,Helvetica,sans-serif;height:16px;margin-left:4px;position:relative;text-align:center;width:50px}.a2a_count:after,.a2a_count:before{border:solid transparent;border-width:4px 4px 4px 0;content:"";height:0;left:0;line-height:0;margin:-4px 0 0 -4px;position:absolute;top:50%;width:0}.a2a_count:before{border-right-color:#ccc}.a2a_count:after{border-right-color:#fff;margin-left:-3px}.a2a_count span{animation:a2aFadeIn .14s ease-in}.a2a_vertical_style .a2a_counter img{display:block}.a2a_vertical_style .a2a_count{float:none;margin-left:0;margin-top:6px}.a2a_vertical_style .a2a_count:after,.a2a_vertical_style .a2a_count:before{border:solid transparent;border-width:0 4px 4px 4px;content:"";height:0;left:50%;line-height:0;margin:-4px 0 0 -4px;position:absolute;top:0;width:0}.a2a_vertical_style .a2a_count:before{border-bottom-color:#ccc}.a2a_vertical_style .a2a_count:after{border-bottom-color:#fff;margin-top:-3px}.a2a_color_buttons .a2a_count,.a2a_color_buttons .a2a_count:after,.a2a_color_buttons .a2a_count:before,.a2a_color_buttons.a2a_vertical_style .a2a_count:after,.a2a_color_buttons.a2a_vertical_style .a2a_count:before{background-color:transparent;border:none;color:#fff;float:none;width:auto}.a2a_color_buttons.a2a_vertical_style .a2a_count{margin-top:0}.a2a_flex_style{display:flex;align-items:flex-start;gap:0}.a2a_default_style.a2a_flex_style{left:0;right:0;width:100%}.a2a_vertical_style.a2a_flex_style{flex-direction:column;top:0;bottom:0}.a2a_flex_style a{display:flex;justify-content:center;flex:1;padding:4px}.a2a_flex_style.a2a_vertical_style a{flex-direction:column}.a2a_floating_style.a2a_color_buttons,.a2a_floating_style.a2a_flex_style{border-radius:0;padding:0}.a2a_floating_style.a2a_default_style.a2a_flex_style{bottom:0}.a2a_kit.a2a_flex_style .a2a_counter img,.a2a_kit.a2a_flex_style .a2a_dd,.a2a_kit.a2a_flex_style .a2a_svg{float:none}.a2a_nowrap{white-space:nowrap}.a2a_note{margin:0 auto;padding:9px;font-size:12px;text-align:center}.a2a_note .a2a_note_note{margin:0;color:#2A2A2A}.a2a_wide a{display:block;margin-top:3px;border-top:1px solid #EEE;text-align:center}.a2a_label{position:absolute!important;clip-path:polygon(0px 0px,0px 0px,0px 0px);-webkit-clip-path:polygon(0px 0px,0px 0px,0px 0px);overflow:hidden;height:1px;width:1px}.a2a_kit,.a2a_menu,.a2a_modal,.a2a_overlay{-ms-touch-action:manipulation;touch-action:manipulation;outline:0}.a2a_dd{-webkit-user-drag:none}.a2a_dd img{border:0}.a2a_button_facebook_like iframe{max-width:none}</style><meta http-equiv="P3P" content="CP=&quot;NOI DSP ADM OUR IND OTC&quot;"><link id="altmetric-embed-css" rel="stylesheet" type="text/css" href="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed-59614f5c46b49b21eeef3bb28c4fb38d1e7069e8d014752fcb66e84942556802.css"></head>
    

    



    
        
        
        
            <body class="pb-ui website-mms-site loaded">
            






    
    
        





    
    
        
        
    
    
    







<input type="hidden" id="isRoMode" name="isRoMode" value="false">

        <div id="pb-page-content" data-ng-non-bindable="">
                
            <div data-pb-dropzone="main" data-pb-dropzone-name="Main">
                
                    
                        



        
        <header data-sticky="false" class="ng-header js_stickyAd"><a href="#mainContent" class="ng-skipToMainContent">Skip to main content</a><div class="ng-header_topAd"><div class="ng-header_topAd-content d-flex justify-content-center align-items-center">



        
        <div id="DTM_Position_Topbanner" class="ad">
 <!--emptycomment-->
</div>
</div></div><div class="ng-header_journal-navbar"><div class="ng-header_journal-navbar-content"><div class="container-fluid"><div class="row"><div class="ng-header_journal-navbar_left col-lg-8 col-sm-12 pr-lg-0 d-flex align-items-center"><div data-location="nejm_group_product_nav" class="ng-header_journalNavMenu">



        
        <nav data-location="nejm_group_product_nav" role="navigation" class="ng-journalNavMenu">
<ul class="ng-journalNavMenu_list">
<li class="ng-journalNavMenu_list-item"><a href="/" class="ng-journalNavMenu_mainLink active" aria-current="page" aria-label="The New England Journal of Medicine selected item"><span class="ng-journalNavMenu_mainLink-text d-lg-block d-none">The New England Journal of Medicine</span><span class="ng-journalNavMenu_mainLink-text d-lg-none d-block">NEJM</span></a></li>
<li class="ng-journalNavMenu_list-item"><a href="https://evidence.nejm.org/" class="ng-journalNavMenu_mainLink"><span class="ng-journalNavMenu_mainLink-text"><span class="ng-journalNavMenu_mainLink-text-firstWord">NEJM</span> Evidence</span></a></li>
<li class="ng-journalNavMenu_list-item"><a href="https://ai.nejm.org/" class="ng-journalNavMenu_mainLink"><span class="ng-journalNavMenu_mainLink-text"><span class="ng-journalNavMenu_mainLink-text-firstWord">NEJM</span> AI</span></a></li>
<li class="ng-journalNavMenu_list-item"><a href="https://catalyst.nejm.org/" class="ng-journalNavMenu_mainLink"><span class="ng-journalNavMenu_mainLink-text"><span class="ng-journalNavMenu_mainLink-text-firstWord">NEJM</span> Catalyst</span></a></li>
<li class="ng-journalNavMenu_list-item"><a href="https://www.jwatch.org/" class="ng-journalNavMenu_mainLink"><span class="ng-journalNavMenu_mainLink-text"><span class="ng-journalNavMenu_mainLink-text-firstWord">NEJM</span> Journal Watch</span></a></li>
</ul>
</nav>

</div></div><div class="ng-header_journal-navbar_right col-lg-4 pl-lg-0 d-none d-xl-flex align-items-center justify-content-end"><div class="ng-header_loginBar d-xl-flex align-items-lg-center">



        
        <div data-location="authstring_nav" class="ng-header_loginBar-menu"><span class="ng-simple-menu_mainLink-icon signIn newIcon-2"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#user2"></use></svg></span></span><span class="ng-header_loginBar-signIn"><a href="/sign-in?uri=/doi/full/10.1056/NEJMoa2203163" class="ng-header_loginBar-signIn-link">Sign In</a></span><span class="ng-header_loginBar-separator">|</span><span class="ng-header_loginBar-createAcc"><a href="/action/storeProxy?action=register&amp;promo=ONFLNRC1" class="ng-header_loginBar-createAcc-link ro-mode_disabled">Create Account</a></span></div><div data-location="authstring_nav" class="ng-header_loginBar-subscribe pl-xl-16"><a href="/action/storeProxy?action=subscribe&amp;promo=ONF4NRS1" class="ng-header_loginBar-subscribe-btn ng-btn_primary ro-mode_disabled">Subscribe</a></div>
</div></div></div></div></div></div><div class="ng-header_instBanner d-none d-lg-block"></div><div class="ng-header_logoBar"><div class="container-fluid"><div class="row"><div data-location="logo" class="ng-header_logoBar_left col-lg-4 col-6 d-flex align-items-center justify-content-start"><a href="/" title="The New England Journal of Medicine homepage" class="ng-header_logo-link"><img src="/specs/products/mms-nextgen/mms/releasedAssets/images/other-images/nejm-logo-166667e91992a5212bc723b03e45d39f.svg" alt="The New England Journal of Medicine homepage" width="366" height="58" class="ng-header_logo-image"></a></div><div class="ng-header_logoBar_right ng-header_navBar col-lg-8 col-sm-12 p-lg-0 align-items-center justify-content-end"><div class="ng-header_navBar-content"><div class="container-fluid"><div class="row"><div class="ng-header_instBanner-md col-12 d-block d-lg-none"></div><div class="ng-header_loginBar-md col-12 d-block d-xl-none">



        
        <div data-location="authstring_nav" class="ng-header_loginBar-menu"><span class="ng-simple-menu_mainLink-icon signIn newIcon-2"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#user2"></use></svg></span></span><span class="ng-header_loginBar-signIn"><a href="/sign-in?uri=/doi/full/10.1056/NEJMoa2203163" class="ng-header_loginBar-signIn-link">Sign In</a></span><span class="ng-header_loginBar-separator">|</span><span class="ng-header_loginBar-createAcc"><a href="/action/storeProxy?action=register&amp;promo=ONFLNRC1" class="ng-header_loginBar-createAcc-link ro-mode_disabled">Create Account</a></span></div><div data-location="authstring_nav" class="ng-header_loginBar-subscribe pl-xl-16"><a href="/action/storeProxy?action=subscribe&amp;promo=ONF4NRS1" class="ng-header_loginBar-subscribe-btn ng-btn_primary ro-mode_disabled">Subscribe</a></div>
</div><div class="ng-header_navBar_left col-lg-8 col-sm-12 d-flex align-items-center"><div class="ng-header_stickyLogo mr-32"><a href="/" title="The New England Journal of Medicine homepage" class="ng-header_stickyLogo-link"><img src="/specs/products/mms-nextgen/mms/releasedAssets/images/other-images/nejm-small-logo-070df7a3f4d8cfa2e71c3c45bb4b172f.svg" alt="The New England Journal of Medicine homepage" class="ng-header_stickyLogo-image"></a></div><div class="ng-header_mainMenu">









    
    
        <div data-widget-def="menuWidget" data-widget-id="97fb3983-db63-4b0b-97dd-d9bb7929fce1" data-location="main_nav">
        



        
        <nav class="ng-menu"><ul class="ng-menu_list ng-simple-menu"><li class="ng-menu_list-item ng-simple-menu_item hasChildren"><a href="/toc/nejm/current" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">current issue</span><span class="ng-simple-menu_mainLink-arrowIcon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-down"></use></svg></span></span></a><div class="ng-simple-menu_dropblock"><div class="ng-simple-menu_dropblock-cont"><div class="ng-simple-menu_list"><ul class="ng-simple-menu_list-items"><li class="ng-simple-menu_list-item"><a href="/toc/nejm/current" class="ng-simple-menu_list-link">VIEW CURRENT ISSUE</a></li><li class="ng-simple-menu_list-item"><a href="/toc/nejm/recently-published" class="ng-simple-menu_list-link">BROWSE RECENTLY PUBLISHED</a></li><li class="ng-simple-menu_list-item"><a href="/loi/nejm" class="ng-simple-menu_list-link">BROWSE ALL ISSUES</a></li></ul></div></div></div></li><li class="ng-menu_list-item ng-simple-menu_item hasChildren"><a href="/medical-specialties" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">SPECIALTIES</span><span class="ng-simple-menu_mainLink-arrowIcon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-down"></use></svg></span></span></a><div class="ng-simple-menu_dropblock"><div class="ng-simple-menu_dropblock-cont"><div class="ng-simple-menu_list"><ul class="ng-simple-menu_list-items"><li class="ng-simple-menu_list-item"><a href="/browse/specialty/cardiology" class="ng-simple-menu_list-link">Cardiology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/clinical-medicine" class="ng-simple-menu_list-link">Clinical Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/endocrinology" class="ng-simple-menu_list-link">Endocrinology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/gastroenterology" class="ng-simple-menu_list-link">Gastroenterology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/hematology-oncology" class="ng-simple-menu_list-link">Hematology/Oncology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/infectious-disease" class="ng-simple-menu_list-link">Infectious Disease</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/nephrology" class="ng-simple-menu_list-link">Nephrology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/neurology-neurosurgery" class="ng-simple-menu_list-link">Neurology/Neurosurgery</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/obstetrics-gynecology" class="ng-simple-menu_list-link">Obstetrics/Gynecology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/pediatrics" class="ng-simple-menu_list-link">Pediatrics</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/pulmonary-critical-care" class="ng-simple-menu_list-link">Pulmonary/Critical Care</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/surgery" class="ng-simple-menu_list-link">Surgery</a></li><li class="ng-simple-menu_list-item"><a href="/medical-specialties" class="ng-simple-menu_list-link">View All Specialties</a></li></ul></div></div></div></li><li class="ng-menu_list-item ng-simple-menu_item hasChildren"><a href="/topics" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">TOPICS</span><span class="ng-simple-menu_mainLink-arrowIcon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-down"></use></svg></span></span></a><div class="ng-simple-menu_dropblock"><div class="ng-simple-menu_dropblock-cont"><div class="ng-simple-menu_list"><ul class="ng-simple-menu_list-items"><li class="ng-simple-menu_list-item"><a href="/ai-in-medicine" class="ng-simple-menu_list-link">AI in Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/climate-change" class="ng-simple-menu_list-link">Climate Change</a></li><li class="ng-simple-menu_list-item"><a href="/coronavirus" class="ng-simple-menu_list-link">Coronavirus</a></li><li class="ng-simple-menu_list-item"><a href="/equity" class="ng-simple-menu_list-link">Efforts toward Equity</a></li><li class="ng-simple-menu_list-item"><a href="/firearm-injury-prevention" class="ng-simple-menu_list-link">Firearm Injury Prevention</a></li><li class="ng-simple-menu_list-item"><a href="/nam" class="ng-simple-menu_list-link">From the National Academy of Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/fundamentals-of-medical-ethics" class="ng-simple-menu_list-link">Fundamentals of Medical Ethics</a></li><li class="ng-simple-menu_list-item"><a href="/gray-matters" class="ng-simple-menu_list-link">Gray Matters</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/health-policy" class="ng-simple-menu_list-link">Health Policy</a></li><li class="ng-simple-menu_list-item"><a href="/medicine-and-society" class="ng-simple-menu_list-link">Medicine and Society</a></li><li class="ng-simple-menu_list-item"><a href="/nutrition-in-medicine" class="ng-simple-menu_list-link">Nutrition in Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/outbreaks" class="ng-simple-menu_list-link">Outbreaks Center</a></li><li class="ng-simple-menu_list-item"><a href="/race-and-medicine" class="ng-simple-menu_list-link">Race and Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/recognizing-historical-injustices" class="ng-simple-menu_list-link">Recognizing Historical Injustices and the Journal</a></li><li class="ng-simple-menu_list-item"><a href="/tobacco-use-reduction" class="ng-simple-menu_list-link">Tobacco Use Reduction</a></li><li class="ng-simple-menu_list-item"><a href="/topics" class="ng-simple-menu_list-link">View All Topics</a></li></ul></div></div></div></li><li class="ng-menu_list-item ng-simple-menu_item hasChildren"><a href="/multimedia" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">MULTIMEDIA</span><span class="ng-simple-menu_mainLink-arrowIcon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-down"></use></svg></span></span></a><div class="ng-simple-menu_dropblock"><div class="ng-simple-menu_dropblock-cont"><div class="ng-simple-menu_list"><ul class="ng-simple-menu_list-items"><li class="ng-simple-menu_list-item"><a href="/rss-feed" class="ng-simple-menu_list-link">Podcasts</a></li><li class="ng-simple-menu_list-item"><a href="/double-take" class="ng-simple-menu_list-link">Double Takes</a></li><li class="ng-simple-menu_list-item"><a href="https://illustrated-glossary.nejm.org/" class="ng-simple-menu_list-link">Illustrated Glossary</a></li><li class="ng-simple-menu_list-item"><a href="/image-challenge" class="ng-simple-menu_list-link">Image Challenge</a></li><li class="ng-simple-menu_list-item"><a href="/browse/nejm-media-type/images-in-clinical-medicine" class="ng-simple-menu_list-link">Images in Clinical Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/browse/nejm-media-type/interactive-medical-case" class="ng-simple-menu_list-link">Interactive Medical Cases</a></li><li class="ng-simple-menu_list-item"><a href="/plain-language-research-summaries" class="ng-simple-menu_list-link">Plain Language/Research Summaries</a></li><li class="ng-simple-menu_list-item"><a href="/multimedia/quick-take-video" class="ng-simple-menu_list-link">Quick Takes</a></li><li class="ng-simple-menu_list-item"><a href="/browse/nejm-media-type/videos-in-clinical-medicine" class="ng-simple-menu_list-link">Videos in Clinical Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/multimedia" class="ng-simple-menu_list-link">View All Multimedia</a></li></ul></div></div></div></li><li class="ng-menu_list-item ng-simple-menu_item hasChildren"><a href="/learning" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">LEARNING/CME</span><span class="ng-simple-menu_mainLink-arrowIcon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-down"></use></svg></span></span></a><div class="ng-simple-menu_dropblock"><div class="ng-simple-menu_dropblock-cont"><div class="ng-simple-menu_list"><ul class="ng-simple-menu_list-items"><li class="ng-simple-menu_list-item"><a href="/continuing-medical-education" class="ng-simple-menu_list-link">Weekly CME</a></li><li class="ng-simple-menu_list-item"><a href="/cme-ce/obesity" class="ng-simple-menu_list-link">Obesity CME/CE</a></li><li class="ng-simple-menu_list-item"><a href="/learning" class="ng-simple-menu_list-link">VIEW ALL LEARNING/CME</a></li></ul></div></div></div></li><li class="ng-menu_list-item ng-simple-menu_item"><a href="/author-center/home" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">AUTHOR CENTER</span></a></li></ul></nav>

        </div>
    

</div><button aria-label="Search" class="ng-header_searchBtn searchBtnNav d-block ml-24"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#search"></use></svg></span></button></div><div class="ng-header_loginBar ng-header_loginBar-sticky col-4">



        
        <div data-location="authstring_nav" class="ng-header_loginBar-menu"><span class="ng-simple-menu_mainLink-icon signIn newIcon-2"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#user2"></use></svg></span></span><span class="ng-header_loginBar-signIn"><a href="/sign-in?uri=/doi/full/10.1056/NEJMoa2203163" class="ng-header_loginBar-signIn-link">Sign In</a></span><span class="ng-header_loginBar-separator">|</span><span class="ng-header_loginBar-createAcc"><a href="/action/storeProxy?action=register&amp;promo=ONFLNRC1" class="ng-header_loginBar-createAcc-link ro-mode_disabled">Create Account</a></span></div><div data-location="authstring_nav" class="ng-header_loginBar-subscribe pl-xl-16"><a href="/action/storeProxy?action=subscribe&amp;promo=ONF4NRS1" class="ng-header_loginBar-subscribe-btn ng-btn_primary ro-mode_disabled">Subscribe</a></div>
</div></div></div></div></div><div class="ng-header_logoBar_right-lg col-lg-8 col-6 d-flex align-items-center justify-content-end d-xl-none"><button aria-label="Search" class="ng-header_searchBtn d-flex justify-content-end"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#search"></use></svg></span></button><div class="ng-header_openCloseBtns d-flex align-items-center justify-content-end"><button aria-label="Open" class="ng-header_openBtn"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#burger"></use></svg></span></button><button aria-label="Close" class="ng-header_closeBtn"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#close"></use></svg></span></button></div></div><div class="ng-header_quickSearch col-12"><div class="ng-header_quickSearch-content">



        
        <div class="ng-quick-search js-ng-quick-search"><form action="/search" method="get" class="ng-quick-search_form js-form"><div class="ng-quick-search_inputArea js-inputArea"><input type="search" name="q" placeholder="Enter keyword, author, title or citation" autocomplete="off" value="" required="required" class="ng-quick-search_allField ng-large-text-input js-allField js-allField-def-tmpl ui-autocomplete-input"><button type="submit" aria-label="Search Button" class="ng-quick-search_iconBtn d-xl-none d-block js-submitBtn"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#search"></use></svg></span></button><ul id="ui-id-1" tabindex="0" class="ui-menu ui-widget ui-widget-content ui-autocomplete ui-front" style="display: none;"></ul></div><div class="ng-quick-search_btnsArea d-none d-xl-flex align-items-center justify-content-end"><a href="/search/advanced" class="ng-quick-search_advSearchLink ng-btn_link js-advancedSearchLink">Advanced Search</a><button type="submit" class="ng-quick-search_textBtn ng-btn_secondary ng-btn_iconRight js-submitBtn"><span class="ng-btn_text">SEARCH</span><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-right"></use></svg></span></button></div></form></div>
</div></div></div></div></div></header><div class="ng-header_overlay"></div><div class="ng-header_after">









    
    
        <div data-widget-def="literatumAd" data-widget-id="4931ddbd-d46e-4597-b4fd-92549e9847ca" id="ad-global-banner-FULLx64-1">
        



        
        



    

    

    
        
    



        </div>
    

</div>

                    
                        



        
        <div>









    
    
        <main data-widget-def="axelPublicationContent" data-widget-id="fcdb5261-d6a2-4a9c-81d5-3a3e2304e9c1" id="mainContent">
        



        
        <div class="article-tools__savePopup"><div class="ng-save"><input type="hidden" value="/action/getSavedTags" class="getKeywordsServiceUrl"><input type="hidden" value="/action/mmsSaveItemsService?itemType=article" class="saveServiceUrl"><input type="hidden" value="article" class="saveType"><input type="hidden" value="10.1056/NEJMoa2203163" class="inputDoi"><input type="hidden" value="A. Papi and Others" class="inputAuthor"><input type="hidden" value="N Engl J Med 2022;386:2071-2083" class="inputCitation"><input type="hidden" value="05-15-2022" class="inputEPubDate"><input type="hidden" value="June 2022" class="inputCoverDate"><input type="hidden" value="Original Article" class="inputContentType"><input type="hidden" value="Albuterol–Budesonide Fixed-Dose Combination Rescue Inhaler for Asthma" class="inputArticleTitle"><input type="hidden" value="/browse/nejm-article-type/original-article" class="inputContentTypeUrl"><button type="button" id="saveArticleShowPopupBtn" aria-hidden="true" tabindex="-1" class="ng-save-btn ng-btn_secondary isLoggedOut">Save</button></div></div><div class="article-tools__articleAlertPopup"><div id="articleAlertModal" tabindex="-1" role="dialog" aria-labelledby="exampleModalCenterTitle" aria-hidden="true" class="ng-modal modal"><div role="document" class="ng-modal_dialog modal-dialog modal-dialog-centered"><div class="ng-modal_content modal-content"><div class="ng-modal_header modal-header"><h5 id="articleAlertModalTitle" class="ng-modal_title modal-title">Create an E-mail Alert for This Article</h5><button type="button" data-dismiss="modal" aria-label="Close" class="ng-modal_close close"><span aria-hidden="true"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#close"></use></svg></span></span></button></div><div class="ng-modal_body modal-body"></div></div></div></div></div><div class="ng-do-media_popup"><div id="doPopup" tabindex="-1" role="dialog" aria-labelledby="exampleModalCenterTitle" aria-hidden="true" class="ng-modal modal"><div role="document" class="ng-modal_dialog modal-dialog modal-dialog-centered"><div class="ng-modal_content modal-content"><div class="ng-modal_header modal-header"><button type="button" data-dismiss="modal" aria-label="Close" class="ng-modal_close close"><span aria-hidden="true"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#close"></use></svg></span></span></button></div><div class="ng-modal_body modal-body"></div></div></div></div></div><link id="build-style-article" rel="stylesheet" type="text/css" href="/products/mms-nextgen/mms/releasedAssets/css/build-article-5b89b331018866a4a965.css"><article xmlns="http://www.w3.org/1999/xhtml" data-design="pill" data-has="right-rail" data-type="research-article" vocab="http://schema.org/" typeof="ScholarlyArticle" lang="en" dir="ltr"><header data-extent="frontmatter" data-location="header_article"><div class="core-container"><div data-article-access="free" data-article-access-type="free" class="meta-panel"><div class="meta-panel__left-content"><div class="meta-panel__type"><a href="/browse/nejm-article-type/original-article">Original Article</a></div></div><div class="meta-panel__right-content"><div class="meta-panel__share">









    
    
        <div data-widget-def="UX3share" data-widget-id="eee5f139-16f2-48f8-97ea-1b114367da16" data-location="share_tools_article">
        



        
        <!-- Go to https://www.addtoany.com/buttons/customize/ to customize your tools --><script type="text/javascript" defer="defer" src="https://static.addtoany.com/menu/page.js" nonce="94d6d44785b61aed-SJC"></script><div class="share"><div class="share__block share__inline-links"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="d-flex list-unstyled a2a a2a_kit a2a_default_style mb-0 a2a_kit_size_32" style="line-height: 32px;"><li class="a2a_listitem_custom"><a role="link" title="Facebook" data-interactiontype="social" class="share__link a2a_button_facebook" target="_blank" rel="nofollow noopener" href="/#facebook"><span class="icon-component " style="height: 24px; width: 24px"><svg aria-hidden="true" style="height: 24px; width: 24px"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#social-facebook"></use></svg></span></a></li><li class="a2a_listitem_custom"><a role="link" title="X (formerly Twitter)" data-interactiontype="social" class="share__link a2a_button_twitter" target="_blank" rel="nofollow noopener" href="/#twitter"><span class="icon-component " style="height: 24px; width: 24px"><svg aria-hidden="true" style="height: 24px; width: 24px"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#social-twitter"></use></svg></span></a></li><li class="a2a_listitem_custom"><a role="link" title="Linked In" data-interactiontype="social" class="share__link a2a_button_linkedin" target="_blank" rel="nofollow noopener" href="/#linkedin"><span class="icon-component " style="height: 24px; width: 24px"><svg aria-hidden="true" style="height: 24px; width: 24px"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#social-linkedin"></use></svg></span></a></li><li class="a2a_listitem_custom"><a role="link" title="Email" data-interactiontype="content_email_click" class="share__link a2a_button_email" target="_blank" rel="nofollow noopener" href="/#email"><span class="icon-component " style="height: 24px; width: 24px"><svg aria-hidden="true" style="height: 24px; width: 24px"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#social-email"></use></svg></span></a></li><li class="a2a_listitem_custom"><a role="link" title="Bluesky" data-interactiontype="social" class="share__link a2a_button_bluesky" target="_blank" rel="nofollow noopener" href="/#bluesky"><span class="icon-component " style="height: 24px; width: 24px"><svg aria-hidden="true" style="height: 24px; width: 24px"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#social-bluesky"></use></svg></span></a></li></ul></div></div>

        </div>
    

</div></div></div><h1 property="name">Albuterol–Budesonide Fixed-Dose Combination Rescue Inhaler for Asthma</h1><div class="core-relations my-3"></div><div class="contributors"><span class="authors"><span class="heading">Authors</span>: <span role="list"><span property="author" typeof="Person" role="listitem"><span property="givenName">Alberto</span> <span property="familyName">Papi</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">Bradley E.</span> <span property="familyName">Chipps</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">Richard</span> <span property="familyName">Beasley</span>, <span property="honorificSuffix">D.Sc.</span> <a class="orcid-id" href="https://orcid.org/0000-0003-0337-406X" property="identifier" aria-label="ORCID identifier" target="_blank">https://orcid.org/0000-0003-0337-406X</a></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">Reynold A.</span> <span property="familyName">Panettieri</span>, Jr., <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">Elliot</span> <span property="familyName">Israel</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">Mark</span> <span property="familyName">Cooper</span>, <span property="honorificSuffix">M.Sc.</span></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">Lynn</span> <span property="familyName">Dunsire</span>, <span property="honorificSuffix">M.Sc.</span></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">Allison</span> <span property="familyName">Jeynes-Ellis</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">Eva</span> <span property="familyName">Johnsson</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">Robert</span> <span property="familyName">Rees</span>, <span property="honorificSuffix">Ph.D.</span></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">Christy</span> <span property="familyName">Cappelletti</span>, <span property="honorificSuffix">Pharm.D.</span></span>, and <span property="author" typeof="Person" role="listitem"><span property="givenName">Frank C.</span> <span property="familyName">Albers</span>, <span property="honorificSuffix">M.D.</span> <a class="orcid-id" href="https://orcid.org/0000-0001-7039-4621" property="identifier" aria-label="ORCID identifier" target="_blank">https://orcid.org/0000-0001-7039-4621</a></span></span></span><a href="#tab-contributors" class="to-authors-affiliations" data-id="article-authors-viewall">Author Info &amp; Affiliations</a></div><div class="core-self-citation"><div class="core-date-published">Published <span property="datePublished">May 15, 2022</span></div><div property="isPartOf" typeof="Periodical"><span property="name">N Engl J Med</span> 2022<span property="isPartOf" typeof="PublicationVolume">;<span property="volumeNumber">386</span></span>:<span property="pageStart">2071</span>-<span property="pageEnd">2083</span></div><div class="doi">DOI: 10.1056/NEJMoa2203163</div><div class="core-enumeration"><a href="/toc/nejm/386/22"><span property="isPartOf" typeof="PublicationVolume">VOL. <span property="volumeNumber">386</span></span> <span property="isPartOf" typeof="PublicationIssue">NO. <span property="issueNumber">22</span></span></a></div><div><a href="#tab-information">Copyright © 2022</a></div></div><div class="info-panel"><div class="info-panel__left-content"><div class="info-panel__metrics info-panel__item"></div></div><div data-location="tools_article" class="info-panel__right-content"><div class="info-panel__article_tools info-panel__item">



        
        <div data-permission="/servlet/linkout?type=rightslink&amp;url=publisherName%3Dmassmed%26author%3DAlberto%2BPapi%252C%2BBradley%2BE.%2BChipps%252C%2BRichard%2BBeasley%252C%2Bet%2Bal%26publication%3Dnejm%26orderBeanReset%3Dtrue%26volumeNum%3D386%26issueNum%3D22%26contentID%3D10.1056%252FNEJMoa2203163%26title%3DAlbuterol%25E2%2580%2593Budesonide%2BFixed-Dose%2BCombination%2BRescue%2BInhaler%2Bfor%2BAsthma%26publicationDate%3D06%252F02%252F2022" class="article-tools"><button id="articleToolsAlertBtn" data-url="/action/addCitationAlert?doi=10.1056%2FNEJMoa2203163" data-toggle="" data-target="#articleAlertModal" aria-label="Sign in or create account to add an article alert" data-interactiontype="article_alert" class="article-tools__citation btn btn--slim isLoggedOut"><span title="" data-toggle="tooltip" class="d-inline-block" data-original-title="Sign in or create account to add an article alert"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#alerts"></use></svg></span></span></button><button id="articleToolsSaveBtn" data-toggle="modal" data-target="#saveArticle" aria-label="Sign in or create account to save this article" data-interactiontype="article_tools_save_click" class="article-tools__favorite btn btn--slim isLoggedOut"><span title="" data-toggle="tooltip" class="d-inline-block" data-original-title="Sign in or create account to save this article"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#bookmarkFilled"></use></svg></span></span></button><a href="/servlet/linkout?type=rightslink&amp;url=publisherName%3Dmassmed%26author%3DAlberto%2BPapi%252C%2BBradley%2BE.%2BChipps%252C%2BRichard%2BBeasley%252C%2Bet%2Bal%26publication%3Dnejm%26orderBeanReset%3Dtrue%26volumeNum%3D386%26issueNum%3D22%26contentID%3D10.1056%252FNEJMoa2203163%26title%3DAlbuterol%25E2%2580%2593Budesonide%2BFixed-Dose%2BCombination%2BRescue%2BInhaler%2Bfor%2BAsthma%26publicationDate%3D06%252F02%252F2022" target="_blank" title="" data-toggle="tooltip" aria-label="Permissions" data-interactiontype="article_tools_permissions_click" class="article-tools__permissions btn btn--slim" data-original-title="Permissions"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#permissions"></use></svg></span></a><a href="/about-nejm/reprints" title="" data-toggle="tooltip" aria-label="Reprints" data-interactiontype="article_tools_reprints_click" class="article-tools__reprints btn btn--slim" data-original-title="Reprints"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#reprints"></use></svg></span></a><a href="/cms/asset/6804b02e-0071-42e4-8048-28dd6a594ae8/nejmoa2203163.pptx" target="_blank" title="" data-toggle="tooltip" aria-label="Download Slides" data-interactiontype="article_tools_slide_set_download" data-multimedia-type="Article Slideset" data-multimedia-filename="nejmoa2203163.pptx" class="article-tools__downloadSlides btn btn--slim" data-original-title="Download Slides"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#download"></use></svg></span></a><div class="article-tools__permissionsPopup"><div id="permissionsModal" tabindex="-1" role="dialog" aria-labelledby="exampleModalCenterTitle" aria-hidden="true" class="ng-modal modal"><div role="document" class="ng-modal_dialog modal-dialog modal-dialog-centered"><div class="ng-modal_content modal-content"><div class="ng-modal_header modal-header"><h5 id="permissionsModalTitle" class="ng-modal_title modal-title">Permissions</h5><button type="button" data-dismiss="modal" aria-label="Close" class="ng-modal_close close"><span aria-hidden="true"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#close"></use></svg></span></span></button></div><div class="ng-modal_body modal-body">For permission requests, please contact NEJM Reprints at <a href="mailto:reprints@nejm.org">reprints@nejm.org</a></div></div></div></div></div></div>
</div><div class="info-panel__citations info-panel__item"><a href="#tab-citations" class="btn btn--slim" aria-label="View Citations" data-toggle="tooltip" data-original-title="View Citations" data-interactiontype="article_tools_citation_download" data-multimedia-type="Citation"><i aria-hidden="true" class="icon-format_quote"></i></a></div><div class="info-panel__formats info-panel__item"><a href="https://www.nejm.org/doi/pdf/10.1056/NEJMoa2203163" class="btn btn--pdf btn--slim" aria-label="View PDF" data-toggle="tooltip" data-original-title="View PDF" data-behavior="trackDownloadEvent" data-doi="10.1056/NEJMoa2203163" data-interactiontype="article_tools_download_pdf" data-multimedia-type="Article PDF" data-multimedia-filename="nejmoa2203163.pdf"><i aria-hidden="true" class="icon-PDF"></i></a></div></div></div></div></header><div data-core-nav="header" data-extent="frontmatter"><div class="core-nav-wrapper core-container" aria-label="Article navigation"><div class="core-sections-menu"><button data-id="article-toolbar-showhide" aria-controls="article_sections_menu" aria-expanded="false" aria-label="Toggle section navigation menu" style="margin-top: 0px;"><i class="icon-list" aria-hidden="true"></i><span>Contents</span></button><nav id="article_sections_menu" aria-label="Contents" data-core-nav="article" style="margin-top: 0px;"><ul><li><a href="#summary-abstract" aria-current="true">Abstract</a></li><li><a href="#sec-1" aria-current="false">Methods</a></li><li><a href="#sec-2" aria-current="false">Results</a></li><li><a href="#sec-3" aria-current="false">Discussion</a></li><li class="bordered"><a href="#backnotes" aria-current="false">Notes</a></li><li><a href="#supplementary-materials" aria-current="false">Supplementary Material</a></li><li><a href="#bibliography" aria-current="false">References</a></li></ul></nav></div><nav id="article_collateral_menu"><ul data-core-nav="collateral" class="collateral-pill" style="margin-top: 0px;"><li><a href="#core-collateral-info" data-id="article-nav-menubar-info" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="Information &amp; Authors"><i aria-hidden="true" class="icon-info"></i><span class="sr-only">Information &amp; Authors</span></a></li><li><a href="#core-collateral-metrics" data-id="article-nav-menubar-metrics" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="Metrics &amp; Citations"><i aria-hidden="true" class="icon-timeline"></i><span class="sr-only">Metrics &amp; Citations</span></a></li><li><a href="#core-collateral-fulltext-options" data-id="article-nav-menubar-metrics" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="View Options"><i aria-hidden="true" class="icon-eye"></i><span class="sr-only">View Options</span></a></li><li><a href="#core-collateral-references" data-id="article-nav-menubar-references" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="References"><i aria-hidden="true" class="icon-references"></i><span class="sr-only">References</span></a></li><li><a href="#core-collateral-media" data-id="article-nav-menubar-media" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="Media"><i aria-hidden="true" class="icon-photo"></i><span class="sr-only">Media</span></a></li><li><a href="#core-collateral-tables" data-id="article-nav-menubar-tables" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="Tables"><i aria-hidden="true" class="icon-tables"></i><span class="sr-only">Tables</span></a></li><li><a href="#core-collateral-share" data-id="article-nav-menubar-share" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="Share"><i aria-hidden="true" class="icon-share"></i><span class="sr-only">Share</span></a></li></ul></nav></div></div><div data-core-wrapper="content"><div id="abstracts" data-extent="frontmatter" data-location="articleTab_article"><div class="core-container"><section id="summary-abstract" property="abstract" typeof="Text" role="doc-abstract"><h2 property="name">Abstract</h2><section id="abs-sec-1"><h3>Background</h3><div role="paragraph">As asthma symptoms worsen, patients typically rely on short-acting β<sub>2</sub>-agonist (SABA) rescue therapy, but SABAs do not address worsening inflammation, which leaves patients at risk for severe asthma exacerbations. The use of a fixed-dose combination of albuterol and budesonide, as compared with albuterol alone, as rescue medication might reduce the risk of severe asthma exacerbation.</div></section><section id="abs-sec-2"><h3>Methods</h3><div role="paragraph">We conducted a multinational, phase 3, double-blind, randomized, event-driven trial to evaluate the efficacy and safety of albuterol–budesonide, as compared with albuterol alone, as rescue medication in patients with uncontrolled moderate-to-severe asthma who were receiving inhaled glucocorticoid-containing maintenance therapies, which were continued throughout the trial. Adults and adolescents (≥12 years of age) were randomly assigned in a 1:1:1 ratio to one of three trial groups: a fixed-dose combination of 180 μg of albuterol and 160 μg of budesonide (with each dose consisting of two actuations of 90 μg and 80 μg, respectively [the higher-dose combination group]), a fixed-dose combination of 180 μg of albuterol and 80 μg of budesonide (with each dose consisting of two actuations of 90 μg and 40 μg, respectively [the lower-dose combination group]), or 180 μg of albuterol (with each dose consisting of two actuations of 90 μg [the albuterol-alone group]). Children 4 to 11 years of age were randomly assigned to only the lower-dose combination group or the albuterol-alone group. The primary efficacy end point was the first event of severe asthma exacerbation in a time-to-event analysis, which was performed in the intention-to-treat population.</div><div class="figure-wrap" data-presentation="diminished-in-flow"><header><!-- There is no content. --><nav><a href="#f0" title="Open in viewer" class="open-in-viewer" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2203163_f0.jpg"><i aria-hidden="true" class="icon-expand"></i></a></nav></header><figure id="f0" class="graphic"><a aria-label="Open figure in viewer" class="open-in-viewer" data-index="0" href="#f0" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2203163_f0.jpg"><img src="/cms/10.1056/NEJMoa2203163/asset/064d7417-8268-4305-aba1-5cd26a8cace9/assets/images/large/nejmoa2203163_f0.jpg" height="3416" width="2640" aria-labelledby="f0" loading="lazy"></a><figcaption>Download a PDF of the <a href="#ap0">Research Summary</a>.</figcaption></figure></div></section><section id="abs-sec-3"><h3>Results</h3><div role="paragraph">A total of 3132 patients underwent randomization, among whom 97% were 12 years of age or older. The risk of severe asthma exacerbation was significantly lower, by 26%, in the higher-dose combination group than in the albuterol-alone group (hazard ratio, 0.74; 95% confidence interval [CI], 0.62 to 0.89; P=0.001). The hazard ratio in the lower-dose combination group, as compared with the albuterol-alone group, was 0.84 (95% CI, 0.71 to 1.00; P=0.052). The incidence of adverse events was similar in the three trial groups.</div></section><section id="abs-sec-4"><h3>Conclusions</h3><div role="paragraph">The risk of severe asthma exacerbation was significantly lower with as-needed use of a fixed-dose combination of 180 μg of albuterol and 160 μg of budesonide than with as-needed use of albuterol alone among patients with uncontrolled moderate-to-severe asthma who were receiving a wide range of inhaled glucocorticoid-containing maintenance therapies. (Funded by Avillion; MANDALA ClinicalTrials.gov number, <a href="http://clinicaltrials.gov/show/NCT03769090" target="_blank">NCT03769090</a>.)</div></section></section><div class="core-digital-object quick-take">
<div class="ng-do-media" style="border-top: 1px solid #e5e5e5; padding-top: 1.5rem;" data-location="inlineArticlePreview">
    <div class="ng-do-media_item">
        <div class="ng-do-media_item-left">
            <a href="/do/10.1056/NEJMdo006554/full/" class="ng-do-media_item-img-link">
                <img src="/cms/asset/e454e702-bd7a-4600-8e8d-68c1e2e17371/media/NEJMdo006554_300x200.jpg" class="ng-do-media_item-img">
                <span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#tooltip-video"></use></svg></span>
            </a>
        </div>
        <div class="ng-do-media_item-right">
            <div class="ng-do-media_item-type">
                <a href="/browse/nejm-media-type/quick-take" class="ng-do-media_item-type-link">Quick Take</a>
            </div>
            <h6 class="ng-do-media_item-title">
                <a href="/do/10.1056/NEJMdo006554/full/" class="ng-do-media_item-title-link">Albuterol–Budesonide Rescue Inhaler in Asthma</a>
            </h6>
            <div class="ng-do-media_item-duration">2m 8s</div>
        </div>
    </div>
</div>
</div></div></div><section id="bodymatter" data-extent="bodymatter" property="articleBody" typeof="Text" data-location="articleTab_article"><div class="core-container"><div role="paragraph">Asthma is a heterogeneous disease that manifests as variable airflow obstruction with recurring symptoms driven by underlying persistent, yet fluctuating, airway inflammation.<sup><a href="#core-r1" role="doc-biblioref" data-xml-rid="r1" id="body-ref-r1-1" href-manipulated="true" aria-label="Reference 1">1</a></sup> During a loss of asthma control, patients often focus on obtaining immediate symptom relief by relying on their rescue medication, typically a short-acting β<sub>2</sub>-agonist (SABA).<sup><a href="#core-r2" role="doc-biblioref" data-xml-rid="r2 r3" id="body-ref-r3" href-manipulated="true">2,3</a></sup> However, SABAs have little effect on underlying airway inflammation,<sup><a href="#core-r1" role="doc-biblioref" data-xml-rid="r1 r4" id="body-ref-r4-1" href-manipulated="true">1,4</a></sup> and overreliance on SABAs serves as a metric for poor asthma control, with an associated risk of severe asthma exacerbation.<sup><a href="#core-r5" role="doc-biblioref" data-xml-rid="r5 r6 r7 r8 r9 r10" id="body-ref-r10" href-manipulated="true">5-10</a></sup> Because severe asthma exacerbations contribute to considerable morbidity and mortality, the prevention of exacerbations is imperative in the management of asthma.</div><div role="paragraph">Concerns regarding adverse consequences associated with overreliance on SABAs and evidence that rescue use of a fixed-dose combination of an inhaled glucocorticoid and formoterol, as compared with a SABA, significantly reduced the risk of exacerbation among patients with a range of asthma severity<sup><a href="#core-r11" role="doc-biblioref" data-xml-rid="r11 r12 r13 r14" id="body-ref-r14-1" href-manipulated="true">11-14</a></sup> led the Global Initiative for Asthma (GINA)<sup><a href="#core-r1" role="doc-biblioref" data-xml-rid="r1 r15 r16" id="body-ref-r16" href-manipulated="true">1,15,16</a></sup> and the National Asthma Education and Prevention Program<sup><a href="#core-r4" role="doc-biblioref" data-xml-rid="r4 r17" id="body-ref-r17" href-manipulated="true">4,17</a></sup> to generally recommend as-needed use of this combination as the preferred rescue-treatment strategy. Rapid-onset bronchodilators, such as formoterol and albuterol, are ideal for a rescue fixed-dose combination with an inhaled glucocorticoid, as compared with slower-onset bronchodilators, such as salmeterol.<sup><a href="#core-r18" role="doc-biblioref" data-xml-rid="r18" id="body-ref-r18" href-manipulated="true" aria-label="Reference 18">18</a></sup> However, among patients with moderate-to-severe asthma, data regarding this strategy are limited to the as-needed use of the same agents (budesonide plus formoterol) in the same inhaler device the patients had been using for maintenance therapy.<sup><a href="#core-r13" role="doc-biblioref" data-xml-rid="r13 r14 r19 r20 r21 r22" id="body-ref-r22-1" href-manipulated="true">13,14,19–22</a></sup> Therefore, evaluation of an inhaled glucocorticoid with a fast-acting bronchodilator in a fixed-dose combination as a rescue medication that could be used in addition to any inhaled glucocorticoid-containing maintenance therapy, as compared with SABA as a rescue medication, is warranted. A fixed-dose combination of inhaled albuterol and budesonide, as compared with albuterol alone, as a rescue medication was considered to be most appropriate, because albuterol is the most commonly used rescue medication worldwide, and SABAs are the only class of rescue medication approved by the Food and Drug Administration in the United States.<sup><a href="#core-r4" role="doc-biblioref" data-xml-rid="r4 r8 r23" id="body-ref-r23" href-manipulated="true">4,8,23</a></sup></div><div role="paragraph">A new formulation of albuterol and budesonide<sup><a href="#core-r24" role="doc-biblioref" data-xml-rid="r24 r25" id="body-ref-r25" href-manipulated="true">24,25</a></sup> in a single pressurized metered-dose inhaler was developed as albuterol–inhaled glucocorticoid rescue therapy for the control of acute asthma symptoms, the treatment and prevention of bronchoconstriction, and the prevention of exacerbations. The primary objective of the MANDALA trial was to evaluate the efficacy and safety of as-needed use of albuterol–budesonide, as compared with as-needed use of albuterol alone, in patients with moderate-to-severe asthma.</div><section id="sec-1" data-type="methods"><h2>Methods</h2><section id="sec-1-1"><h3>Patients</h3><div role="paragraph"><a id="exam-tint-three-b"></a><span id="tint1" class="named-content" data-type="exam-tint" data-answer-ids="three-b">Symptomatic patients with asthma who were 4 years of age or older and had had at least one severe asthma exacerbation in the previous 12 months were recruited.</span> Severe asthma exacerbation was defined as clinical deterioration of asthma, with a worsening or a new onset of symptoms leading to at least one of the following events: 3 or more consecutive days of treatment with a systemic glucocorticoid to treat worsening symptoms of asthma (a single depot injection was considered to be equivalent to a 3-day burst); an emergency department or urgent care visit of less than 24 hours during which systemic glucocorticoids were used to treat worsening symptoms of asthma; or an in-patient hospitalization for 24 hours or more because of asthma. Additional inclusion criteria were a forced expiratory volume in 1 second (FEV<sub>1</sub>) of 40 to less than 90% of the predicted normal value (with no upper limit for patients 4 to 17 years of age); FEV<sub>1</sub> reversibility of at least 12%, as measured during an in-clinic screening visit; and a score on the Asthma Control Questionnaire–5 (ACQ-5) of 1.5 or greater at visit 2 (day 1 of the double-blind treatment period), which indicates poorly controlled asthma.<sup><a href="#core-r26" role="doc-biblioref" data-xml-rid="r26" id="body-ref-r26" href-manipulated="true" aria-label="Reference 26">26</a></sup></div><div role="paragraph">The patients had been receiving a medium-to-high dose of inhaled glucocorticoid or a low-to-high dose of inhaled glucocorticoid–long-acting β<sub>2</sub>-agonist combination, as defined by GINA,<sup><a href="#core-r1" role="doc-biblioref" data-xml-rid="r1" id="body-ref-r1-4" href-manipulated="true" aria-label="Reference 1">1</a></sup> with or without another controller, for at least 3 months with stable dosing for at least 4 weeks before screening. They continued to receive their maintenance medications throughout the trial. Major exclusion criteria were chronic obstructive pulmonary disease or other notable lung disease, use of a systemic glucocorticoid within 3 months before screening, and use of biologic treatments within 3 months or for a duration of 5 half-lives before screening.</div></section><section id="sec-1-2"><h3>Trial Design</h3><div role="paragraph">The MANDALA trial was a multinational, phase 3, double-blind, randomized, parallel-group, event-driven trial with a minimum duration of 24 weeks. The trial was conducted at 295 sites in North America, South America, Europe, and South Africa<sup><a href="#core-r27" role="doc-biblioref" data-xml-rid="r27" id="body-ref-r27-1" href-manipulated="true" aria-label="Reference 27">27</a></sup> and was continued until at least 570 first events of severe asthma exacerbation had been reported (Fig. S1 in the <a href="#ap2">Supplementary Appendix</a>, available with the full text of this article at NEJM.org).<sup><a href="#core-r27" role="doc-biblioref" data-xml-rid="r27" id="body-ref-r27-2" href-manipulated="true" aria-label="Reference 27">27</a></sup></div><div role="paragraph">Adults and adolescents were randomly assigned in a 1:1:1 ratio to one of three treatment groups: a fixed-dose combination of 180 μg of albuterol and 160 μg of budesonide (with each dose consisting of two actuations of 90 μg and 80 μg, respectively [the higher-dose combination group]), a fixed-dose combination of 180 μg of albuterol and 80 μg of budesonide (with each dose consisting of two actuations of 90 μg and 40 μg, respectively [the lower-dose combination group]), or 180 μg of albuterol (with each dose consisting of two actuations of 90 μg [the albuterol-alone group]). The trial medications were delivered through a pressurized metered-dose inhaler. Children 4 to 11 years of age were randomly assigned to the lower-dose combination group or to the albuterol-alone group owing to concerns about higher doses of inhaled glucocorticoids in this younger population. The patients were instructed on the proper technique for using the pressurized metered-dose inhaler, and their technique was checked and confirmed by the staff at the trial site. The patients were told to use the trial medications as needed in response to symptoms and that the trial medications could be used before exercise. Rescue use was limited to the trial medications throughout the trial; additional fast-acting bronchodilators, including nebulizers, were prohibited for rescue use. Changes in maintenance therapy were discouraged unless clinically indicated. Details on permitted and prohibited medication use during the trial are provided in the <a href="#ap2">Supplementary Appendix</a>.</div><div role="paragraph">The trial procedures have been described previously.<sup><a href="#core-r27" role="doc-biblioref" data-xml-rid="r27" id="body-ref-r27-3" href-manipulated="true" aria-label="Reference 27">27</a></sup> Adherence to maintenance therapy and the use of the assigned trial medication were documented by the patients or their parents or guardians with the use of an electronic diary and were monitored by the investigators and staff at the trial site and by the sponsor (Avillion). The maximum daily dose of a trial medication was 12 inhalations (i.e., 6 doses) for all the patients. Patients who had three or more severe asthma exacerbations within a 3-month period or a total of five or more severe asthma exacerbations were assessed for possible discontinuation of the trial medication.</div></section><section id="sec-1-3"><h3>Trial Oversight</h3><div role="paragraph">The trial design was approved by the appropriate institutional and national regulatory authorities and ethics committees; all the patients or their guardians provided written informed consent (and assent, if appropriate). An independent data and safety monitoring board reviewed unblinded data every 3 months to monitor safety. Avillion coordinated data management and the statistical analyses in conjunction with the responsible contract research organizations (Syneos Health and Phastar, respectively). All the authors contributed to the design of the trial and the interpretation of the data. The first draft of the manuscript was written by a medical writer (funded by AstraZeneca) under the direction of the authors and in accordance with Good Publication Practice guidelines. All the authors provided critical feedback on the first and subsequent drafts of the manuscript and, along with the sponsor, made the decision to submit the manuscript for publication. All the authors had access to the data and vouch for the completeness and accuracy of the data and for the fidelity of the trial to the <a href="#ap1">protocol,</a> available at NEJM.org.</div></section><section id="sec-1-4"><h3>End Points</h3><div role="paragraph">The primary efficacy end point was the first event of severe asthma exacerbation in a time-to-event analysis. Secondary efficacy end points were the annualized rate of severe asthma exacerbations, total systemic glucocorticoid exposure for asthma during the treatment period, and “response” at week 24 on the ACQ-5 (validated for persons ≥6 years of age),<sup><a href="#core-r28" role="doc-biblioref" data-xml-rid="r28" id="body-ref-r28" href-manipulated="true" aria-label="Reference 28">28</a></sup> the Asthma Quality of Life Questionnaire (AQLQ+12, validated for persons ≥12 years of age), and the Pediatric Asthma Quality of Life Questionnaire (PAQLQ, validated for persons aged 7 to 11 years); patients 4 to 6 years of age completed the PAQLQ with the help of a caregiver.<sup><a href="#core-r29" role="doc-biblioref" data-xml-rid="r29" id="body-ref-r29" href-manipulated="true" aria-label="Reference 29">29</a></sup> Scores on the ACQ-5 range from 0 to 6, with lower scores indicating better asthma control (minimum clinically important difference, −0.5 points).<sup><a href="#core-r30" role="doc-biblioref" data-xml-rid="r30" id="body-ref-r30" href-manipulated="true" aria-label="Reference 30">30</a></sup> Scores on both the AQLQ+12 and the PAQLQ range from 1 to 7, with higher scores indicating better asthma-related quality of life (minimum clinically important difference, 0.5 points).<sup><a href="#core-r31" role="doc-biblioref" data-xml-rid="r31 r32" id="body-ref-r32" href-manipulated="true">31,32</a></sup> A response was defined as a decrease (in the ACQ-5 score) or an increase (in the AQLQ+12 or PAQLQ score) of at least 0.5 points from the baseline score.</div><div role="paragraph">Safety end points were incident adverse events and incident serious adverse events. These events were assessed from the time that written informed consent (and assent, as appropriate) was obtained through the end of the safety follow-up period (2 weeks after the last in-clinic visit).</div></section><section id="sec-1-5"><h3>Statistical Analysis</h3><div role="paragraph"><a id="exam-tint-one-a"></a><a id="exam-tint-one-b"></a><a id="exam-tint-one-c"></a><a id="exam-tint-one-d"></a><span id="tint2" class="named-content" data-type="exam-tint" data-answer-ids="one-a one-b one-c one-d">The preplanned efficacy analyses were designed to answer the clinical question of interest, that is, whether budesonide, administered in a fixed-dose combination with albuterol on an as-needed basis, provides a benefit that is greater than that with as-needed use of albuterol alone in patients who continued to receive their prescribed maintenance therapy. These analyses used data that were collected during the on-treatment period before treatment discontinuation or a change in maintenance therapy; in the primary end-point analysis, data were censored at the date of treatment discontinuation or a change in maintenance therapy.<sup><a href="#core-r27" role="doc-biblioref" data-xml-rid="r27" id="body-ref-r27-4" href-manipulated="true" aria-label="Reference 27">27</a></sup> The results of an alternative, prespecified intention-to-treat analysis that was consistent with the <i>Journal’s</i> statistical guidelines and included all the data, regardless of a change in maintenance therapy or treatment discontinuation, are presented first in the article.</span> The term “preplanned” is used when referring to the primary efficacy analysis stated in the statistical analysis plan (with type 1 error control), and the term “prespecified” is used when referring to the intention-to-treat analysis.</div><div role="paragraph">According to the statistical analysis plan (available with the <a href="#ap1">protocol</a>) for the preplanned efficacy analyses, the type I error for the primary end point was controlled for comparisons between each albuterol–budesonide dose group and the albuterol-alone group with the use of the Hochberg step-up procedure. Secondary end points were controlled with the use of a hierarchical testing sequence for treatment comparisons between the higher-dose combination group and the albuterol-alone group and between the lower-dose combination group and the albuterol-alone group with respect to each secondary end point. In the alternative intention-to-treat analysis, these type 1 error control procedures were applied in this same manner as in the preplanned efficacy analyses of the primary and secondary end points.</div><div role="paragraph">We estimated that a sample of 1000 adults and adolescents per trial group and 570 first events of severe asthma exacerbation would provide the trial with 87% power to detect a 25% lower risk of severe asthma exacerbation with the fixed-dose combination of albuterol–budesonide than with albuterol alone, assuming a two-sided significance level of 5% and a probability of a first severe exacerbation event of 0.22 with the use of albuterol alone.<sup><a href="#core-r27" role="doc-biblioref" data-xml-rid="r27" id="body-ref-r27-5" href-manipulated="true" aria-label="Reference 27">27</a></sup> In addition, our aim was to recruit 100 children 4 to 11 years of age in accordance with regulatory input.</div><div role="paragraph">All patients who had undergone randomization and received any amount of a trial medication, which was classified according to the trial medication they had been assigned to receive, were included in both efficacy analyses comparing the lower-dose combination group with the albuterol-alone group. Children 4 to 11 years of age were not assigned to the higher-dose combination group. Therefore, children 4 to 11 years of age were not included in the albuterol-alone group in the comparison with the higher-dose combination group. The safety analyses included all the patients who had received any amount of a trial medication, which was classified according to the trial medication they had actually received.</div><div role="paragraph">The time-to-event analysis of the primary end point of the first severe asthma exacerbation was performed with the use of a Cox proportional-hazards regression model that adjusted for the randomization stratification factors of age group (≥4 to &lt;12, ≥12 to &lt;18, ≥18 to &lt;65, and ≥65 years), geographic region (North America, Western Europe, or South Africa vs. South America and the rest of Europe), and the number of severe asthma exacerbations in the 12 months before screening. The ratio of the hazard rates (hazard ratio) obtained in the primary end-point analysis was used as a measure of the (relative) risk of a severe asthma exacerbation event in order to make it distinct from the annualized rate of severe asthma exacerbations obtained in the secondary analysis.</div><div role="paragraph">The annualized rate of severe asthma exacerbations was analyzed with the use of a negative binomial regression model that adjusted for age, geographic region, number of severe asthma exacerbations in the 12 months before screening, and person-time at risk. Total systemic glucocorticoid exposure per patient was calculated as the annualized total dose of systemic glucocorticoids (in milligrams per year), which was analyzed with the use of a Wilcoxon rank-sum test. The response variables with respect to the ACQ-5, the AQLQ+12, and the PAQLQ at week 24 were compared among the trial groups with the use of a logistic-regression model that adjusted for baseline values, the randomization stratification factors, and the number of severe asthma exacerbations in the 12 months before screening.</div></section></section><section id="sec-2" data-type="results"><h2>Results</h2><section id="sec-2-1"><h3>Patients</h3><div role="paragraph">A total of 5620 patients were enrolled in the trial between December 27, 2018, and July 30, 2021. Among these patients, 3132 underwent randomization, 3123 were assessed with respect to the efficacy end points (5 patients who had not received any trial medication and 4 who had been withdrawn because of randomization at more than one site were excluded), and 3127 were assessed with respect to the safety end points (<a href="#f1">Figure 1</a>). Data are presented up to August 23, 2021, the time of the primary database lock; a total of 37 children and adolescents remained in the treatment phase of the trial after database lock to complete 24 weeks, and 1 adolescent remained in the 2-week safety follow-up period after database lock.</div><div class="figure-wrap" data-presentation="diminished-in-flow"><header><div class="label">Figure 1</div><nav><a href="#f1" title="Open in viewer" class="open-in-viewer" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2203163_f1.jpg"><i aria-hidden="true" class="icon-expand"></i></a></nav></header><figure id="f1" class="graphic"><a aria-label="Open figure in viewer" class="open-in-viewer" data-index="0" href="#f1" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2203163_f1.jpg"><img src="/cms/10.1056/NEJMoa2203163/asset/9aa4eec4-18e3-49aa-9cbc-666fcfd02336/assets/images/large/nejmoa2203163_f1.jpg" height="3119" width="2640" aria-labelledby="f1" loading="lazy"></a><figcaption><div class="caption">Screening, Randomization, and Analyses.</div><div class="notes"><div role="doc-footnote">All 37 patients who remained in the treatment phase of the trial after the primary database lock to complete 24 weeks across the three trial groups were children or adolescents; the 1 patient in the lower-dose combination group who remained in the 2-week safety follow-up period after the primary database lock was an adolescent.</div></div></figcaption></figure></div><div role="paragraph">The characteristics of the patients at screening are provided in <a href="#t1">Table 1</a> and Table S1. At baseline, the mean ACQ-5 score was 2.6 across the three trial groups, a result indicating poorly controlled asthma. During the trial, patients reported that the mean (±SD) percentage of days they had taken their maintenance medication was 74.7±25.6% (median, 84.6%). Adherence was similar in the three trial groups (Table S2). Overall, 39 (1.2%) of the patients had a change in maintenance therapy during the trial (see the <a href="#ap2">Supplementary Appendix</a>).</div><div class="figure-wrap" data-presentation="diminished-in-flow"><header><div class="label">Table 1</div><nav><a href="#t1" title="Open in viewer" class="open-in-viewer" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2203163_t1.jpg"><i aria-hidden="true" class="icon-expand"></i></a></nav></header><figure id="t1" class="table"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><a aria-label="Open figure in viewer" class="open-in-viewer" data-index="0" href="#t1" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2203163_t1.jpg"><img src="/cms/10.1056/NEJMoa2203163/asset/2ae32759-7283-45c1-9265-3717c530477b/assets/images/large/nejmoa2203163_t1.jpg" height="2742" width="1999" loading="lazy"></a></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1"><th class="txlx-borders" data-xml-align="left">Characteristic</th><th class="txxx-borders">Albuterol (180 μg)–<br>Budesonide (160 μg)<br>(N=1013)</th><th class="txxx-borders">Albuterol (180 μg)–<br>Budesonide (80 μg)<br>(N=1054)</th><th class="txxx-borders">Albuterol<br>(180 μg)<br>(N=1056)</th><th class="txxr-borders">All Patients<br>(N=3123)</th></tr></thead><tbody><tr data-type="row"><td class="xxlx-borders hanging03 shading">Age</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">Mean — yr</td><td class="xxxx-borders">50.6±15.1</td><td class="xxxx-borders">48.5±16.7</td><td class="xxxx-borders">49.1±17.2</td><td class="xxxr-borders">49.4±16.4</td></tr><tr data-type="row"><td class="xxlx-borders hanging13 shading">Distribution — no. (%)</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23" data-xml-align="left">≥4 to &lt;12 yr</td><td class="xxxx-borders">0</td><td class="xxxx-borders">41 (3.9)</td><td class="xxxx-borders">42 (4.0)</td><td class="xxxr-borders">83 (2.7)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23 shading" data-xml-align="left">≥12 to &lt;18 yr</td><td class="xxxx-borders shading">34 (3.4)</td><td class="xxxx-borders shading">32 (3.0)</td><td class="xxxx-borders shading">34 (3.2)</td><td class="xxxr-borders shading">100 (3.2)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23" data-xml-align="left">≥18 to &lt;65 yr</td><td class="xxxx-borders">787 (77.7)</td><td class="xxxx-borders">804 (76.3)</td><td class="xxxx-borders">783 (74.1)</td><td class="xxxr-borders">2374 (76.0)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23 shading" data-xml-align="left">≥65 yr</td><td class="xxxx-borders shading">192 (19.0)</td><td class="xxxx-borders shading">177 (16.8)</td><td class="xxxx-borders shading">197 (18.7)</td><td class="xxxr-borders shading">566 (18.1)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging03" data-xml-align="left">Female sex — no. (%)</td><td class="xxxx-borders">645 (63.7)</td><td class="xxxx-borders">685 (65.0)</td><td class="xxxx-borders">694 (65.7)</td><td class="xxxr-borders">2024 (64.8)</td></tr><tr data-type="row"><td class="xxlx-borders hanging03 shading">Race or ethnic group — no. (%)</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">White</td><td class="xxxx-borders">818 (80.8)</td><td class="xxxx-borders">847 (80.4)</td><td class="xxxx-borders">868 (82.2)</td><td class="xxxr-borders">2533 (81.1)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">Black</td><td class="xxxx-borders shading">139 (13.7)</td><td class="xxxx-borders shading">141 (13.4)</td><td class="xxxx-borders shading">137 (13.0)</td><td class="xxxr-borders shading">417 (13.4)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">Asian</td><td class="xxxx-borders">29 (2.9)</td><td class="xxxx-borders">33 (3.1)</td><td class="xxxx-borders">23 (2.2)</td><td class="xxxr-borders">85 (2.7)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">American Indian or Alaska Native</td><td class="xxxx-borders shading">1 (0.1)</td><td class="xxxx-borders shading">1 (0.1)</td><td class="xxxx-borders shading">0</td><td class="xxxr-borders shading">2 (0.1)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">Other</td><td class="xxxx-borders">26 (2.6)</td><td class="xxxx-borders">32 (3.0)</td><td class="xxxx-borders">28 (2.7)</td><td class="xxxr-borders">86 (2.8)</td></tr><tr data-type="row"><td class="xxlx-borders hanging03 shading">Hispanic or Latinx — no. (%)</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">Yes</td><td class="xxxx-borders">233 (23.0)</td><td class="xxxx-borders">260 (24.7)</td><td class="xxxx-borders">315 (29.8)</td><td class="xxxr-borders">808 (25.9)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">No</td><td class="xxxx-borders shading">780 (77.0)</td><td class="xxxx-borders shading">794 (75.3)</td><td class="xxxx-borders shading">741 (70.2)</td><td class="xxxr-borders shading">2315 (74.1)</td></tr><tr data-type="row"><td class="xxlx-borders hanging03">Geographic region — no. (%)</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">North America, Western Europe, and South Africa</td><td class="xxxx-borders shading">536 (52.9)</td><td class="xxxx-borders shading">556 (52.8)</td><td class="xxxx-borders shading">563 (53.3)</td><td class="xxxr-borders shading">1655 (53.0)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">South America and rest of Europe</td><td class="xxxx-borders">477 (47.1)</td><td class="xxxx-borders">498 (47.2)</td><td class="xxxx-borders">493 (46.7)</td><td class="xxxr-borders">1468 (47.0)</td></tr><tr data-type="row"><td class="xxlx-borders hanging03 shading">Prebronchodilator FEV<sub>1</sub></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">Mean volume — liters<a href="#t1fn2" role="doc-noteref">†</a></td><td class="xxxx-borders">1.9±0.6</td><td class="xxxx-borders">1.9 ±0.6</td><td class="xxxx-borders">1.9±0.6</td><td class="xxxr-borders">1.9±0.6</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">Mean percent of predicted value<a href="#t1fn2" role="doc-noteref">†</a></td><td class="xxxx-borders shading">63.4±12.8</td><td class="xxxx-borders shading">64.0±13.7</td><td class="xxxx-borders shading">64.4±13.3</td><td class="xxxr-borders shading">63.9±13.3</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging03" data-xml-align="left">Mean reversibility in FEV<sub>1</sub> — %<a href="#t1fn3" role="doc-noteref">‡</a></td><td class="xxxx-borders">27.7±17.2</td><td class="xxxx-borders">27.2±14.2</td><td class="xxxx-borders">27.8±15.9</td><td class="xxxr-borders">27.6±15.8</td></tr><tr data-type="row"><td class="xxlx-borders hanging03 shading">Maintenance treatment — no. (%)</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">Low-dose inhaled glucocorticoid–LABA or medium-dose inhaled glucocorticoid</td><td class="xxxx-borders">314 (31.0)</td><td class="xxxx-borders">334 (31.7)</td><td class="xxxx-borders">308 (29.2)</td><td class="xxxr-borders">956 (30.6)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">Medium-dose inhaled glucocorticoid–LABA or high-dose inhaled glucocorticoid</td><td class="xxxx-borders shading">385 (38.0)</td><td class="xxxx-borders shading">435 (41.3)</td><td class="xxxx-borders shading">441 (41.8)</td><td class="xxxr-borders shading">1261 (40.4)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">High-dose inhaled glucocorticoid–LABA</td><td class="xxxx-borders">295 (29.1)</td><td class="xxxx-borders">267 (25.3)</td><td class="xxxx-borders">285 (27.0)</td><td class="xxxr-borders">847 (27.1)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">Missing</td><td class="xxxx-borders shading">19 (1.9)</td><td class="xxxx-borders shading">18 (1.7)</td><td class="xxxx-borders shading">22 (2.1)</td><td class="xxxr-borders shading">59 (1.9)</td></tr><tr data-type="row"><td class="xxlx-borders hanging03">Severe asthma exacerbations in the 12 mo before screening — no. (%)</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">1</td><td class="xxxx-borders shading">788 (77.8)</td><td class="xxxx-borders shading">822 (78.0)</td><td class="xxxx-borders shading">840 (79.5)</td><td class="xxxr-borders shading">2450 (78.5)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">2</td><td class="xxxx-borders">185 (18.3)</td><td class="xxxx-borders">185 (17.6)</td><td class="xxxx-borders">164 (15.5)</td><td class="xxxr-borders">534 (17.1)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">3</td><td class="xxxx-borders shading">27 (2.7)</td><td class="xxxx-borders shading">38 (3.6)</td><td class="xxxx-borders shading">45 (4.3)</td><td class="xxxr-borders shading">110 (3.5)</td></tr><tr data-xml-align="center" data-type="row"><td class="xblx-borders hanging13" data-xml-align="left">≥4</td><td class="xbxx-borders">13 (1.3)</td><td class="xbxx-borders">9 (0.9)</td><td class="xbxx-borders">7 (0.7)</td><td class="xbxr-borders">29 (0.9)</td></tr></tbody></table></div><figcaption><div class="caption">Demographic and Clinical Characteristics of the Patients at Screening.<a href="#t1fn1" role="doc-noteref">*</a></div><div class="notes"><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="t1fn1" role="paragraph">Plus–minus values are means ±SD. The analysis includes 3123 patients; 5 patients who had not received any amount of a trial medication and 4 who had been withdrawn because of randomization at more than one site were excluded. Medications for rescue use were limited to the trial medications throughout the trial; additional fast-acting bronchodilators, including nebulizers, were prohibited. Additional controller medications were used by approximately 15% of the patients: approximately 10% used a leukotriene-receptor antagonist, 4% a long-acting muscarinic antagonist, and 2% a xanthine. Changes to maintenance therapy were allowed when clinically indicated (see the <a href="#ap2">Supplementary Appendix</a>). FEV<sub>1</sub> denotes forced expiratory volume in 1 second, and LABA long-acting β<sub>2</sub>-agonist.</div></div><div role="doc-footnote" data-has="label"><div class="label">†</div><div id="t1fn2" role="paragraph">The results were obtained from the visit in which the prebronchodilator FEV<sub>1</sub> was assessed for eligibility.</div></div><div role="doc-footnote" data-has="label"><div class="label">‡</div><div id="t1fn3" role="paragraph">The results were obtained from the visit in which reversibility in FEV<sub>1</sub> was assessed for eligibility. The reversibility in FEV<sub>1</sub> was calculated as the postbronchodilator FEV<sub>1</sub> (in liters) minus the prebronchodilator FEV<sub>1</sub> (in liters) divided by the prebronchodilator FEV<sub>1</sub> (in liters).</div></div></div></figcaption></figure></div></section><section id="sec-2-2"><h3>Primary End Point</h3><section id="sec-2-2-1"><h4>Intention-to-Treat Analysis</h4><div role="paragraph"><span id="tint3" class="named-content" data-type="exam-tint" data-answer-ids="one-a one-c one-d">The intention-to-treat analysis showed that the risk of a severe asthma exacerbation, in a time-to-event analysis, was significantly lower, by 26%, in the higher-dose combination group than in the albuterol-alone group (hazard ratio, 0.74; 95% confidence interval [CI], 0.62 to 0.89; P=0.001) (<a href="#f2">Figure 2A</a>). The hazard ratio in the lower-dose combination group, as compared with the albuterol-alone group, was 0.84 (95% CI, 0.71 to 1.00; P=0.052).</span> Further inferential testing was not performed, in accordance with the hierarchical testing strategy applied to this alternative, prespecified analysis to control for type I error.</div><div class="figure-wrap" data-presentation="diminished-in-flow"><header><div class="label">Figure 2</div><nav><a href="#f2" title="Open in viewer" class="open-in-viewer" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2203163_f2.jpg"><i aria-hidden="true" class="icon-expand"></i></a></nav></header><figure id="f2" class="graphic"><a aria-label="Open figure in viewer" class="open-in-viewer" data-index="0" href="#f2" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2203163_f2.jpg"><img src="/cms/10.1056/NEJMoa2203163/asset/351e096a-ce26-4ce4-867e-6b566ef5e868/assets/images/large/nejmoa2203163_f2.jpg" height="3142" width="2640" aria-labelledby="f2" loading="lazy"></a><figcaption><div class="caption">Time-to-Event Analysis of the First Event of Severe Asthma Exacerbation (Primary End Point).</div><div class="notes"><div role="doc-footnote">Data are presented for all the patients. Children 4 to 11 years of age were excluded in the comparison between the higher-dose combination group and the albuterol-alone group; therefore, the number of patients in the albuterol-alone group in this comparison (1014 patients) was lower than that in the comparison with the lower-dose combination group, in which children 4 to 11 years of age were included. The anticipated probability of a first event of severe asthma exacerbation among the patients who received albuterol alone was 0.22.</div></div></figcaption></figure></div></section><section id="sec-2-2-2"><h4>Preplanned On-Treatment Efficacy Analysis</h4><div role="paragraph">In the preplanned efficacy analysis that included data collected during the on-treatment period before treatment discontinuation or a change in maintenance therapy, the hazard ratio for severe asthma exacerbation in the higher-dose combination group, as compared with the albuterol-alone group, was 0.73 (95% CI, 0.61 to 0.88). The hazard ratio in the lower-dose combination group, as compared with the albuterol-alone group, was 0.83 (95% CI, 0.70 to 0.99) (<a href="#f2">Figure 2B</a>). The results of the preplanned time-to-event analyses of the first severe asthma exacerbation according to subgroups are provided in Figure S2.</div></section></section><section id="sec-2-3"><h3>Secondary End Points</h3><section id="sec-2-3-1"><h4>Intention-to-Treat Analysis</h4><div role="paragraph">The annualized rate of severe asthma exacerbations was 0.43 (95% CI, 0.33 to 0.58) in the higher-dose combination group and 0.58 (95% CI, 0.44 to 0.77) in the albuterol-alone group (rate ratio, 0.75; 95% CI, 0.61 to 0.91) (<a href="#t2">Table 2</a>). The annualized rate of severe asthma exacerbations was 0.48 (95% CI, 0.37 to 0.63) in the lower-dose combination group and 0.60 (95% CI, 0.46 to 0.79) in the albuterol-alone group (rate ratio, 0.81; 95% CI, 0.66 to 0.98).</div><div class="figure-wrap" data-presentation="diminished-in-flow"><header><div class="label">Table 2</div><nav><a href="#t2" title="Open in viewer" class="open-in-viewer" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2203163_t2.jpg"><i aria-hidden="true" class="icon-expand"></i></a></nav></header><figure id="t2" class="table"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><a aria-label="Open figure in viewer" class="open-in-viewer" data-index="0" href="#t2" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2203163_t2.jpg"><img src="/cms/10.1056/NEJMoa2203163/asset/495eda5d-250a-4f77-a9d5-8494e367d7c1/assets/images/large/nejmoa2203163_t2.jpg" height="2305" width="2615" loading="lazy"></a></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1"><th class="txlx-borders" data-xml-align="left">Analysis</th><th class="txxx-borders" colspan="4"><span>Intention-to-Treat Analysis</span></th><th class="txxr-borders" colspan="4"><span>Preplanned On-Treatment Efficacy Analysis</span></th></tr><tr class="head2" data-type="row head2"><td class="xxlx-borders">&nbsp;</td><th class="xxxx-borders" colspan="2"><span>Adults and Adolescents<a href="#t2fn2" role="doc-noteref">†</a></span></th><th class="xxxx-borders" data-xml-align="left" colspan="2"><span>Adults, Adolescents, and Children<a href="#t2fn3" role="doc-noteref">‡</a></span></th><th class="xxxx-borders" colspan="2"><span>Adults and Adolescents<a href="#t2fn2" role="doc-noteref">†</a></span></th><th class="xxxr-borders" data-xml-align="left" colspan="2"><span>Adults, Adolescents, and Children<a href="#t2fn3" role="doc-noteref">‡</a></span></th></tr><tr class="head2" data-type="row head2"><td class="xxlx-borders">&nbsp;</td><th class="xxxx-borders">Albuterol<br>(180 μg)–<br>Budesonide<br>(160 μg)</th><th class="xxxx-borders">Albuterol<br>(180 μg)</th><th class="xxxx-borders">Albuterol<br>(180 μg)–<br>Budesonide<br>(80 μg)</th><th class="xxxx-borders">Albuterol<br>(180 μg)<br>Alone</th><th class="xxxx-borders">Albuterol<br>(180 μg)–<br>Budesonide<br>(160 μg)</th><th class="xxxx-borders">Albuterol<br>(180 μg)</th><th class="xxxx-borders">Albuterol<br>(180 μg)–<br>Budesonide<br>(80 μg)</th><th class="xxxr-borders">Albuterol<br>(180 μg)</th></tr></thead><tbody><tr data-type="row"><td class="xxlx-borders hanging02 shading"><b>Annualized rate of severe asthma exacerbation</b></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Patients — no.</td><td class="xxxx-borders">1013</td><td class="xxxx-borders">1014</td><td class="xxxx-borders">1054</td><td class="xxxx-borders">1056</td><td class="xxxx-borders">1013</td><td class="xxxx-borders">1014</td><td class="xxxx-borders">1054</td><td class="xxxr-borders">1056</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Severe exacerbations — no.</td><td class="xxxx-borders shading">345</td><td class="xxxx-borders shading">427</td><td class="xxxx-borders shading">372</td><td class="xxxx-borders shading">441</td><td class="xxxx-borders shading">334</td><td class="xxxx-borders shading">413</td><td class="xxxx-borders shading">354</td><td class="xxxr-borders shading">426</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Annualized rate (95% CI)</td><td class="xxxx-borders">0.43 (0.33–0.58)</td><td class="xxxx-borders">0.58 (0.44–0.77)</td><td class="xxxx-borders">0.48 (0.37–0.63)</td><td class="xxxx-borders">0.60 (0.46–0.79)</td><td class="xxxx-borders">0.45 (0.34–0.60)</td><td class="xxxx-borders">0.59 (0.44–0.78)</td><td class="xxxx-borders">0.49 (0.37–0.64)</td><td class="xxxr-borders">0.61 (0.46–0.80)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Rate ratio (95% CI)</td><td class="xxxx-borders shading">0.75 (0.61–0.91)</td><td class="xxxx-borders shading">Reference</td><td class="xxxx-borders shading">0.81 (0.66–0.98)</td><td class="xxxx-borders shading">Reference</td><td class="xxxx-borders shading">0.76 (0.62–0.93)</td><td class="xxxx-borders shading">Reference</td><td class="xxxx-borders shading">0.80 (0.66–0.98)</td><td class="xxxr-borders shading">Reference</td></tr><tr data-type="row"><td class="xxlx-borders hanging02"><b>Annualized total dose of systemic glucocorticoid</b><a href="#t2fn4" role="doc-noteref">§</a></td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Patients — no.</td><td class="xxxx-borders shading">1012</td><td class="xxxx-borders shading">1011</td><td class="xxxx-borders shading">1052</td><td class="xxxx-borders shading">1052</td><td class="xxxx-borders shading">1012</td><td class="xxxx-borders shading">1011</td><td class="xxxx-borders shading">1052</td><td class="xxxr-borders shading">1052</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Median value (5th–95th percentile) — mg/yr</td><td class="xxxx-borders">0.0 (0.0–459.2)</td><td class="xxxx-borders">0.0 (0.0–484.3)</td><td class="xxxx-borders">0.0 (0.0–494.4)</td><td class="xxxx-borders">0.0 (0.0–600.8)</td><td class="xxxx-borders">0.0 (0.0–496.1)</td><td class="xxxx-borders">0.0 (0.0–622.1)</td><td class="xxxx-borders">0.0 (0.0–487.0)</td><td class="xxxr-borders">0.0 (0.0–615.9)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Mean value — mg/yr</td><td class="xxxx-borders shading">83.6±247.7</td><td class="xxxx-borders shading">130.0±630.3</td><td class="xxxx-borders shading">94.7±318.2</td><td class="xxxx-borders shading">127.6±619.8</td><td class="xxxx-borders shading">86.2±262.9</td><td class="xxxx-borders shading">129.3±657.2</td><td class="xxxx-borders shading">95.5±335.4</td><td class="xxxr-borders shading">127.1±646.2</td></tr><tr data-type="row"><td class="xxlx-borders hanging02"><b>Response analysis at wk 24</b><a href="#t2fn5" role="doc-noteref">¶</a></td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-type="row"><td class="xxlx-borders hanging02 shading">ACQ-5</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Patients — no.</td><td class="xxxx-borders">1013</td><td class="xxxx-borders">1014</td><td class="xxxx-borders">1052</td><td class="xxxx-borders">1055</td><td class="xxxx-borders">1013</td><td class="xxxx-borders">1014</td><td class="xxxx-borders">1052</td><td class="xxxr-borders">1055</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Patients with response — no. (%)</td><td class="xxxx-borders shading">682 (67.3)</td><td class="xxxx-borders shading">636 (62.7)</td><td class="xxxx-borders shading">690 (65.6)</td><td class="xxxx-borders shading">656 (62.2)</td><td class="xxxx-borders shading">677 (66.8)</td><td class="xxxx-borders shading">630 (62.1)</td><td class="xxxx-borders shading">681 (64.7)</td><td class="xxxr-borders shading">650 (61.6)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Odds ratio (95% CI)</td><td class="xxxx-borders">1.22 (1.01–1.46)</td><td class="xxxx-borders">Reference</td><td class="xxxx-borders">1.15 (0.96–1.37)</td><td class="xxxx-borders">Reference</td><td class="xxxx-borders">1.22 (1.02–1.47)</td><td class="xxxx-borders">Reference</td><td class="xxxx-borders">1.13 (0.95–1.35)</td><td class="xxxr-borders">Reference</td></tr><tr data-type="row"><td class="xxlx-borders hanging02 shading">AQLQ+12</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Patients — no.</td><td class="xxxx-borders">994</td><td class="xxxx-borders">993</td><td class="xxxx-borders">987</td><td class="xxxx-borders">NA</td><td class="xxxx-borders">994</td><td class="xxxx-borders">993</td><td class="xxxx-borders">987</td><td class="xxxr-borders">NA</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Patients with response — no. (%)</td><td class="xxxx-borders shading">515 (51.8)</td><td class="xxxx-borders shading">464 (46.7)</td><td class="xxxx-borders shading">496 (50.3)</td><td class="xxxx-borders shading">NA</td><td class="xxxx-borders shading">508 (51.1)</td><td class="xxxx-borders shading">461 (46.4)</td><td class="xxxx-borders shading">489 (49.5)</td><td class="xxxr-borders shading">NA</td></tr><tr data-xml-align="center" data-type="row"><td class="xblx-borders hanging12" data-xml-align="left">Odds ratio (95% CI)</td><td class="xbxx-borders">1.25 (1.04–1.50)</td><td class="xbxx-borders">Reference</td><td class="xbxx-borders">1.13 (0.94–1.36)</td><td class="xbxx-borders">NA</td><td class="xbxx-borders">1.23 (1.02–1.48)</td><td class="xbxx-borders">Reference</td><td class="xbxx-borders">1.11 (0.93–1.34)</td><td class="xbxr-borders">NA</td></tr></tbody></table></div><figcaption><div class="caption">Intention-to-Treat and Preplanned On-Treatment Efficacy Analyses of the Secondary End Points.<a href="#t2fn1" role="doc-noteref">*</a></div><div class="notes"><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="t2fn1" role="paragraph">Plus–minus values are means ±SD. The hierarchical testing procedure was stopped after the comparison between the lower-dose combination group and the albuterol-alone group in the intention-to-treat analysis of the primary end point; therefore, 95% confidence intervals cannot be used to infer treatment effects. A total of 3123 patients were assessed with respect to the efficacy end points (5 patients who had not received any trial medication and 4 who had been withdrawn because of randomization at more than one site were excluded). The comparisons between the higher-dose combination group and the albuterol-alone group excluded children 4 to 11 years of age; therefore, the number of patients in the albuterol-alone group in these comparisons was less than that in the comparisons between the lower-dose combination group and the albuterol-alone group. NA denotes not applicable.</div></div><div role="doc-footnote" data-has="label"><div class="label">†</div><div id="t2fn2" role="paragraph">Analyses included patients 12 years of age or older.</div></div><div role="doc-footnote" data-has="label"><div class="label">‡</div><div id="t2fn3" role="paragraph">Analyses included patients 4 years of age or older, except for the Asthma Control Questionnaire–5 (ACQ-5) response analysis, in which patients 4 and 5 years of age were excluded, and the Asthma Quality of Life Questionnaire (AQLQ+12) response analysis, in which patients 4 to 11 years of age were excluded.</div></div><div role="doc-footnote" data-has="label"><div class="label">§</div><div id="t2fn4" role="paragraph">The annualized total dose of systemic glucocorticoid is given in prednisone equivalents.</div></div><div role="doc-footnote" data-has="label"><div class="label">¶</div><div id="t2fn5" role="paragraph">Intention-to-treat analyses for the ACQ-5 response and the AQLQ+12 response are post hoc. Scores on the ACQ-5 range from 0 to 6, with lower scores indicating better asthma control (minimum clinically important difference, 0.5 points). Scores on the AQLQ+12 range from 1 to 7, with higher scores indicating better asthma-related quality of life (minimum clinically important difference, 0.5 points). A response was defined as a decrease (in the ACQ-5 score) or an increase (in the AQLQ+12 score) of at least 0.5 points from the baseline score.</div></div></div></figcaption></figure></div><div role="paragraph">The mean (±SD) annualized total dose of systemic glucocorticoid (in prednisone equivalents) was 83.6±247.7 mg in the higher-dose combination group and 130.0±630.3 mg in the albuterol-alone group. The mean annualized total dose of systemic glucocorticoid was 94.7±318.2 mg in the lower-dose combination group and 127.6±619.8 mg in the albuterol-alone group. Post hoc results of the intention-to-treat analyses of response on the ACQ-5 and the AQLQ+12 are provided in <a href="#t2">Table 2</a>.</div></section><section id="sec-2-3-2"><h4>Preplanned On-Treatment Efficacy Analysis</h4><div role="paragraph">The annualized rate of severe asthma exacerbations was 0.45 (95% CI, 0.34 to 0.60) in the higher-dose combination group and 0.59 (95% CI, 0.44 to 0.78) in the albuterol-alone group (rate ratio, 0.76; 95% CI, 0.62 to 0.93). The annualized rate of severe asthma exacerbations was 0.49 (95% CI, 0.37 to 0.64) in the lower-dose combination group and 0.61 (95% CI, 0.46 to 0.80) in the albuterol-alone group (rate ratio, 0.80; 95% CI, 0.66 to 0.98) (<a href="#t2">Table 2</a>). The number of patients with at least one severe asthma exacerbation that led to hospitalization was 9 in the higher-dose combination group, 10 in the lower-dose combination group, and 17 in the albuterol-alone group (Table S3). The number of patients with at least one severe asthma exacerbation that led to emergency department or urgent care visits was 49 in the higher-dose combination group, 50 in the lower-dose combination group, and 66 in the albuterol-alone group.</div><div role="paragraph">The mean annualized total dose of systemic glucocorticoid (in prednisone equivalents) was 86.2±262.9 mg in the higher-dose combination group and 129.3±657.2 mg in the albuterol-alone group (<a href="#t2">Table 2</a>). The mean annualized total dose of systemic glucocorticoid was 95.5±335.4 mg in the lower-dose combination group and 127.1±646.2 mg in the albuterol-alone group.</div><div role="paragraph">At week 24, a response on the ACQ-5 (i.e., a decrease of at least 0.5 points from the baseline score) was observed in 66.8% of the patients in the higher-dose combination group and in 62.1% of those in the albuterol-alone group, for an odds ratio of 1.22 (95% CI, 1.02 to 1.47). A response on the ACQ-5 was observed in 64.7% of the patients in the lower-dose combination group and in 61.6% of those in the albuterol-alone group, for an odds ratio of 1.13 (95% CI, 0.95 to 1.35). A response on the AQLQ+12 at week 24 (i.e., an increase of at least 0.5 points from the baseline score) was observed in 51.1% of the patients in the higher-dose combination group, in 49.5% of those in the lower-dose combination group, and in 46.4% of those in the albuterol-alone group, for an odds ratio of 1.23 (95% CI, 1.02 to 1.48) in the comparison between the higher-dose combination group and the albuterol-alone group and an odds ratio of 1.11 (95% CI, 0.93 to 1.34) in the comparison between the lower-dose combination group and the albuterol-alone group. The results of the ACQ-5, AQLQ+12, and PAQLQ response analyses are provided in <a href="#t2">Table 2</a> and Table S4. The results with respect to the preplanned exploratory end points of prebronchodilator FEV<sub>1</sub>, morning and evening peak expiratory flow, and daytime and night-time symptoms of asthma are summarized in the <a href="#ap2">Supplementary Appendix</a>.</div></section></section><section id="sec-2-4"><h3>Trial Medication Use</h3><div role="paragraph">The overall pattern of as-needed use of trial medications was similar in the three trial groups, with increased use around the time of clinical deterioration of asthma (Fig. S3). Patients reported using 2 or fewer inhalations on the majority of trial days (mean percentage of days with ≤2 inhalations: 53.7% in the higher-dose combination group, 52.6% in the lower-dose combination group, and 51.0% in the albuterol-alone group), and patients reported using more than 8 inhalations on less than 2% of trial days (Fig. S4). Average daily as-needed use was similar in the three trial groups, with a mean of 2.6 inhalations per day in the higher-dose combination group, 2.7 inhalations per day in the lower-dose combination group, and 2.8 inhalations per day in the albuterol-alone group, which is equal to approximately 1.3, 1.3, and 1.4 doses, respectively, of trial medication per day.</div></section><section id="sec-2-5"><h3>Safety End Points</h3><div role="paragraph"><a id="exam-tint-two-c"></a><a id="exam-tint-two-d"></a><span id="tint4" class="named-content" data-type="exam-tint" data-answer-ids="two-c two-d">The percentage of patients with any adverse event was similar in the three trial groups: 46.2% in the higher-dose combination group, 47.1% in the lower-dose combination group, and 46.4% in the albuterol-alone group (Table S5). The percentage of patients with serious adverse events, including deaths, was 5.2% in the higher-dose combination group, 3.8% in the lower-dose combination group, and 4.5% in the albuterol-alone group. The percentage of patients with adverse events leading to discontinuation of the trial medication was 1.0% in the higher-dose combination group, 0.9% in the lower-dose combination group, and 0.9% in the albuterol-alone group.</span> Seven patients had died — four in the higher-dose combination group (two from coronavirus disease 2019 [Covid-19], one from an elevated glucose level, and one from cardiac arrest), two in the lower-dose combination group (one from Covid-19 and one from lung metastasis with pneumothorax), and one in the albuterol-alone group (from Covid-19). <a id="exam-tint-two-a"></a><span id="tint5" class="named-content" data-type="exam-tint" data-answer-ids="two-a">No deaths were considered by the trial investigators to be related to the trial medication.</span></div><div role="paragraph">The most common adverse events were nasopharyngitis, headache, and upper respiratory tract infections; Covid-19 was recorded in 4.2 to 4.9% of patients (<a href="#t3">Table 3</a>). The percentage of patients with adverse events associated with the use of inhaled glucocorticoids was similar in the three trial groups, ranging from 1.3% in the albuterol-alone group to 2.0% in the higher-dose combination group (Table S6). <a id="exam-tint-two-b"></a><span id="tint6" class="named-content" data-type="exam-tint" data-answer-ids="two-b">The three most common adverse events associated with the use of inhaled glucocorticoids were oral candidiasis (1.0% in the higher-dose combination group, 0.9% in the lower-dose combination group, and 0.5% in the albuterol-alone group), dysphonia (0.4%, 0.6%, and 0.4%, respectively), and oropharyngeal candidiasis (0.3%, 0.3%, and 0.1%, respectively).</span></div><div class="figure-wrap" data-presentation="diminished-in-flow"><header><div class="label">Table 3</div><nav><a href="#t3" title="Open in viewer" class="open-in-viewer" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2203163_t3.jpg"><i aria-hidden="true" class="icon-expand"></i></a></nav></header><figure id="t3" class="table"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><a aria-label="Open figure in viewer" class="open-in-viewer" data-index="0" href="#t3" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2203163_t3.jpg"><img src="/cms/10.1056/NEJMoa2203163/asset/a0bd2a6a-b6e8-4ac6-8563-34b2cb1ab4aa/assets/images/large/nejmoa2203163_t3.jpg" height="1080" width="1711" loading="lazy"></a></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1"><th class="txlx-borders" data-xml-align="left">Event</th><th class="txxx-borders">Albuterol (180 μg)–<br>Budesonide (160 μg)<br>(N=1015)</th><th class="txxx-borders">Albuterol (180 μg)–<br>Budesonide (80 μg)<br>(N=1055)</th><th class="txxr-borders">Albuterol<br>(180 μg)<br>(N=1057)</th></tr><tr class="head3" data-type="row head3"><td class="xxlx-borders">&nbsp;</td><th class="xxxr-borders" colspan="3"><span>number of patients (percent)</span></th></tr></thead><tbody><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01 shading" data-xml-align="left">Any adverse event</td><td class="xxxx-borders shading">469 (46.2)</td><td class="xxxx-borders shading">497 (47.1)</td><td class="xxxr-borders shading">490 (46.4)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01" data-xml-align="left">Nasopharyngitis</td><td class="xxxx-borders">76 (7.5)</td><td class="xxxx-borders">61 (5.8)</td><td class="xxxr-borders">54 (5.1)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01 shading" data-xml-align="left">Headache</td><td class="xxxx-borders shading">44 (4.3)</td><td class="xxxx-borders shading">50 (4.7)</td><td class="xxxr-borders shading">50 (4.7)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01" data-xml-align="left">Covid-19</td><td class="xxxx-borders">43 (4.2)</td><td class="xxxx-borders">52 (4.9)</td><td class="xxxr-borders">46 (4.4)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01 shading" data-xml-align="left">Upper respiratory tract infection</td><td class="xxxx-borders shading">26 (2.6)</td><td class="xxxx-borders shading">31 (2.9)</td><td class="xxxr-borders shading">26 (2.5)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01" data-xml-align="left">Bronchitis</td><td class="xxxx-borders">25 (2.5)</td><td class="xxxx-borders">27 (2.6)</td><td class="xxxr-borders">28 (2.6)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01 shading" data-xml-align="left">Hypertension</td><td class="xxxx-borders shading">22 (2.2)</td><td class="xxxx-borders shading">27 (2.6)</td><td class="xxxr-borders shading">26 (2.5)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01" data-xml-align="left">Asthma</td><td class="xxxx-borders">18 (1.8)</td><td class="xxxx-borders">20 (1.9)</td><td class="xxxr-borders">35 (3.3)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01 shading" data-xml-align="left">Back pain</td><td class="xxxx-borders shading">27 (2.7)</td><td class="xxxx-borders shading">23 (2.2)</td><td class="xxxr-borders shading">20 (1.9)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01" data-xml-align="left">Influenza</td><td class="xxxx-borders">21 (2.1)</td><td class="xxxx-borders">23 (2.2)</td><td class="xxxr-borders">14 (1.3)</td></tr><tr data-xml-align="center" data-type="row"><td class="xblx-borders hanging01 shading" data-xml-align="left">Sinusitis</td><td class="xbxx-borders shading">15 (1.5)</td><td class="xbxx-borders shading">17 (1.6)</td><td class="xbxr-borders shading">24 (2.3)</td></tr></tbody></table></div><figcaption><div class="caption">Adverse Events Occurring in at Least 2% of Patients in Any Trial Group.<a href="#t3fn1" role="doc-noteref">*</a></div><div class="notes"><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="t3fn1" role="paragraph">Adverse events are sorted in decreasing total frequency of preferred term in the <i>Medical Dictionary for Regulatory Activities</i>, version 24.0. Patients with multiple events in the same category are counted only once in that category.</div></div></div></figcaption></figure></div></section></section><section id="sec-3" data-type="discussion"><h2>Discussion</h2><div role="paragraph">Among patients with uncontrolled moderate-to-severe asthma who were receiving inhaled glucocorticoid-containing maintenance therapy, the risk of severe asthma exacerbation was significantly lower with a fixed-dose combination of 180 μg of albuterol and 160 μg of budesonide, administered on an as-needed basis in two actuations of 90 μg and 80 μg, respectively, than with as-needed albuterol alone. The results were similar in the intention-to-treat analysis and in the analysis that included data collected during the on-treatment period before treatment discontinuation or a change in maintenance therapy. <span id="tint7" class="named-content" data-type="exam-tint" data-answer-ids="one-b">The findings in both analyses showed that the annualized rate of severe asthma exacerbations was numerically lower with each albuterol–budesonide dose than with albuterol and that the mean total systemic glucocorticoid exposure among the patients in the higher-dose combination group was numerically lower than that in the albuterol-alone group.</span> Both doses of albuterol–budesonide had an acceptable safety profile that was consistent with that of the active components, with no safety concerns identified.</div><div role="paragraph">The pattern of rescue use of the trial medications was similar in the three trial groups, as assessed on the basis of the percentage of trial days with rescue use and use around the time of clinical deterioration of asthma, which was increased in all three groups. The finding of a mean number of medication doses per day of less than 1.5 across the three trial groups shows that the patients used the albuterol–budesonide combination as they used albuterol alone. Unlike albuterol monotherapy, the fixed-dose combination allows patients to adjust the dose of inhaled glucocorticoid according to their own symptom-driven use of a bronchodilator in response to worsening asthma episodes.</div><div role="paragraph">The findings from the MANDALA trial with respect to a reduction in the risk of exacerbations are consistent with those from previous trials of the inclusion of an inhaled glucocorticoid when rescue medication is taken, as shown in a trial of as-needed use of albuterol–beclomethasone as compared with as-needed use of albuterol alone in patients with mild asthma<sup><a href="#core-r33" role="doc-biblioref" data-xml-rid="r33" id="body-ref-r33" href-manipulated="true" aria-label="Reference 33">33</a></sup> and in a more recent real-world, open-label trial of a free combination of beclomethasone in addition to a rescue medication in Black patients and Latinx patients with uncontrolled moderate-to-severe asthma.<sup><a href="#core-r34" role="doc-biblioref" data-xml-rid="r34" id="body-ref-r34" href-manipulated="true" aria-label="Reference 34">34</a></sup> Similarly, multiple trials that evaluated the single maintenance and reliever therapy (SMART) strategy, in which the same agents (budesonide plus formoterol) used as maintenance therapy are used as rescue therapy, as compared with rescue therapy with a SABA in addition to budesonide plus formoterol as maintenance therapy, showed a reduction in the risk of exacerbation in patients with moderate-to-severe asthma.<sup><a href="#core-r12" role="doc-biblioref" data-xml-rid="r12 r22 r35" id="body-ref-r35" href-manipulated="true">12,22,35</a></sup> The use of albuterol–budesonide as rescue medication in the current trial addresses the limited data regarding the rescue use of inhaled glucocorticoid–formoterol, for which data are lacking in patients receiving maintenance treatment with an alternative inhaled glucocorticoid–long-acting β<sub>2</sub>-agonist combination or inhaled glucocorticoid alone. Given the risks and limitations of SABA alone as rescue therapy, national and international recommendations call for an inhaled glucocorticoid-containing rescue medication as the preferred as-needed treatment; the data from this trial support that approach. Given its acceptable safety profile, the greater efficacy of the fixed-dose combination than of albuterol alone, as well as the absence of a need to change underlying maintenance therapy, indicates that this fixed-dose combination could replace SABA alone as rescue therapy in patients with moderate-to-severe asthma.</div><div role="paragraph"><a id="exam-tint-three-a"></a><a id="exam-tint-three-c"></a><a id="exam-tint-three-d"></a><span id="tint8" class="named-content" data-type="exam-tint" data-answer-ids="three-a three-c three-d">The strengths of our trial are the low dropout rate, with 93% of the patients completing at least 24 weeks of the treatment period, despite the trial having been conducted during the global Covid-19 pandemic, and the multinational and double-blind trial design, which increased external and internal validity, respectively. Albuterol–budesonide was used in addition to the usual maintenance therapy the patients were receiving, which included a range of inhaled glucocorticoid-containing medications, with the aim of reflecting a real-world population and improving the generalizability of our results. The limitations of our trial are the lack of measurements of the fraction of exhaled nitric oxide level, which would have allowed for a direct assessment of antiinflammatory effects; the small number of children, which precludes conclusions being drawn in this important subpopulation; and the fact that growth indexes could not be assessed because of the small numbers and short period of observation of children in this trial.</span></div><div role="paragraph">In the current phase 3 trial involving patients with uncontrolled moderate-to-severe asthma, the risk of severe asthma exacerbation was significantly lower with as-needed use of a fixed-dose combination of 180 μg of albuterol and 160 μg of budesonide than with as-needed use of albuterol alone.</div></section>



        
        
</div></section><section id="backmatter" data-extent="backmatter" data-location="articleTab_article"><div class="core-container"><section id="backnotes" data-location="notes_article"><h2>Notes</h2><div data-type="published/updated" role="paragraph">This article was published on May 15, 2022, at NEJM.org.</div><div data-type="data-sharing" role="paragraph">A <a href="#ap4">data sharing statement</a> provided by the authors is available with the full text of this article at NEJM.org.</div><div role="paragraph">Supported by <span class="named-content" data-type="funder">Avillion</span>.</div><div role="paragraph"><a href="#ap3">Disclosure forms</a> provided by the authors are available with the full text of this article at NEJM.org.</div><div role="paragraph">We thank the trial patients and their families; the investigators and staff at the trial sites; the team at Syneos Health and Phastar; the members of the independent data and safety monitoring committee; the full clinical team at Avillion and AstraZeneca; and Marco E. Favretto and Samantha Blakemore at inScience Communications, Springer Healthcare, United Kingdom, for providing medical writing support (funded by AstraZeneca).</div></section><section id="supplementary-materials" class="core-supplementary-materials"><h2>Supplementary Material</h2><div role="list"><div id="ap0" class="core-supplementary-material" role="listitem"><div class="core-description"><span class="core-label">Research Summary</span> <span class="core-filename">(nejmoa2203163_research-summary.pdf)</span></div><div class="core-link"><ul><li><a href="/doi/suppl/10.1056/NEJMoa2203163/suppl_file/nejmoa2203163_research-summary.pdf" download="nejmoa2203163_research-summary.pdf" data-interactiontype="multimedia_download" data-multimedia-type="Supplementary Material" data-behavior="trackDownloadEvent" data-multimedia-filename="nejmoa2203163_research-summary.pdf" data-doi="10.1056/NEJMoa2203163">Download</a></li><li>410.43 KB</li></ul></div></div><div id="ap1" class="core-supplementary-material" role="listitem"><div class="core-description"><span class="core-label">Protocol</span> <span class="core-filename">(nejmoa2203163_protocol.pdf)</span></div><div class="core-link"><ul><li><a href="/doi/suppl/10.1056/NEJMoa2203163/suppl_file/nejmoa2203163_protocol.pdf" download="nejmoa2203163_protocol.pdf" data-interactiontype="multimedia_download" data-multimedia-type="Supplementary Material" data-behavior="trackDownloadEvent" data-multimedia-filename="nejmoa2203163_protocol.pdf" data-doi="10.1056/NEJMoa2203163">Download</a></li><li>13.82 MB</li></ul></div></div><div id="ap2" class="core-supplementary-material" role="listitem"><div class="core-description"><span class="core-label">Supplementary Appendix</span> <span class="core-filename">(nejmoa2203163_appendix.pdf)</span></div><div class="core-link"><ul><li><a href="/doi/suppl/10.1056/NEJMoa2203163/suppl_file/nejmoa2203163_appendix.pdf" download="nejmoa2203163_appendix.pdf" data-interactiontype="multimedia_download" data-multimedia-type="Supplementary Material" data-behavior="trackDownloadEvent" data-multimedia-filename="nejmoa2203163_appendix.pdf" data-doi="10.1056/NEJMoa2203163">Download</a></li><li>1.23 MB</li></ul></div></div><div id="ap3" class="core-supplementary-material" role="listitem"><div class="core-description"><span class="core-label">Disclosure Forms</span> <span class="core-filename">(nejmoa2203163_disclosures.pdf)</span></div><div class="core-link"><ul><li><a href="/doi/suppl/10.1056/NEJMoa2203163/suppl_file/nejmoa2203163_disclosures.pdf" download="nejmoa2203163_disclosures.pdf" data-interactiontype="multimedia_download" data-multimedia-type="Supplementary Material" data-behavior="trackDownloadEvent" data-multimedia-filename="nejmoa2203163_disclosures.pdf" data-doi="10.1056/NEJMoa2203163">Download</a></li><li>633.75 KB</li></ul></div></div><div id="ap4" class="core-supplementary-material" role="listitem"><div class="core-description"><span class="core-label">Data Sharing Statement</span> <span class="core-filename">(nejmoa2203163_data-sharing.pdf)</span></div><div class="core-link"><ul><li><a href="/doi/suppl/10.1056/NEJMoa2203163/suppl_file/nejmoa2203163_data-sharing.pdf" download="nejmoa2203163_data-sharing.pdf" data-interactiontype="multimedia_download" data-multimedia-type="Supplementary Material" data-behavior="trackDownloadEvent" data-multimedia-filename="nejmoa2203163_data-sharing.pdf" data-doi="10.1056/NEJMoa2203163">Download</a></li><li>70.00 KB</li></ul></div></div></div></section><section id="bibliography" class="core-reference-list" role="doc-bibliography" data-location="references_article"><h2>References</h2><div role="list" data-method="clamp" id="collapsible-text"><div role="listitem" data-has="label"><div class="label">1.</div><div id="r1" class="citations"><div class="citation"><div class="citation-content">Global Initiative for Asthma. Global strategy for asthma management and prevention. 2022 (<a href="https://ginasthma.org/gina-reports/">https://ginasthma.org/gina-reports/</a>).</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r1" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Global+strategy+for+asthma+management+and+prevention&amp;publication_year=2022" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r1" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r1-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] yet fluctuating, airway inflammation. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r4-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] effect on underlying airway inflammation, </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r16" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>c [...] led the Global Initiative for Asthma (GINA) </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r1-4" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>d [...] -agonist combination, as defined by GINA, </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">2.</div><div id="r2" class="citations"><div class="citation"><div class="citation-content">O’Byrne PM, Jenkins C, Bateman ED. The paradoxes of asthma management: time for a new approach? <em>Eur Respir J</em> 2017;50:1701103-1701103.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r3"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1183/13993003.01103-2017" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/28889114/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000410089300024" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=The+paradoxes+of+asthma+management%3A+time+for+a+new+approach%3F&amp;publication_year=2017&amp;journal=Eur+Respir+J&amp;pages=1701103-1701103&amp;doi=10.1183%2F13993003.01103-2017&amp;pmid=28889114" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">3.</div><div id="r3" class="citations"><div class="citation"><div class="citation-content">Reddel HK, FitzGerald JM, Bateman ED, et al. GINA 2019: a fundamental change in asthma management: treatment of asthma with short-acting bronchodilators alone is no longer recommended for adults and adolescents. <em>Eur Respir J</em> 2019;53:1901046-1901046.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r3"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1183/13993003.01046-2019" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/31249014/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000474194800043" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=GINA+2019%3A+a+fundamental+change+in+asthma+management%3A+treatment+of+asthma+with+short-acting+bronchodilators+alone+is+no+longer+recommended+for+adults+and+adolescents.&amp;publication_year=2019&amp;journal=Eur+Respir+J&amp;pages=1901046-1901046&amp;doi=10.1183%2F13993003.01046-2019&amp;pmid=31249014" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">4.</div><div id="r4" class="citations"><div class="citation"><div class="citation-content">2020 focused updates to the asthma management guidelines: a report from the National Asthma Education and Prevention Program Coordinating Committee Expert Panel Working Group. 2020 (<a href="https://www.nhlbi.nih.gov/health-topics/all-publications-and-resources/2020-focused-updates-asthma-management-guidelines">https://www.nhlbi.nih.gov/health-topics/all-publications-and-resources/2020-focused-updates-asthma-management-guidelines</a>).</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r4" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=2020+focused+updates+to+the+asthma+management+guidelines%3A+a+report+from+the+National+Asthma+Education+and+Prevention+Program+Coordinating+Committee+Expert+Panel+Working+Group&amp;publication_year=2020" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r4" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r4-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] effect on underlying airway inflammation, </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r17" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] Asthma Education and Prevention Program </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r23" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>c [...] Drug Administration in the United States. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">5.</div><div id="r5" class="citations"><div class="citation"><div class="citation-content">Bloom CI, Cabrera C, Arnetorp S, et al. Asthma-related health outcomes associated with short-acting β<sub>2</sub>-agonist inhaler use: an observational UK study as part of the SABINA Global Program. <em>Adv Ther</em> 2020;37:4190-4208.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r10"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1007/s12325-020-01444-5" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32720299/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000552933100001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Asthma-related+health+outcomes+associated+with+short-acting+%CE%B22-agonist+inhaler+use%3A+an+observational+UK+study+as+part+of+the+SABINA+Global+Program.&amp;publication_year=2020&amp;journal=Adv+Ther&amp;pages=4190-4208&amp;doi=10.1007%2Fs12325-020-01444-5&amp;pmid=32720299" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">6.</div><div id="r6" class="citations"><div class="citation"><div class="citation-content">Lugogo N, Gilbert I, Tkacz J, Gandhi H, Goshi N, Lanz MJ. Real-world patterns and implications of short-acting β<sub>2</sub>-agonist use in patients with asthma in the United States. <em>Ann Allergy Asthma Immunol</em> 2021;126(6):681-689.e1.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r10"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.anai.2021.01.024" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/33515710/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000663638900012" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Real-world+patterns+and+implications+of+short-acting+%CE%B22-agonist+use+in+patients+with+asthma+in+the+United+States.&amp;publication_year=2021&amp;journal=Ann+Allergy+Asthma+Immunol&amp;pages=681-689.e1&amp;doi=10.1016%2Fj.anai.2021.01.024&amp;pmid=33515710" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">7.</div><div id="r7" class="citations"><div class="citation"><div class="citation-content">Nwaru BI, Ekström M, Hasvold P, Wiklund F, Telg G, Janson C. Overuse of short-acting β<sub>2</sub>-agonists in asthma is associated with increased risk of exacerbation and mortality: a nationwide cohort study of the global SABINA programme. <em>Eur Respir J</em> 2020;55:1901872-1901872.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r10"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1183/13993003.01872-2019" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/31949111/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000531099900018" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Overuse+of+short-acting+%CE%B22-agonists+in+asthma+is+associated+with+increased+risk+of+exacerbation+and+mortality%3A+a+nationwide+cohort+study+of+the+global+SABINA+programme.&amp;publication_year=2020&amp;journal=Eur+Respir+J&amp;pages=1901872-1901872&amp;doi=10.1183%2F13993003.01872-2019&amp;pmid=31949111" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">8.</div><div id="r8" class="citations"><div class="citation"><div class="citation-content">Bateman ED, Price DB, Wang HC, et al. Short-acting β<sub>2</sub>-agonist prescriptions are associated with poor clinical outcomes of asthma: the multi-country, cross-sectional SABINA III study. <em>Eur Respir J</em> 2021 September 24 (Epub ahead of print).</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r8" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/34561293/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000830088400010" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Short-acting+%CE%B22-agonist+prescriptions+are+associated+with+poor+clinical+outcomes+of+asthma%3A+the+multi-country%2C+cross-sectional+SABINA+III+study.&amp;publication_year=2021&amp;journal=Eur+Respir+J&amp;pmid=34561293" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r8" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r10" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] risk of severe asthma exacerbation. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r23" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] Drug Administration in the United States. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">9.</div><div id="r9" class="citations"><div class="citation"><div class="citation-content">Janson C, Menzies-Gow A, Nan C, et al. SABINA: an overview of short-acting β<sub>2</sub>-agonist use in asthma in European countries. <em>Adv Ther</em> 2020;37:1124-1135.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r10"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1007/s12325-020-01233-0" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/31981105/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000509236800004" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=SABINA%3A+an+overview+of+short-acting+%CE%B22-agonist+use+in+asthma+in+European+countries.&amp;publication_year=2020&amp;journal=Adv+Ther&amp;pages=1124-1135&amp;doi=10.1007%2Fs12325-020-01233-0&amp;pmid=31981105" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">10.</div><div id="r10" class="citations"><div class="citation"><div class="citation-content">Quint JK, Arnetorp S, Kocks JWH, et al. Short-acting β<sub>2</sub>-agonist exposure and severe asthma exacerbations: SABINA findings from Europe and North America. <em>J Allergy Clin Immunol Pract</em> 2022 March 29 (Epub ahead of print).</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r10"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.jaip.2022.02.047" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/35364341/" target="_blank">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Short-acting+%CE%B22-agonist+exposure+and+severe+asthma+exacerbations%3A+SABINA+findings+from+Europe+and+North+America.&amp;publication_year=2022&amp;journal=J+Allergy+Clin+Immunol+Pract&amp;doi=10.1016%2Fj.jaip.2022.02.047&amp;pmid=35364341" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">11.</div><div id="r11" class="citations"><div class="citation"><div class="citation-content">O’Byrne P, Fabbri LM, Pavord ID, Papi A, Petruzzelli S, Lange P. Asthma progression and mortality: the role of inhaled corticosteroids. <em>Eur Respir J</em> 2019;54:1900491-1900491.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r14-1"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1183/13993003.00491-2019" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/31048346/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000486537500034" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Asthma+progression+and+mortality%3A+the+role+of+inhaled+corticosteroids.&amp;publication_year=2019&amp;journal=Eur+Respir+J&amp;pages=1900491-1900491&amp;doi=10.1183%2F13993003.00491-2019&amp;pmid=31048346" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">12.</div><div id="r12" class="citations"><div class="citation"><div class="citation-content">Rabe KF, Atienza T, Magyar P, Larsson P, Jorup C, Lalloo UG. Effect of budesonide in combination with formoterol for reliever therapy in asthma exacerbations: a randomised controlled, double-blind study. <em>Lancet</em> 2006;368:744-753.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r12" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S0140-6736(06)69284-2" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/16935685/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000240240200026" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Effect+of+budesonide+in+combination+with+formoterol+for+reliever+therapy+in+asthma+exacerbations%3A+a+randomised+controlled%2C+double-blind+study.&amp;publication_year=2006&amp;journal=Lancet&amp;pages=744-753&amp;doi=10.1016%2FS0140-6736%2806%2969284-2&amp;pmid=16935685" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r12" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r14-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] patients with a range of asthma severity </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r35" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] in patients with moderate-to-severe asthma. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">13.</div><div id="r13" class="citations"><div class="citation"><div class="citation-content">Rogliani P, Ritondo BL, Ora J, Cazzola M, Calzetta L. SMART and as-needed therapies in mild-to-severe asthma: a network meta-analysis. <em>Eur Respir J</em> 2020;56:2000625-2000625.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r13" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1183/13993003.00625-2020" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32430423/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000571572000019" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=SMART+and+as-needed+therapies+in+mild-to-severe+asthma%3A+a+network+meta-analysis.&amp;publication_year=2020&amp;journal=Eur+Respir+J&amp;pages=2000625-2000625&amp;doi=10.1183%2F13993003.00625-2020&amp;pmid=32430423" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r13" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r14-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] patients with a range of asthma severity </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r22-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] had been using for maintenance therapy. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">14.</div><div id="r14" class="citations"><div class="citation"><div class="citation-content">Sobieraj DM, Weeda ER, Nguyen E, et al. Association of inhaled corticosteroids and long-acting β-agonists as controller and quick relief therapy with exacerbations and symptom control in persistent asthma: a systematic review and meta-analysis. <em>JAMA</em> 2018;319:1485-1496.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r14" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1001/jama.2018.2769" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/29554195/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000429590200017" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Association+of+inhaled+corticosteroids+and+long-acting+%CE%B2-agonists+as+controller+and+quick+relief+therapy+with+exacerbations+and+symptom+control+in+persistent+asthma%3A+a+systematic+review+and+meta-analysis.&amp;publication_year=2018&amp;journal=JAMA&amp;pages=1485-1496&amp;doi=10.1001%2Fjama.2018.2769&amp;pmid=29554195" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r14" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r14-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] patients with a range of asthma severity </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r22-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] had been using for maintenance therapy. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">15.</div><div id="r15" class="citations"><div class="citation"><div class="citation-content">Global Initiative for Asthma. Global strategy for asthma management and prevention. 2019 (<a href="https://ginasthma.org/wp-content/uploads/2019/06/GINA-2019-main-report-June-2019-wms.pdf">https://ginasthma.org/wp-content/uploads/2019/06/GINA-2019-main-report-June-2019-wms.pdf</a>).</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r16"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Global+strategy+for+asthma+management+and+prevention&amp;publication_year=2019" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">16.</div><div id="r16" class="citations"><div class="citation"><div class="citation-content">Reddel HK, Bacharier LB, Bateman ED, et al. Global Initiative for Asthma Strategy 2021: executive summary and rationale for key changes. <em>Am J Respir Crit Care Med</em> 2022;205:17-35.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r16"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1164/rccm.202109-2205PP" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/34658302/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000738848700011" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Global+Initiative+for+Asthma+Strategy+2021%3A+executive+summary+and+rationale+for+key+changes.&amp;publication_year=2022&amp;journal=Am+J+Respir+Crit+Care+Med&amp;pages=17-35&amp;doi=10.1164%2Frccm.202109-2205PP&amp;pmid=34658302" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">17.</div><div id="r17" class="citations"><div class="citation"><div class="citation-content">Cloutier MM, Baptist AP, Blake KV, et al. 2020 focused updates to the asthma management guidelines: a report from the National Asthma Education and Prevention Program Coordinating Committee Expert Panel Working Group. <em>J Allergy Clin Immunol</em> 2020;146:1217-1270.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r17"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.jaci.2020.10.003" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/33280709/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000596937900002" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=2020+focused+updates+to+the+asthma+management+guidelines%3A+a+report+from+the+National+Asthma+Education+and+Prevention+Program+Coordinating+Committee+Expert+Panel+Working+Group.&amp;publication_year=2020&amp;journal=J+Allergy+Clin+Immunol&amp;pages=1217-1270&amp;doi=10.1016%2Fj.jaci.2020.10.003&amp;pmid=33280709" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">18.</div><div id="r18" class="citations"><div class="citation"><div class="citation-content">Bodzenta-Lukaszyk A, Dymek A, McAulay K, Mansikka H. Fluticasone/formoterol combination therapy is as effective as fluticasone/salmeterol in the treatment of asthma, but has a more rapid onset of action: an open-label, randomized study. <em>BMC Pulm Med</em> 2011;11:28-28.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r18"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1186/1471-2466-11-28" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/21605396/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000208592800028" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Fluticasone%2Fformoterol+combination+therapy+is+as+effective+as+fluticasone%2Fsalmeterol+in+the+treatment+of+asthma%2C+but+has+a+more+rapid+onset+of+action%3A+an+open-label%2C+randomized+study.&amp;publication_year=2011&amp;journal=BMC+Pulm+Med&amp;pages=28-28&amp;doi=10.1186%2F1471-2466-11-28&amp;pmid=21605396" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">19.</div><div id="r19" class="citations"><div class="citation"><div class="citation-content">Bousquet J, Boulet LP, Peters MJ, et al. Budesonide/formoterol for maintenance and relief in uncontrolled asthma vs. high-dose salmeterol/fluticasone. <em>Respir Med</em> 2007;101:2437-2446.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r22-1"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.rmed.2007.07.014" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/17905575/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000251212700002" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Budesonide%2Fformoterol+for+maintenance+and+relief+in+uncontrolled+asthma+vs.+high-dose+salmeterol%2Ffluticasone.&amp;publication_year=2007&amp;journal=Respir+Med&amp;pages=2437-2446&amp;doi=10.1016%2Fj.rmed.2007.07.014&amp;pmid=17905575" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">20.</div><div id="r20" class="citations"><div class="citation"><div class="citation-content">Kuna P, Peters MJ, Manjra AI, et al. Effect of budesonide/formoterol maintenance and reliever therapy on asthma exacerbations. <em>Int J Clin Pract</em> 2007;61:725-736.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r22-1"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1111/j.1742-1241.2007.01338.x" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/17362472/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000245608700007" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Effect+of+budesonide%2Fformoterol+maintenance+and+reliever+therapy+on+asthma+exacerbations.&amp;publication_year=2007&amp;journal=Int+J+Clin+Pract&amp;pages=725-736&amp;doi=10.1111%2Fj.1742-1241.2007.01338.x&amp;pmid=17362472" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">21.</div><div id="r21" class="citations"><div class="citation"><div class="citation-content">O’Byrne PM, Bisgaard H, Godard PP, et al. Budesonide/formoterol combination therapy as both maintenance and reliever medication in asthma. <em>Am J Respir Crit Care Med</em> 2005;171:129-136.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r22-1"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1164/rccm.200407-884OC" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/15502112/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000226258400008" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Budesonide%2Fformoterol+combination+therapy+as+both+maintenance+and+reliever+medication+in+asthma.&amp;publication_year=2005&amp;journal=Am+J+Respir+Crit+Care+Med&amp;pages=129-136&amp;doi=10.1164%2Frccm.200407-884OC&amp;pmid=15502112" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">22.</div><div id="r22" class="citations"><div class="citation"><div class="citation-content">Scicchitano R, Aalbers R, Ukena D, et al. Efficacy and safety of budesonide/formoterol single inhaler therapy versus a higher dose of budesonide in moderate to severe asthma. <em>Curr Med Res Opin</em> 2004;20:1403-1418.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r22" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1185/030079904X2051" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/15383189/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000224343100010" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Efficacy+and+safety+of+budesonide%2Fformoterol+single+inhaler+therapy+versus+a+higher+dose+of+budesonide+in+moderate+to+severe+asthma.&amp;publication_year=2004&amp;journal=Curr+Med+Res+Opin&amp;pages=1403-1418&amp;doi=10.1185%2F030079904X2051&amp;pmid=15383189" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r22" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r22-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] had been using for maintenance therapy. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r35" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] in patients with moderate-to-severe asthma. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">23.</div><div id="r23" class="citations"><div class="citation"><div class="citation-content">Food and Drug Administration. Albuterol sulfate HFA (<a href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2005/021457s001lbl.pdf">https://www.accessdata.fda.gov/drugsatfda_docs/label/2005/021457s001lbl.pdf</a>).</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r23"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Albuterol+sulfate+HFA" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">24.</div><div id="r24" class="citations"><div class="citation"><div class="citation-content">Usmani OS, Roche N, Jenkins M, Stjepanovic N, Mack P, De Backer W. Consistent pulmonary drug delivery with whole lung deposition using the aerosphere inhaler: a review of the evidence. <em>Int J Chron Obstruct Pulmon Dis</em> 2021;16:113-124.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r25"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.2147/COPD.S274846" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/33500616/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000610875700001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Consistent+pulmonary+drug+delivery+with+whole+lung+deposition+using+the+aerosphere+inhaler%3A+a+review+of+the+evidence.&amp;publication_year=2021&amp;journal=Int+J+Chron+Obstruct+Pulmon+Dis&amp;pages=113-124&amp;doi=10.2147%2FCOPD.S274846&amp;pmid=33500616" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">25.</div><div id="r25" class="citations"><div class="citation"><div class="citation-content">Cappelletti C, Maes A, Rossman K, et al. Dose-ranging and cumulative dose studies of Albuterol Sulfate MDI in Co-Suspension Delivery technology (AS MDI; PT007) in patients with asthma: the ASPEN and ANTORA trials. <em>Clin Drug Investig</em> 2021;41:579-590.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r25"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1007/s40261-021-01040-7" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/34089147/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000658107800001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Dose-ranging+and+cumulative+dose+studies+of+Albuterol+Sulfate+MDI+in+Co-Suspension+Delivery+technology+%28AS+MDI%3B+PT007%29+in+patients+with+asthma%3A+the+ASPEN+and+ANTORA+trials.&amp;publication_year=2021&amp;journal=Clin+Drug+Investig&amp;pages=579-590&amp;doi=10.1007%2Fs40261-021-01040-7&amp;pmid=34089147" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">26.</div><div id="r26" class="citations"><div class="citation"><div class="citation-content">Juniper EF, Bousquet J, Abetz L, Bateman ED, GOAL Committee. Identifying ‘well-controlled’ and ‘not well-controlled’ asthma using the Asthma Control Questionnaire. <em>Respir Med</em> 2006;100:616-621.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r26"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.rmed.2005.08.012" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/16226443/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000236643300005" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Identifying+%E2%80%98well-controlled%E2%80%99+and+%E2%80%98not+well-controlled%E2%80%99+asthma+using+the+Asthma+Control+Questionnaire.&amp;publication_year=2006&amp;journal=Respir+Med&amp;pages=616-621&amp;doi=10.1016%2Fj.rmed.2005.08.012&amp;pmid=16226443" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">27.</div><div id="r27" class="citations"><div class="citation"><div class="citation-content">Chipps BE, Albers FC, Reilly L, Johnsson E, Cappelletti C, Papi A. Efficacy and safety of as-needed albuterol/budesonide versus albuterol in adults and children aged ≥4 years with moderate-to-severe asthma: rationale and design of the randomised, double-blind, active-controlled MANDALA study. <em>BMJ Open Respir Res</em> 2021;8(1):e001077-e001077.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r27" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1136/bmjresp-2021-001077" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/34887317/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000729565200001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Efficacy+and+safety+of+as-needed+albuterol%2Fbudesonide+versus+albuterol+in+adults+and+children+aged+%E2%89%A54+years+with+moderate-to-severe+asthma%3A+rationale+and+design+of+the+randomised%2C+double-blind%2C+active-controlled+MANDALA+study.&amp;publication_year=2021&amp;journal=BMJ+Open+Respir+Res&amp;pages=e001077-e001077&amp;doi=10.1136%2Fbmjresp-2021-001077&amp;pmid=34887317" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r27" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r27-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] South America, Europe, and South Africa </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r27-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] the full text of this article at NEJM.org). </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r27-3" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>c [...] procedures have been described previously. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r27-4" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>d [...] or a change in maintenance therapy. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r27-5" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>e [...] of 0.22 with the use of albuterol alone. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">28.</div><div id="r28" class="citations"><div class="citation"><div class="citation-content">Juniper EF, O’Byrne PM, Guyatt GH, Ferrie PJ, King DR. Development and validation of a questionnaire to measure asthma control. <em>Eur Respir J</em> 1999;14:902-907.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r28"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1034/j.1399-3003.1999.14d29.x" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/10573240/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000083614800029" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Development+and+validation+of+a+questionnaire+to+measure+asthma+control.&amp;publication_year=1999&amp;journal=Eur+Respir+J&amp;pages=902-907&amp;doi=10.1034%2Fj.1399-3003.1999.14d29.x&amp;pmid=10573240" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">29.</div><div id="r29" class="citations"><div class="citation"><div class="citation-content">Juniper EF, Buist AS, Cox FM, Ferrie PJ, King DR. Validation of a standardized version of the Asthma Quality of Life Questionnaire. <em>Chest</em> 1999;115:1265-1270.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r29"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1378/chest.115.5.1265" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/10334138/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000080299400013" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Validation+of+a+standardized+version+of+the+Asthma+Quality+of+Life+Questionnaire.&amp;publication_year=1999&amp;journal=Chest&amp;pages=1265-1270&amp;doi=10.1378%2Fchest.115.5.1265&amp;pmid=10334138" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">30.</div><div id="r30" class="citations"><div class="citation"><div class="citation-content">Bonini M, Di Paolo M, Bagnasco D, et al. Minimal clinically important difference for asthma endpoints: an expert consensus report. <em>Eur Respir Rev</em> 2020;29:190137-190137.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r30"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1183/16000617.0137-2019" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32499305/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000552492900007" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Minimal+clinically+important+difference+for+asthma+endpoints%3A+an+expert+consensus+report.&amp;publication_year=2020&amp;journal=Eur+Respir+Rev&amp;pages=190137-190137&amp;doi=10.1183%2F16000617.0137-2019&amp;pmid=32499305" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">31.</div><div id="r31" class="citations"><div class="citation"><div class="citation-content">Juniper EF, Guyatt GH, Feeny DH, Ferrie PJ, Griffith LE, Townsend M. Measuring quality of life in children with asthma. <em>Qual Life Res</em> 1996;5:35-46.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r32"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1007/BF00435967" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/8901365/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=A1996UB23400005" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Measuring+quality+of+life+in+children+with+asthma.&amp;publication_year=1996&amp;journal=Qual+Life+Res&amp;pages=35-46&amp;doi=10.1007%2FBF00435967&amp;pmid=8901365" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">32.</div><div id="r32" class="citations"><div class="citation"><div class="citation-content">Juniper EF, Guyatt GH, Willan A, Griffith LE. Determining a minimal important change in a disease-specific Quality of Life Questionnaire. <em>J Clin Epidemiol</em> 1994;47:81-87.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r32"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/0895-4356(94)90036-1" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/8283197/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=A1994MT27800009" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Determining+a+minimal+important+change+in+a+disease-specific+Quality+of+Life+Questionnaire.&amp;publication_year=1994&amp;journal=J+Clin+Epidemiol&amp;pages=81-87&amp;doi=10.1016%2F0895-4356%2894%2990036-1&amp;pmid=8283197" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">33.</div><div id="r33" class="citations"><div class="citation"><div class="citation-content">Papi A, Canonica GW, Maestrelli P, et al. Rescue use of beclomethasone and albuterol in a single inhaler for mild asthma. <em>N Engl J Med</em> 2007;356:2040-2052.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r33"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_5_34_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa2203163&amp;key=10.1056%2FNEJMoa063861&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/17507703/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000246490500005" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Rescue+use+of+beclomethasone+and+albuterol+in+a+single+inhaler+for+mild+asthma.&amp;publication_year=2007&amp;journal=N+Engl+J+Med&amp;pages=2040-2052&amp;doi=10.1056%2FNEJMoa063861&amp;pmid=17507703" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">34.</div><div id="r34" class="citations"><div class="citation"><div class="citation-content">Israel E, Cardet J-C, Carroll JK, et al. Reliever-triggered inhaled glucocorticoid in Black and Latinx adults with asthma. <em>N Engl J Med</em> 2022;386:1505-1518.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r34"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_5_35_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa2203163&amp;key=10.1056%2FNEJMoa2118813&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/35213105/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000761375000001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Reliever-triggered+inhaled+glucocorticoid+in+Black+and+Latinx+adults+with+asthma.&amp;publication_year=2022&amp;journal=N+Engl+J+Med&amp;pages=1505-1518&amp;doi=10.1056%2FNEJMoa2118813&amp;pmid=35213105" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">35.</div><div id="r35" class="citations"><div class="citation"><div class="citation-content">Jenkins CR, Bateman ED, Sears MR, O’Byrne PM. What have we learnt about asthma control from trials of budesonide/formoterol as maintenance and reliever? <em>Respirology</em> 2020;25:804-815.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r35"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1111/resp.13804" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32237004/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000522536700001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=What+have+we+learnt+about+asthma+control+from+trials+of+budesonide%2Fformoterol+as+maintenance+and+reliever%3F&amp;publication_year=2020&amp;journal=Respirology&amp;pages=804-815&amp;doi=10.1111%2Fresp.13804&amp;pmid=32237004" target="_blank">Google Scholar</a></div></div></div></div></div></div><div class="citations-truncation"><button data-label-expand="Show all references" data-label-collapse="Show fewer" data-label-remaining="references remaining" class="btn btn--secondary" aria-expanded="false" aria-controls="collapsible-text"><span>Show all references</span></button></div></section></div></section></div><div class="core-collateral"><div id="core-collateral-info" role="tabpanel" data-core-tabs="core-collateral-info" tabindex="-1" aria-labelledby="pane-core-collateral-info"><header><h2 id="pane-core-collateral-info"><i class="icon-info" aria-hidden="true"></i>Information &amp; Authors</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><div role="tablist"><button aria-controls="tab-information" role="tab" id="tab-information-label" aria-selected="true" class="active">Information</button><button aria-controls="tab-contributors" role="tab" id="tab-contributors-label" tabindex="-1" aria-selected="false">Authors</button></div><section id="tab-information" aria-labelledby="tab-information-label" role="tabpanel" tabindex="0"><h3>Information</h3><section class="core-self-citation"><h4>Published In</h4><div class="core-journal-presentation"><div class="core-journal-description"><div property="isPartOf" typeof="Periodical"><span property="name">New England Journal of Medicine</span></div><div class="core-enumeration"><a href="/toc/nejm/386/22"><span property="isPartOf" typeof="PublicationVolume">Volume <span property="volumeNumber">386</span></span> • <span property="isPartOf" typeof="PublicationIssue">Number <span property="issueNumber">22</span></span> • <span property="datePublished">June 2, 2022</span></a></div><div class="core-pagination"><span class="heading">Pages</span>: <span class="content"><span property="pageStart">2071</span>-<span property="pageEnd">2083</span></span></div></div></div></section><section class="core-copyright"><h4>Copyright</h4><div role="paragraph">Copyright © 2022 Massachusetts Medical Society. All rights reserved.</div><div>For personal use only. Any commercial reuse of NEJM Group content requires <a href="mailto:permissions@nejm.org">permission</a>.</div></section><section class="core-history"><h4>History</h4><div><b class="core-label">Published online</b>: May 15, 2022</div><div><b class="core-label">Published in issue</b>: June 2, 2022</div></section><section data-location="recirc_topics_article" class="core-classifications"><h4>Topics</h4><div class="keywords"><ol><li><a href="/browse/topic/adolescent-medicine" alt="View article keyword Adolescent Medicine" data-interactiontype="article_recirculation_click">Adolescent Medicine</a></li><li role="presentation" aria-hidden="true" class="list-line-break"></li><li><a href="/browse/topic/asthma-allergy-immunology" alt="View article keyword Asthma (Allergy/Immunology)" data-interactiontype="article_recirculation_click">Asthma (Allergy/Immunology)</a></li><li role="presentation" aria-hidden="true" class="list-line-break"></li><li><a href="/browse/topic/asthma-pulmonary-critical-care" alt="View article keyword Asthma (Pulmonary/Critical Care)" data-interactiontype="article_recirculation_click">Asthma (Pulmonary/Critical Care)</a></li><li role="presentation" aria-hidden="true" class="list-line-break"></li><li><a href="/browse/topic/clinical-medicine-general" alt="View article keyword Clinical Medicine General" data-interactiontype="article_recirculation_click">Clinical Medicine General</a></li><li role="presentation" aria-hidden="true" class="list-line-break"></li><li><a href="/browse/topic/outpatient-based-clinical-medicine" alt="View article keyword Outpatient-Based Clinical Medicine" data-interactiontype="article_recirculation_click">Outpatient-Based Clinical Medicine</a></li><li role="presentation" aria-hidden="true" class="list-line-break"></li><li><a href="/browse/topic/pediatrics-general" alt="View article keyword Pediatrics General" data-interactiontype="article_recirculation_click">Pediatrics General</a></li><li role="presentation" aria-hidden="true" class="list-line-break"></li></ol></div></section></section><section id="tab-contributors" aria-labelledby="tab-contributors-label" role="tabpanel" tabindex="-1"><h3>Authors</h3><section class="core-authors"><h4>Authors</h4><div role="paragraph"><span property="author" typeof="Person"><span property="givenName">Alberto</span> <span property="familyName">Papi</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Bradley E.</span> <span property="familyName">Chipps</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Richard</span> <span property="familyName">Beasley</span>, <span property="honorificSuffix">D.Sc.</span> <a class="orcid-id" href="https://orcid.org/0000-0003-0337-406X" property="identifier" aria-label="ORCID identifier" target="_blank">https://orcid.org/0000-0003-0337-406X</a></span>, <span property="author" typeof="Person"><span property="givenName">Reynold A.</span> <span property="familyName">Panettieri</span>, Jr., <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Elliot</span> <span property="familyName">Israel</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Mark</span> <span property="familyName">Cooper</span>, <span property="honorificSuffix">M.Sc.</span></span>, <span property="author" typeof="Person"><span property="givenName">Lynn</span> <span property="familyName">Dunsire</span>, <span property="honorificSuffix">M.Sc.</span></span>, <span property="author" typeof="Person"><span property="givenName">Allison</span> <span property="familyName">Jeynes-Ellis</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Eva</span> <span property="familyName">Johnsson</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Robert</span> <span property="familyName">Rees</span>, <span property="honorificSuffix">Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Christy</span> <span property="familyName">Cappelletti</span>, <span property="honorificSuffix">Pharm.D.</span></span>, and <span property="author" typeof="Person"><span property="givenName">Frank C.</span> <span property="familyName">Albers</span>, <span property="honorificSuffix">M.D.</span> <a class="orcid-id" href="https://orcid.org/0000-0001-7039-4621" property="identifier" aria-label="ORCID identifier" target="_blank">https://orcid.org/0000-0001-7039-4621</a></span></div></section><section class="core-affiliations"><h4>Affiliations</h4><div property="affiliation" typeof="Organization"><span property="name">From the Department of Respiratory Medicine, University of Ferrara Medical School, Ferrara, Italy (A.P.); the Capital Allergy and Respiratory Disease Center, Sacramento, CA (B.E.C.); the Medical Research Institute of New Zealand, Capital and Coast District Health Board, and Victoria University Wellington — all in Wellington, New Zealand (R.B.); Rutgers Institute for Translational Medicine and Science, Child Health Institute of New Jersey, Rutgers, the State University of New Jersey, New Brunswick (R.A.P.); Brigham and Women’s Hospital, Harvard Medical School, Boston (E.I.); BioPharmaceuticals Research and Development, AstraZeneca, Cambridge (M.C., L.D.), and Avillion, London (A.J.-E., R.R.) — both in the United Kingdom; BioPharmaceuticals Research and Development, AstraZeneca, Gothenburg, Sweden (E.J.); BioPharmaceuticals Research and Development, AstraZeneca, Durham, NC (C.C.); and Avillion, Northbrook, IL (F.C.A.).</span></div></section><section class="core-authors-notes"><h4>Notes</h4><div role="doc-footnote">Dr. Papi can be contacted at <a href="mailto:ppa@unife.it">ppa@unife.it</a> or at the University of Ferrara Medical School, Via Aldo Moro, 8, 44141, Ferrara, Italy.</div><div role="doc-footnote"><div id="fn1" role="paragraph">Drs. Papi and Chipps contributed equally to this article.</div></div></section></section></div><div id="core-collateral-metrics" role="tabpanel" data-core-tabs="core-collateral-metrics" tabindex="-1" aria-labelledby="pane-core-collateral-metrics"><header><h2 id="pane-core-collateral-metrics"><i class="icon-timeline" aria-hidden="true"></i>Metrics &amp; Citations</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><div role="tablist"><button aria-controls="tab-metrics-inner" role="tab" id="tab-metrics-inner-label" aria-selected="true" class="active" data-interactiontype="article_tab" data-tabname="metricsWindow">Metrics</button><button aria-controls="tab-citations" role="tab" id="tab-citations-label" tabindex="-1" aria-selected="false" data-interactiontype="article_tab" data-tabname="metricsWindow">Citations<span class="citations-count">81</span></button></div><section id="tab-metrics-inner" aria-labelledby="tab-metrics-inner-label" role="tabpanel" tabindex="0"><h3>Metrics</h3><section>









    
    
        <div data-widget-def="UX3HTMLWidget" data-widget-id="95ea9f58-ec0e-4db2-b2ab-280fc876af53" data-location="article_metrics_article">
        



        
            <h4 class="">
                Altmetrics
            </h4>
        
        <div data-badge-details="right" data-badge-type="large-donut" data-doi="10.1056/NEJMoa2203163" data-hide-no-mentions="true" data-link-target="_blank" class="altmetric-embed" data-uuid="54a40cbd-b089-16db-5425-803cb9a29d7d"><div style="overflow:hidden;">
    <div class="altmetric-normal-legend">
        <a target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=128287873" style="display:inline-block;">
                <img alt="Article has an altmetric score of 811" src="https://badges.altmetric.com/?size=320&amp;score=811&amp;types=mabcttwf" width="180" height="180" style="border:0; margin:0; max-width: none;">
        </a>
        <p class="altmetric-see-more-details" style="padding-top: 10px; text-align: center;"><a target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=128287873">See more details</a></p>
    </div>
    <div id="_altmetric_popover_el_54a40cbd-b089-16db-5425-803cb9a29d7d" class="altmetric-embed right" style="margin:0; padding:0; display:inline-block; float:left; position:relative;">
        <div class="altmetric_container">
            <div class="altmetric-embed altmetric-popover-inner right">
                <div style="padding:0; margin: 0;" class="altmetric-embed altmetric-popover-content">
                        <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #FF0000;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=128287873&amp;tab=news">
          Picked up by <b>91</b> news outlets
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #ffd140;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=128287873&amp;tab=blogs">
          Blogged by <b>5</b>
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #74CFED;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=128287873&amp;tab=twitter">
          Posted by <b>203</b> X users
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #f27700;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=128287873&amp;tab=patents">
          Referenced in <b>4</b> patents
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #2445bd;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=128287873&amp;tab=facebook">
          On <b>5</b> Facebook pages
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #958899;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=128287873&amp;tab=wikipedia">
          Referenced in <b>1</b> Wikipedia pages
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #A1E3E4;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=128287873&amp;tab=guidelines">
          Referenced in <b>1</b> clinical guideline sources
      </a>
    </div>

    <div class="altmetric-embed readers" style="margin-top: 10px;">
          <div class="altmetric-embed tip_mendeley" style="padding-left: 10px; line-height:18px; border-left: 16px solid #A60000;">
              <b>183</b> readers on Mendeley
          </div>
    </div>

                </div>
            </div>
        </div>
    </div>
</div></div>
<script async="" type="text/javascript" src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" nonce="94d6d44785b61aed-SJC"></script>

        </div>
    

</section></section><section id="tab-citations" aria-labelledby="tab-citations-label" role="tabpanel" tabindex="-1"><h3>Citations</h3><section>



        
            <h4 class="">
                Export citation
            </h4>
        
        <div class="citation-download cd-sec">
<p class="citation-download_msg">Select the format you want to export the citation of this publication.</p>
<form action="/action/downloadCitation" name="frmCitmgr" method="post" target="_self" class="citation-download_form"><input type="hidden" name="doi" value="10.1056/NEJMoa2203163"> <input type="hidden" name="downloadFileName" value="csp_386_"> <input type="hidden" name="include" value="abs">
<div class="dropdown dropdown-selectable dropdown-selectable--form-control"><input type="hidden" name="format" value=""> <label class="form-label">Format*</label> <button id="slct_format" type="button" data-toggle="dropdown" aria-haspopup="true" aria-expanded="false" class="btn dropdown-toggle d-flex align-items-center justify-content-between">Please Select </button>
<div aria-labelledby="slct_format" role="listbox" class="dropdown-menu"><a href="#" data-value="ris" class="dropdown-item">RIS (ProCite, Reference Manager)</a><a href="#" data-value="endnote" class="dropdown-item">EndNote</a><a href="#" data-value="bibtex" class="dropdown-item">BibTex</a><a href="#" data-value="medlars" class="dropdown-item">Medlars</a><a href="#" data-value="refworks" class="dropdown-item">RefWorks</a></div>
<div class="invalid-feedback">Please select an item in the list</div>
</div>
<div class="citation-download_checkbox"><label class="checkbox--primary"><input type="checkbox" name="direct" value="true"><span class="checkbox--primary-icons"><span class="checkbox--primary-unchecked"><span class="icon-component "><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#toggles-checboxUnchecked"></use></svg></span></span><span class="checkbox--primary-checked"><span class="icon-component "><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#toggles-checboxChecked"></use></svg></span></span></span><span class="checkbox--primary-label"><span class="checkbox--primary-label-text">Direct Import</span></span></label></div>
<div class="citation-download_btn"><button type="submit" name="submit" value="Download" class="ng-btn_default ng-btn_iconLeft" data-interactiontype="article_tools_citation_download" data-multimedia-type="Citation"><span class="icon-component "><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#citations"></use></svg></span><span class="ng-btn_text">Export citation</span></button></div>
</form></div>
</section><section>









    
    
        <div data-widget-def="UX3CitedByWidget" data-widget-id="efb4df9a-8e1a-47f9-bfb7-271959277a9f" data-location="citedby_article">
        



        
            <h4 class="">
                Cited by
            </h4>
        
        <section id="cited-by" class="cited-by"><div class="cited-by__wrapper"><div id="cited-by__content" class="cited-by__content"><ol data-source="/pb/widgets/citedBy?page=1&amp;widgetId=efb4df9a-8e1a-47f9-bfb7-271959277a9f&amp;pbContext=%3BrequestedJournal%3Ajournal%3Anejm%3Bpage%3Astring%3AArticle%2FChapter+View%3Bissue%3Aissue%3Adoi%5C%3A10.1056%2Fnejm_2022.386.issue-22%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AMMS+NextGen+Website+Group%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text%3Bwebsite%3Awebsite%3Amms-site%3Barticle%3Aarticle%3Adoi%5C%3A10.1056%2FNEJMoa2203163%3Bjournal%3Ajournal%3Anejms" data-lazyload="false" data-total="81" class="cited-by__list list-unstyled"><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Göran Wennergren, </li><li class="list-inline-item cited-by__entry__author">Anne Lindberg, </li><li class="list-inline-item cited-by__entry__author">Paula Kauppi, </li><li class="list-inline-item cited-by__entry__author">Hannu Kankaanranta, </li><li class="list-inline-item cited-by__entry__author">Arnulf Langhammer, </li><li class="list-inline-item cited-by__entry__author">Helena Backman, </li></ul><span class="cited-by__entry__title">Glimpses of diagnostic tools and treatment of asthma in Sweden, Norway, and Finland from a medico-historical perspective, </span><span class="cited-by__entry__series-title">Respiratory Medicine, </span><span class="cited-by__entry__volume"><strong>243</strong>, </span><span class="cited-by__entry__page-range">(108139), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1016/j.rmed.2025.108139" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1016/j.rmed.2025.108139</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1016/j.rmed.2025.108139" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">August D. Sigelko, </li><li class="list-inline-item cited-by__entry__author">Mary E. Strek, </li><li class="list-inline-item cited-by__entry__author">Krysta S. Wolfe, </li></ul><span class="cited-by__entry__title">Asthma in Pregnancy, </span><span class="cited-by__entry__series-title">Obstetrics &amp; Gynecology, </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1097/AOG.0000000000005948" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1097/AOG.0000000000005948</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1097/AOG.0000000000005948" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Rui Dang, </li><li class="list-inline-item cited-by__entry__author">Zhejun Xie, </li><li class="list-inline-item cited-by__entry__author">Fujie Cai, </li><li class="list-inline-item cited-by__entry__author">Xin Sun, </li><li class="list-inline-item cited-by__entry__author">Qinqin Fang, </li><li class="list-inline-item cited-by__entry__author">Guangdong Wang, </li><li class="list-inline-item cited-by__entry__author">Huida Guan, </li><li class="list-inline-item cited-by__entry__author">Changhong Wang, </li></ul><span class="cited-by__entry__title">Revealing the mechanism of Sanfu Patch dorsal application for alleviating OVA-induced asthma: an integrated approach combining TMT quantitative proteomics and molecular docking, </span><span class="cited-by__entry__series-title">Journal of Ethnopharmacology, </span><span class="cited-by__entry__volume"><strong>348</strong>, </span><span class="cited-by__entry__page-range">(119867), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1016/j.jep.2025.119867" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1016/j.jep.2025.119867</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1016/j.jep.2025.119867" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Jiadong Pang, </li><li class="list-inline-item cited-by__entry__author">Xiaoyu Chen, </li><li class="list-inline-item cited-by__entry__author">Zhijun Lin, </li><li class="list-inline-item cited-by__entry__author">Shuo Yao, </li><li class="list-inline-item cited-by__entry__author">Wanyan Wang, </li><li class="list-inline-item cited-by__entry__author">Hong Wu, </li><li class="list-inline-item cited-by__entry__author">Wei Xing, </li><li class="list-inline-item cited-by__entry__author">Jiang Yang, </li></ul><span class="cited-by__entry__title">Inhalable pH-responsive charge-reversal polymer-small interfering RNA polyplexes for directed gene therapy of anaplastic lymphoma kinase fusion-positive lung cancer, </span><span class="cited-by__entry__series-title">Journal of Controlled Release, </span><span class="cited-by__entry__volume"><strong>381</strong>, </span><span class="cited-by__entry__page-range">(113644), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1016/j.jconrel.2025.113644" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1016/j.jconrel.2025.113644</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1016/j.jconrel.2025.113644" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Njira L. Lugogo, </li><li class="list-inline-item cited-by__entry__author">Ileen A. Gilbert, </li><li class="list-inline-item cited-by__entry__author">Hitesh N. Gandhi, </li><li class="list-inline-item cited-by__entry__author">Joseph P. Tkacz, </li><li class="list-inline-item cited-by__entry__author">Miguel J. Lanz, </li></ul><span class="cited-by__entry__title">Exacerbation burden in patients treated as intermittent or mild-persistent asthma using short-acting β2-agonist rescue, </span><span class="cited-by__entry__series-title">Annals of Allergy, Asthma &amp; Immunology, </span><span class="cited-by__entry__volume"><strong>134</strong>, </span><span class="cited-by__entry__issue">5, </span><span class="cited-by__entry__page-range">(539-547.e1), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1016/j.anai.2025.02.009" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1016/j.anai.2025.02.009</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1016/j.anai.2025.02.009" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Kelsey A. Finkel, </li><li class="list-inline-item cited-by__entry__author">Rini Patadia, </li><li class="list-inline-item cited-by__entry__author">Alan P. Baptist, </li><li class="list-inline-item cited-by__entry__author">Juan Carlos Cardet, </li></ul><span class="cited-by__entry__title">Controversies in Allergy: Should I Combine an ICS With a SABA or With Formoterol for Reliever Therapy?, </span><span class="cited-by__entry__series-title">The Journal of Allergy and Clinical Immunology: In Practice, </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1016/j.jaip.2025.04.016" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1016/j.jaip.2025.04.016</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1016/j.jaip.2025.04.016" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Maria Elisa Di Cicco, </li><li class="list-inline-item cited-by__entry__author">Diego Peroni, </li><li class="list-inline-item cited-by__entry__author">Gian Luigi Marseglia, </li><li class="list-inline-item cited-by__entry__author">Amelia Licari, </li></ul><span class="cited-by__entry__title">Unveiling the Complexities of Pediatric Asthma Treatment:&nbsp;Evidence, Controversies, and Emerging Approaches, </span><span class="cited-by__entry__series-title">Pediatric Drugs, </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1007/s40272-025-00694-6" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1007/s40272-025-00694-6</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1007/s40272-025-00694-6" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Nazrin Yusufova, </li><li class="list-inline-item cited-by__entry__author">Ileen A. Gilbert, </li><li class="list-inline-item cited-by__entry__author">Frank Trudo, </li><li class="list-inline-item cited-by__entry__author">Theodore Barlows, </li><li class="list-inline-item cited-by__entry__author">Scott Salvato, </li><li class="list-inline-item cited-by__entry__author">Omar Motawakel, </li><li class="list-inline-item cited-by__entry__author">James M. Eudicone, </li><li class="list-inline-item cited-by__entry__author">Kevin R. Murphy, </li></ul><span class="cited-by__entry__title">Evaluation of a disease-state education program in asthma: Application of the Knowledge-to-Action Framework, </span><span class="cited-by__entry__series-title">Allergy and Asthma Proceedings, </span><span class="cited-by__entry__volume"><strong>46</strong>, </span><span class="cited-by__entry__issue">2, </span><span class="cited-by__entry__page-range">(126-134), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.2500/aap.2025.46.240112" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.2500/aap.2025.46.240112</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.2500/aap.2025.46.240112" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Anne L. Fuhlbrigge, </li><li class="list-inline-item cited-by__entry__author">Stanley J. Szefler, </li></ul><span class="cited-by__entry__title">Systemic Corticosteroids: The Importance of Limiting Their Use in Asthma, </span><span class="cited-by__entry__series-title">The Journal of Allergy and Clinical Immunology: In Practice, </span><span class="cited-by__entry__volume"><strong>13</strong>, </span><span class="cited-by__entry__issue">2, </span><span class="cited-by__entry__page-range">(308-309), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1016/j.jaip.2024.12.010" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1016/j.jaip.2024.12.010</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1016/j.jaip.2024.12.010" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Daniel G. Rayner, </li><li class="list-inline-item cited-by__entry__author">Dario M. Ferri, </li><li class="list-inline-item cited-by__entry__author">Gordon H. Guyatt, </li><li class="list-inline-item cited-by__entry__author">Paul M. O’Byrne, </li><li class="list-inline-item cited-by__entry__author">Romina Brignardello-Petersen, </li><li class="list-inline-item cited-by__entry__author">Farid Foroutan, </li><li class="list-inline-item cited-by__entry__author">Bradley Chipps, </li><li class="list-inline-item cited-by__entry__author">Kaharu Sumino, </li><li class="list-inline-item cited-by__entry__author">Tamara T. Perry, </li><li class="list-inline-item cited-by__entry__author">Sharmilee Nyenhuis, </li><li class="list-inline-item cited-by__entry__author">John Oppenheimer, </li><li class="list-inline-item cited-by__entry__author">Elliot Israel, </li><li class="list-inline-item cited-by__entry__author">Flavia Hoyte, </li><li class="list-inline-item cited-by__entry__author">Katherine Rivera-Spoljaric, </li><li class="list-inline-item cited-by__entry__author">Ellen McCabe, </li><li class="list-inline-item cited-by__entry__author">Susana Rangel, </li><li class="list-inline-item cited-by__entry__author">Lindsay E. Shade, </li><li class="list-inline-item cited-by__entry__author">Valerie G. Press, </li><li class="list-inline-item cited-by__entry__author">Lisa Hall, </li><li class="list-inline-item cited-by__entry__author">Dia Sue-Wah-Sing, </li><li class="list-inline-item cited-by__entry__author">Angel Melendez, </li><li class="list-inline-item cited-by__entry__author">Hilarry Orr, </li><li class="list-inline-item cited-by__entry__author">Tonya Winders, </li><li class="list-inline-item cited-by__entry__author">Donna D. Gardner, </li><li class="list-inline-item cited-by__entry__author">Kathyrn Przywara, </li><li class="list-inline-item cited-by__entry__author">Matthew A. Rank, </li><li class="list-inline-item cited-by__entry__author">Leonard B. Bacharier, </li><li class="list-inline-item cited-by__entry__author">Giselle Mosnaim, </li><li class="list-inline-item cited-by__entry__author">Derek K. Chu, </li></ul><span class="cited-by__entry__title">Inhaled Reliever Therapies for Asthma, </span><span class="cited-by__entry__series-title">JAMA, </span><span class="cited-by__entry__volume"><strong>333</strong>, </span><span class="cited-by__entry__issue">2, </span><span class="cited-by__entry__page-range">(143), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1001/jama.2024.22700" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1001/jama.2024.22700</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1001/jama.2024.22700" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry--see-more"><a href="javascript:void(0)" data-source="/pb/widgets/citedBy?page=1&amp;widgetId=efb4df9a-8e1a-47f9-bfb7-271959277a9f&amp;pbContext=%3BrequestedJournal%3Ajournal%3Anejm%3Bpage%3Astring%3AArticle%2FChapter+View%3Bissue%3Aissue%3Adoi%5C%3A10.1056%2Fnejm_2022.386.issue-22%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AMMS+NextGen+Website+Group%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text%3Bwebsite%3Awebsite%3Amms-site%3Barticle%3Aarticle%3Adoi%5C%3A10.1056%2FNEJMoa2203163%3Bjournal%3Ajournal%3Anejms" class="cited-by__see-more">See more</a></li></ol></div><div class="cited-by__spinner justify-content-center align-items-center d-none"><div role="status" class="spinner-border text-gray"><span class="sr-only">Loading...</span></div></div></div></section>

        </div>
    

</section></section></div><div id="core-collateral-fulltext-options" role="tabpanel" data-core-tabs="core-collateral-fulltext-options" tabindex="-1" aria-labelledby="pane-core-collateral-fulltext-options"><header><h2 id="pane-core-collateral-fulltext-options"><i class="icon-eye" aria-hidden="true"></i>View Options</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><div class="section--wrapper"><h3>View options</h3><section class="format--pdf"><h4> <abbr title="Portable Document Format">PDF</abbr></h4><a href="https://www.nejm.org/doi/pdf/10.1056/NEJMoa2203163" class="btn btn--pdf" aria-label="View PDF" data-behavior="trackDownloadEvent" data-doi="10.1056/NEJMoa2203163" data-interactiontype="article_tools_download_pdf" data-multimedia-type="Article PDF" data-multimedia-filename="nejmoa2203163.pdf"><i aria-hidden="true" class="icon-pdf"></i><span>View PDF</span></a></section></div><!-- Its needed to duplicate this for PB check Collateral.js as well--></div><div id="core-collateral-media" role="tabpanel" data-core-tabs="core-collateral-media" tabindex="-1" aria-labelledby="pane-core-collateral-media"><header><h2 id="pane-core-collateral-media"><i class="icon-photo" aria-hidden="true"></i>Media</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><div role="tablist"><button aria-controls="tab-figures" role="tab" id="tab-figures-label" aria-selected="true" class="active">Figures</button><button aria-controls="tab-other" role="tab" id="tab-other-label" tabindex="-1" aria-selected="false" class="inactive" aria-disabled="true">Other</button></div><section id="tab-figures" aria-labelledby="tab-figures-label" role="tabpanel" tabindex="0"><h3>Figures</h3><div class="text-right"><a class="btn btn--inverse  open-in-viewer" href="#figures"><span>Open all in viewer</span><i class="icon-open_in_new" aria-hidden="true"></i></a></div><div id="core-f0"><figure class="graphic"><a class="open-in-viewer" href="#f0" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2203163_f0.jpg"><img src="/cms/10.1056/NEJMoa2203163/asset/064d7417-8268-4305-aba1-5cd26a8cace9/assets/images/large/nejmoa2203163_f0.jpg" height="3416" width="2640" aria-labelledby="f0" loading="lazy"></a><figcaption>Download a PDF of the <a href="#ap0">Research Summary</a>.</figcaption></figure><div class="external-links"><a class="pill__to-original" href="#f0"><i class="icon-return" aria-hidden="true"></i><span>Go to Figure</span></a><a class="open-in-viewer" href="#f0" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2203163_f0.jpg"><span>Open in Viewer</span><i class="icon-expand" aria-hidden="true"></i></a></div></div><div id="core-f1"><figure class="graphic"><a class="open-in-viewer" href="#f1" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2203163_f1.jpg"><img src="/cms/10.1056/NEJMoa2203163/asset/9aa4eec4-18e3-49aa-9cbc-666fcfd02336/assets/images/large/nejmoa2203163_f1.jpg" height="3119" width="2640" aria-labelledby="f1" loading="lazy"></a><figcaption><div class="caption">Screening, Randomization, and Analyses.</div><div class="notes"><div role="doc-footnote">All 37 patients who remained in the treatment phase of the trial after the primary database lock to complete 24 weeks across the three trial groups were children or adolescents; the 1 patient in the lower-dose combination group who remained in the 2-week safety follow-up period after the primary database lock was an adolescent.</div></div></figcaption></figure><div class="external-links"><a class="pill__to-original" href="#f1"><i class="icon-return" aria-hidden="true"></i><span>Go to Figure</span></a><a class="open-in-viewer" href="#f1" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2203163_f1.jpg"><span>Open in Viewer</span><i class="icon-expand" aria-hidden="true"></i></a></div></div><div id="core-f2"><figure class="graphic"><a class="open-in-viewer" href="#f2" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2203163_f2.jpg"><img src="/cms/10.1056/NEJMoa2203163/asset/351e096a-ce26-4ce4-867e-6b566ef5e868/assets/images/large/nejmoa2203163_f2.jpg" height="3142" width="2640" aria-labelledby="f2" loading="lazy"></a><figcaption><div class="caption">Time-to-Event Analysis of the First Event of Severe Asthma Exacerbation (Primary End Point).</div><div class="notes"><div role="doc-footnote">Data are presented for all the patients. Children 4 to 11 years of age were excluded in the comparison between the higher-dose combination group and the albuterol-alone group; therefore, the number of patients in the albuterol-alone group in this comparison (1014 patients) was lower than that in the comparison with the lower-dose combination group, in which children 4 to 11 years of age were included. The anticipated probability of a first event of severe asthma exacerbation among the patients who received albuterol alone was 0.22.</div></div></figcaption></figure><div class="external-links"><a class="pill__to-original" href="#f2"><i class="icon-return" aria-hidden="true"></i><span>Go to Figure</span></a><a class="open-in-viewer" href="#f2" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2203163_f2.jpg"><span>Open in Viewer</span><i class="icon-expand" aria-hidden="true"></i></a></div></div></section><section id="tab-other" aria-labelledby="tab-other-label" role="tabpanel" tabindex="-1"><h3>Other</h3></section></div><div id="core-collateral-tables" role="tabpanel" data-core-tabs="core-collateral-tables" tabindex="-1" aria-labelledby="pane-core-collateral-tables"><header><h2 id="pane-core-collateral-tables"><i class="icon-tables" aria-hidden="true"></i>Tables</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><!-- There is no content. --><div class="section--wrapper"><div class="text-right"><a class="btn btn--inverse  open-in-viewer" href="#tables"><span>Open all in viewer</span><i class="icon-open_in_new" aria-hidden="true"></i></a></div><div id="core-t1"><figure class="table"><a class="open-in-viewer" href="#t1" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2203163_t1.jpg"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><img src="/cms/10.1056/NEJMoa2203163/asset/2ae32759-7283-45c1-9265-3717c530477b/assets/images/large/nejmoa2203163_t1.jpg" height="2742" width="1999" loading="lazy"></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1"><th class="txlx-borders" data-xml-align="left">Characteristic</th><th class="txxx-borders">Albuterol (180 μg)–<br>Budesonide (160 μg)<br>(N=1013)</th><th class="txxx-borders">Albuterol (180 μg)–<br>Budesonide (80 μg)<br>(N=1054)</th><th class="txxx-borders">Albuterol<br>(180 μg)<br>(N=1056)</th><th class="txxr-borders">All Patients<br>(N=3123)</th></tr></thead><tbody><tr data-type="row"><td class="xxlx-borders hanging03 shading">Age</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">Mean — yr</td><td class="xxxx-borders">50.6±15.1</td><td class="xxxx-borders">48.5±16.7</td><td class="xxxx-borders">49.1±17.2</td><td class="xxxr-borders">49.4±16.4</td></tr><tr data-type="row"><td class="xxlx-borders hanging13 shading">Distribution — no. (%)</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23" data-xml-align="left">≥4 to &lt;12 yr</td><td class="xxxx-borders">0</td><td class="xxxx-borders">41 (3.9)</td><td class="xxxx-borders">42 (4.0)</td><td class="xxxr-borders">83 (2.7)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23 shading" data-xml-align="left">≥12 to &lt;18 yr</td><td class="xxxx-borders shading">34 (3.4)</td><td class="xxxx-borders shading">32 (3.0)</td><td class="xxxx-borders shading">34 (3.2)</td><td class="xxxr-borders shading">100 (3.2)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23" data-xml-align="left">≥18 to &lt;65 yr</td><td class="xxxx-borders">787 (77.7)</td><td class="xxxx-borders">804 (76.3)</td><td class="xxxx-borders">783 (74.1)</td><td class="xxxr-borders">2374 (76.0)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23 shading" data-xml-align="left">≥65 yr</td><td class="xxxx-borders shading">192 (19.0)</td><td class="xxxx-borders shading">177 (16.8)</td><td class="xxxx-borders shading">197 (18.7)</td><td class="xxxr-borders shading">566 (18.1)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging03" data-xml-align="left">Female sex — no. (%)</td><td class="xxxx-borders">645 (63.7)</td><td class="xxxx-borders">685 (65.0)</td><td class="xxxx-borders">694 (65.7)</td><td class="xxxr-borders">2024 (64.8)</td></tr><tr data-type="row"><td class="xxlx-borders hanging03 shading">Race or ethnic group — no. (%)</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">White</td><td class="xxxx-borders">818 (80.8)</td><td class="xxxx-borders">847 (80.4)</td><td class="xxxx-borders">868 (82.2)</td><td class="xxxr-borders">2533 (81.1)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">Black</td><td class="xxxx-borders shading">139 (13.7)</td><td class="xxxx-borders shading">141 (13.4)</td><td class="xxxx-borders shading">137 (13.0)</td><td class="xxxr-borders shading">417 (13.4)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">Asian</td><td class="xxxx-borders">29 (2.9)</td><td class="xxxx-borders">33 (3.1)</td><td class="xxxx-borders">23 (2.2)</td><td class="xxxr-borders">85 (2.7)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">American Indian or Alaska Native</td><td class="xxxx-borders shading">1 (0.1)</td><td class="xxxx-borders shading">1 (0.1)</td><td class="xxxx-borders shading">0</td><td class="xxxr-borders shading">2 (0.1)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">Other</td><td class="xxxx-borders">26 (2.6)</td><td class="xxxx-borders">32 (3.0)</td><td class="xxxx-borders">28 (2.7)</td><td class="xxxr-borders">86 (2.8)</td></tr><tr data-type="row"><td class="xxlx-borders hanging03 shading">Hispanic or Latinx — no. (%)</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">Yes</td><td class="xxxx-borders">233 (23.0)</td><td class="xxxx-borders">260 (24.7)</td><td class="xxxx-borders">315 (29.8)</td><td class="xxxr-borders">808 (25.9)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">No</td><td class="xxxx-borders shading">780 (77.0)</td><td class="xxxx-borders shading">794 (75.3)</td><td class="xxxx-borders shading">741 (70.2)</td><td class="xxxr-borders shading">2315 (74.1)</td></tr><tr data-type="row"><td class="xxlx-borders hanging03">Geographic region — no. (%)</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">North America, Western Europe, and South Africa</td><td class="xxxx-borders shading">536 (52.9)</td><td class="xxxx-borders shading">556 (52.8)</td><td class="xxxx-borders shading">563 (53.3)</td><td class="xxxr-borders shading">1655 (53.0)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">South America and rest of Europe</td><td class="xxxx-borders">477 (47.1)</td><td class="xxxx-borders">498 (47.2)</td><td class="xxxx-borders">493 (46.7)</td><td class="xxxr-borders">1468 (47.0)</td></tr><tr data-type="row"><td class="xxlx-borders hanging03 shading">Prebronchodilator FEV<sub>1</sub></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">Mean volume — liters<a href="#core-t1fn2" role="doc-noteref">†</a></td><td class="xxxx-borders">1.9±0.6</td><td class="xxxx-borders">1.9 ±0.6</td><td class="xxxx-borders">1.9±0.6</td><td class="xxxr-borders">1.9±0.6</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">Mean percent of predicted value<a href="#core-t1fn2" role="doc-noteref">†</a></td><td class="xxxx-borders shading">63.4±12.8</td><td class="xxxx-borders shading">64.0±13.7</td><td class="xxxx-borders shading">64.4±13.3</td><td class="xxxr-borders shading">63.9±13.3</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging03" data-xml-align="left">Mean reversibility in FEV<sub>1</sub> — %<a href="#core-t1fn3" role="doc-noteref">‡</a></td><td class="xxxx-borders">27.7±17.2</td><td class="xxxx-borders">27.2±14.2</td><td class="xxxx-borders">27.8±15.9</td><td class="xxxr-borders">27.6±15.8</td></tr><tr data-type="row"><td class="xxlx-borders hanging03 shading">Maintenance treatment — no. (%)</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">Low-dose inhaled glucocorticoid–LABA or medium-dose inhaled glucocorticoid</td><td class="xxxx-borders">314 (31.0)</td><td class="xxxx-borders">334 (31.7)</td><td class="xxxx-borders">308 (29.2)</td><td class="xxxr-borders">956 (30.6)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">Medium-dose inhaled glucocorticoid–LABA or high-dose inhaled glucocorticoid</td><td class="xxxx-borders shading">385 (38.0)</td><td class="xxxx-borders shading">435 (41.3)</td><td class="xxxx-borders shading">441 (41.8)</td><td class="xxxr-borders shading">1261 (40.4)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">High-dose inhaled glucocorticoid–LABA</td><td class="xxxx-borders">295 (29.1)</td><td class="xxxx-borders">267 (25.3)</td><td class="xxxx-borders">285 (27.0)</td><td class="xxxr-borders">847 (27.1)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">Missing</td><td class="xxxx-borders shading">19 (1.9)</td><td class="xxxx-borders shading">18 (1.7)</td><td class="xxxx-borders shading">22 (2.1)</td><td class="xxxr-borders shading">59 (1.9)</td></tr><tr data-type="row"><td class="xxlx-borders hanging03">Severe asthma exacerbations in the 12 mo before screening — no. (%)</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">1</td><td class="xxxx-borders shading">788 (77.8)</td><td class="xxxx-borders shading">822 (78.0)</td><td class="xxxx-borders shading">840 (79.5)</td><td class="xxxr-borders shading">2450 (78.5)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">2</td><td class="xxxx-borders">185 (18.3)</td><td class="xxxx-borders">185 (17.6)</td><td class="xxxx-borders">164 (15.5)</td><td class="xxxr-borders">534 (17.1)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">3</td><td class="xxxx-borders shading">27 (2.7)</td><td class="xxxx-borders shading">38 (3.6)</td><td class="xxxx-borders shading">45 (4.3)</td><td class="xxxr-borders shading">110 (3.5)</td></tr><tr data-xml-align="center" data-type="row"><td class="xblx-borders hanging13" data-xml-align="left">≥4</td><td class="xbxx-borders">13 (1.3)</td><td class="xbxx-borders">9 (0.9)</td><td class="xbxx-borders">7 (0.7)</td><td class="xbxr-borders">29 (0.9)</td></tr></tbody></table></div></a><figcaption><a class="open-in-viewer" href="#t1" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2203163_t1.jpg"></a><div class="notes"><a class="open-in-viewer" href="#t1" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2203163_t1.jpg"></a><div role="doc-footnote" data-has="label"><a class="open-in-viewer" href="#t1" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2203163_t1.jpg"><div class="label">*</div></a><div id="core-t1fn1" role="paragraph" data-to-manipulate="true"><a class="open-in-viewer" href="#t1" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2203163_t1.jpg">Plus–minus values are means ±SD. The analysis includes 3123 patients; 5 patients who had not received any amount of a trial medication and 4 who had been withdrawn because of randomization at more than one site were excluded. Medications for rescue use were limited to the trial medications throughout the trial; additional fast-acting bronchodilators, including nebulizers, were prohibited. Additional controller medications were used by approximately 15% of the patients: approximately 10% used a leukotriene-receptor antagonist, 4% a long-acting muscarinic antagonist, and 2% a xanthine. Changes to maintenance therapy were allowed when clinically indicated (see the </a><a href="#ap2">Supplementary Appendix</a>). FEV<sub>1</sub> denotes forced expiratory volume in 1 second, and LABA long-acting β<sub>2</sub>-agonist.</div></div><div role="doc-footnote" data-has="label"><div class="label">†</div><div id="core-t1fn2" role="paragraph" data-to-manipulate="true">The results were obtained from the visit in which the prebronchodilator FEV<sub>1</sub> was assessed for eligibility.</div></div><div role="doc-footnote" data-has="label"><div class="label">‡</div><div id="core-t1fn3" role="paragraph" data-to-manipulate="true">The results were obtained from the visit in which reversibility in FEV<sub>1</sub> was assessed for eligibility. The reversibility in FEV<sub>1</sub> was calculated as the postbronchodilator FEV<sub>1</sub> (in liters) minus the prebronchodilator FEV<sub>1</sub> (in liters) divided by the prebronchodilator FEV<sub>1</sub> (in liters).</div></div></div></figcaption><figcaption><div class="caption">Demographic and Clinical Characteristics of the Patients at Screening.<a href="#core-t1fn1" role="doc-noteref">*</a></div></figcaption></figure><div class="external-links"><a class="pill__to-original" href="#t1"><i class="icon-return" aria-hidden="true"></i><span>Go to Table</span></a><a class="open-in-viewer" href="#t1" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2203163_t1.jpg"><span>Open in Viewer</span><i class="icon-expand" aria-hidden="true"></i></a></div></div><div id="core-t2"><figure class="table"><a class="open-in-viewer" href="#t2" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2203163_t2.jpg"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><img src="/cms/10.1056/NEJMoa2203163/asset/495eda5d-250a-4f77-a9d5-8494e367d7c1/assets/images/large/nejmoa2203163_t2.jpg" height="2305" width="2615" loading="lazy"></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1"><th class="txlx-borders" data-xml-align="left">Analysis</th><th class="txxx-borders" colspan="4"><span>Intention-to-Treat Analysis</span></th><th class="txxr-borders" colspan="4"><span>Preplanned On-Treatment Efficacy Analysis</span></th></tr><tr class="head2" data-type="row head2"><td class="xxlx-borders">&nbsp;</td><th class="xxxx-borders" colspan="2"><span>Adults and Adolescents<a href="#core-t2fn2" role="doc-noteref">†</a></span></th><th class="xxxx-borders" data-xml-align="left" colspan="2"><span>Adults, Adolescents, and Children<a href="#core-t2fn3" role="doc-noteref">‡</a></span></th><th class="xxxx-borders" colspan="2"><span>Adults and Adolescents<a href="#core-t2fn2" role="doc-noteref">†</a></span></th><th class="xxxr-borders" data-xml-align="left" colspan="2"><span>Adults, Adolescents, and Children<a href="#core-t2fn3" role="doc-noteref">‡</a></span></th></tr><tr class="head2" data-type="row head2"><td class="xxlx-borders">&nbsp;</td><th class="xxxx-borders">Albuterol<br>(180 μg)–<br>Budesonide<br>(160 μg)</th><th class="xxxx-borders">Albuterol<br>(180 μg)</th><th class="xxxx-borders">Albuterol<br>(180 μg)–<br>Budesonide<br>(80 μg)</th><th class="xxxx-borders">Albuterol<br>(180 μg)<br>Alone</th><th class="xxxx-borders">Albuterol<br>(180 μg)–<br>Budesonide<br>(160 μg)</th><th class="xxxx-borders">Albuterol<br>(180 μg)</th><th class="xxxx-borders">Albuterol<br>(180 μg)–<br>Budesonide<br>(80 μg)</th><th class="xxxr-borders">Albuterol<br>(180 μg)</th></tr></thead><tbody><tr data-type="row"><td class="xxlx-borders hanging02 shading"><b>Annualized rate of severe asthma exacerbation</b></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Patients — no.</td><td class="xxxx-borders">1013</td><td class="xxxx-borders">1014</td><td class="xxxx-borders">1054</td><td class="xxxx-borders">1056</td><td class="xxxx-borders">1013</td><td class="xxxx-borders">1014</td><td class="xxxx-borders">1054</td><td class="xxxr-borders">1056</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Severe exacerbations — no.</td><td class="xxxx-borders shading">345</td><td class="xxxx-borders shading">427</td><td class="xxxx-borders shading">372</td><td class="xxxx-borders shading">441</td><td class="xxxx-borders shading">334</td><td class="xxxx-borders shading">413</td><td class="xxxx-borders shading">354</td><td class="xxxr-borders shading">426</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Annualized rate (95% CI)</td><td class="xxxx-borders">0.43 (0.33–0.58)</td><td class="xxxx-borders">0.58 (0.44–0.77)</td><td class="xxxx-borders">0.48 (0.37–0.63)</td><td class="xxxx-borders">0.60 (0.46–0.79)</td><td class="xxxx-borders">0.45 (0.34–0.60)</td><td class="xxxx-borders">0.59 (0.44–0.78)</td><td class="xxxx-borders">0.49 (0.37–0.64)</td><td class="xxxr-borders">0.61 (0.46–0.80)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Rate ratio (95% CI)</td><td class="xxxx-borders shading">0.75 (0.61–0.91)</td><td class="xxxx-borders shading">Reference</td><td class="xxxx-borders shading">0.81 (0.66–0.98)</td><td class="xxxx-borders shading">Reference</td><td class="xxxx-borders shading">0.76 (0.62–0.93)</td><td class="xxxx-borders shading">Reference</td><td class="xxxx-borders shading">0.80 (0.66–0.98)</td><td class="xxxr-borders shading">Reference</td></tr><tr data-type="row"><td class="xxlx-borders hanging02"><b>Annualized total dose of systemic glucocorticoid</b><a href="#core-t2fn4" role="doc-noteref">§</a></td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Patients — no.</td><td class="xxxx-borders shading">1012</td><td class="xxxx-borders shading">1011</td><td class="xxxx-borders shading">1052</td><td class="xxxx-borders shading">1052</td><td class="xxxx-borders shading">1012</td><td class="xxxx-borders shading">1011</td><td class="xxxx-borders shading">1052</td><td class="xxxr-borders shading">1052</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Median value (5th–95th percentile) — mg/yr</td><td class="xxxx-borders">0.0 (0.0–459.2)</td><td class="xxxx-borders">0.0 (0.0–484.3)</td><td class="xxxx-borders">0.0 (0.0–494.4)</td><td class="xxxx-borders">0.0 (0.0–600.8)</td><td class="xxxx-borders">0.0 (0.0–496.1)</td><td class="xxxx-borders">0.0 (0.0–622.1)</td><td class="xxxx-borders">0.0 (0.0–487.0)</td><td class="xxxr-borders">0.0 (0.0–615.9)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Mean value — mg/yr</td><td class="xxxx-borders shading">83.6±247.7</td><td class="xxxx-borders shading">130.0±630.3</td><td class="xxxx-borders shading">94.7±318.2</td><td class="xxxx-borders shading">127.6±619.8</td><td class="xxxx-borders shading">86.2±262.9</td><td class="xxxx-borders shading">129.3±657.2</td><td class="xxxx-borders shading">95.5±335.4</td><td class="xxxr-borders shading">127.1±646.2</td></tr><tr data-type="row"><td class="xxlx-borders hanging02"><b>Response analysis at wk 24</b><a href="#core-t2fn5" role="doc-noteref">¶</a></td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-type="row"><td class="xxlx-borders hanging02 shading">ACQ-5</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Patients — no.</td><td class="xxxx-borders">1013</td><td class="xxxx-borders">1014</td><td class="xxxx-borders">1052</td><td class="xxxx-borders">1055</td><td class="xxxx-borders">1013</td><td class="xxxx-borders">1014</td><td class="xxxx-borders">1052</td><td class="xxxr-borders">1055</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Patients with response — no. (%)</td><td class="xxxx-borders shading">682 (67.3)</td><td class="xxxx-borders shading">636 (62.7)</td><td class="xxxx-borders shading">690 (65.6)</td><td class="xxxx-borders shading">656 (62.2)</td><td class="xxxx-borders shading">677 (66.8)</td><td class="xxxx-borders shading">630 (62.1)</td><td class="xxxx-borders shading">681 (64.7)</td><td class="xxxr-borders shading">650 (61.6)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Odds ratio (95% CI)</td><td class="xxxx-borders">1.22 (1.01–1.46)</td><td class="xxxx-borders">Reference</td><td class="xxxx-borders">1.15 (0.96–1.37)</td><td class="xxxx-borders">Reference</td><td class="xxxx-borders">1.22 (1.02–1.47)</td><td class="xxxx-borders">Reference</td><td class="xxxx-borders">1.13 (0.95–1.35)</td><td class="xxxr-borders">Reference</td></tr><tr data-type="row"><td class="xxlx-borders hanging02 shading">AQLQ+12</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Patients — no.</td><td class="xxxx-borders">994</td><td class="xxxx-borders">993</td><td class="xxxx-borders">987</td><td class="xxxx-borders">NA</td><td class="xxxx-borders">994</td><td class="xxxx-borders">993</td><td class="xxxx-borders">987</td><td class="xxxr-borders">NA</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Patients with response — no. (%)</td><td class="xxxx-borders shading">515 (51.8)</td><td class="xxxx-borders shading">464 (46.7)</td><td class="xxxx-borders shading">496 (50.3)</td><td class="xxxx-borders shading">NA</td><td class="xxxx-borders shading">508 (51.1)</td><td class="xxxx-borders shading">461 (46.4)</td><td class="xxxx-borders shading">489 (49.5)</td><td class="xxxr-borders shading">NA</td></tr><tr data-xml-align="center" data-type="row"><td class="xblx-borders hanging12" data-xml-align="left">Odds ratio (95% CI)</td><td class="xbxx-borders">1.25 (1.04–1.50)</td><td class="xbxx-borders">Reference</td><td class="xbxx-borders">1.13 (0.94–1.36)</td><td class="xbxx-borders">NA</td><td class="xbxx-borders">1.23 (1.02–1.48)</td><td class="xbxx-borders">Reference</td><td class="xbxx-borders">1.11 (0.93–1.34)</td><td class="xbxr-borders">NA</td></tr></tbody></table></div><figcaption><div class="notes"><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="core-t2fn1" role="paragraph" data-to-manipulate="true">Plus–minus values are means ±SD. The hierarchical testing procedure was stopped after the comparison between the lower-dose combination group and the albuterol-alone group in the intention-to-treat analysis of the primary end point; therefore, 95% confidence intervals cannot be used to infer treatment effects. A total of 3123 patients were assessed with respect to the efficacy end points (5 patients who had not received any trial medication and 4 who had been withdrawn because of randomization at more than one site were excluded). The comparisons between the higher-dose combination group and the albuterol-alone group excluded children 4 to 11 years of age; therefore, the number of patients in the albuterol-alone group in these comparisons was less than that in the comparisons between the lower-dose combination group and the albuterol-alone group. NA denotes not applicable.</div></div><div role="doc-footnote" data-has="label"><div class="label">†</div><div id="core-t2fn2" role="paragraph" data-to-manipulate="true">Analyses included patients 12 years of age or older.</div></div><div role="doc-footnote" data-has="label"><div class="label">‡</div><div id="core-t2fn3" role="paragraph" data-to-manipulate="true">Analyses included patients 4 years of age or older, except for the Asthma Control Questionnaire–5 (ACQ-5) response analysis, in which patients 4 and 5 years of age were excluded, and the Asthma Quality of Life Questionnaire (AQLQ+12) response analysis, in which patients 4 to 11 years of age were excluded.</div></div><div role="doc-footnote" data-has="label"><div class="label">§</div><div id="core-t2fn4" role="paragraph" data-to-manipulate="true">The annualized total dose of systemic glucocorticoid is given in prednisone equivalents.</div></div><div role="doc-footnote" data-has="label"><div class="label">¶</div><div id="core-t2fn5" role="paragraph" data-to-manipulate="true">Intention-to-treat analyses for the ACQ-5 response and the AQLQ+12 response are post hoc. Scores on the ACQ-5 range from 0 to 6, with lower scores indicating better asthma control (minimum clinically important difference, 0.5 points). Scores on the AQLQ+12 range from 1 to 7, with higher scores indicating better asthma-related quality of life (minimum clinically important difference, 0.5 points). A response was defined as a decrease (in the ACQ-5 score) or an increase (in the AQLQ+12 score) of at least 0.5 points from the baseline score.</div></div></div></figcaption></a><figcaption><div class="caption">Intention-to-Treat and Preplanned On-Treatment Efficacy Analyses of the Secondary End Points.<a href="#core-t2fn1" role="doc-noteref">*</a></div></figcaption></figure><div class="external-links"><a class="pill__to-original" href="#t2"><i class="icon-return" aria-hidden="true"></i><span>Go to Table</span></a><a class="open-in-viewer" href="#t2" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2203163_t2.jpg"><span>Open in Viewer</span><i class="icon-expand" aria-hidden="true"></i></a></div></div><div id="core-t3"><figure class="table"><a class="open-in-viewer" href="#t3" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2203163_t3.jpg"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><img src="/cms/10.1056/NEJMoa2203163/asset/a0bd2a6a-b6e8-4ac6-8563-34b2cb1ab4aa/assets/images/large/nejmoa2203163_t3.jpg" height="1080" width="1711" loading="lazy"></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1"><th class="txlx-borders" data-xml-align="left">Event</th><th class="txxx-borders">Albuterol (180 μg)–<br>Budesonide (160 μg)<br>(N=1015)</th><th class="txxx-borders">Albuterol (180 μg)–<br>Budesonide (80 μg)<br>(N=1055)</th><th class="txxr-borders">Albuterol<br>(180 μg)<br>(N=1057)</th></tr><tr class="head3" data-type="row head3"><td class="xxlx-borders">&nbsp;</td><th class="xxxr-borders" colspan="3"><span>number of patients (percent)</span></th></tr></thead><tbody><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01 shading" data-xml-align="left">Any adverse event</td><td class="xxxx-borders shading">469 (46.2)</td><td class="xxxx-borders shading">497 (47.1)</td><td class="xxxr-borders shading">490 (46.4)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01" data-xml-align="left">Nasopharyngitis</td><td class="xxxx-borders">76 (7.5)</td><td class="xxxx-borders">61 (5.8)</td><td class="xxxr-borders">54 (5.1)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01 shading" data-xml-align="left">Headache</td><td class="xxxx-borders shading">44 (4.3)</td><td class="xxxx-borders shading">50 (4.7)</td><td class="xxxr-borders shading">50 (4.7)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01" data-xml-align="left">Covid-19</td><td class="xxxx-borders">43 (4.2)</td><td class="xxxx-borders">52 (4.9)</td><td class="xxxr-borders">46 (4.4)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01 shading" data-xml-align="left">Upper respiratory tract infection</td><td class="xxxx-borders shading">26 (2.6)</td><td class="xxxx-borders shading">31 (2.9)</td><td class="xxxr-borders shading">26 (2.5)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01" data-xml-align="left">Bronchitis</td><td class="xxxx-borders">25 (2.5)</td><td class="xxxx-borders">27 (2.6)</td><td class="xxxr-borders">28 (2.6)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01 shading" data-xml-align="left">Hypertension</td><td class="xxxx-borders shading">22 (2.2)</td><td class="xxxx-borders shading">27 (2.6)</td><td class="xxxr-borders shading">26 (2.5)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01" data-xml-align="left">Asthma</td><td class="xxxx-borders">18 (1.8)</td><td class="xxxx-borders">20 (1.9)</td><td class="xxxr-borders">35 (3.3)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01 shading" data-xml-align="left">Back pain</td><td class="xxxx-borders shading">27 (2.7)</td><td class="xxxx-borders shading">23 (2.2)</td><td class="xxxr-borders shading">20 (1.9)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01" data-xml-align="left">Influenza</td><td class="xxxx-borders">21 (2.1)</td><td class="xxxx-borders">23 (2.2)</td><td class="xxxr-borders">14 (1.3)</td></tr><tr data-xml-align="center" data-type="row"><td class="xblx-borders hanging01 shading" data-xml-align="left">Sinusitis</td><td class="xbxx-borders shading">15 (1.5)</td><td class="xbxx-borders shading">17 (1.6)</td><td class="xbxr-borders shading">24 (2.3)</td></tr></tbody></table></div><figcaption><div class="notes"><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="core-t3fn1" role="paragraph" data-to-manipulate="true">Adverse events are sorted in decreasing total frequency of preferred term in the <i>Medical Dictionary for Regulatory Activities</i>, version 24.0. Patients with multiple events in the same category are counted only once in that category.</div></div></div></figcaption></a><figcaption><div class="caption">Adverse Events Occurring in at Least 2% of Patients in Any Trial Group.<a href="#core-t3fn1" role="doc-noteref">*</a></div></figcaption></figure><div class="external-links"><a class="pill__to-original" href="#t3"><i class="icon-return" aria-hidden="true"></i><span>Go to Table</span></a><a class="open-in-viewer" href="#t3" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2203163_t3.jpg"><span>Open in Viewer</span><i class="icon-expand" aria-hidden="true"></i></a></div></div></div></div><div id="core-collateral-share" role="tabpanel" data-core-tabs="core-collateral-share" tabindex="-1" aria-labelledby="pane-core-collateral-share"><header><h2 id="pane-core-collateral-share"><i class="icon-share" aria-hidden="true"></i>Share</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><h3>Share</h3><div class="section--wrapper"><section><h4>CONTENT LINK</h4><div id="share-self"><p data-id="article-share-self-link" class="share-self__source">https://www.nejm.org/doi/full/10.1056/NEJMoa2203163</p><button data-id="article-share-access" aria-label="CONTENT LINK" class="share-self__action btn btn--inverse"><i aria-hidden="true" class="icon-copy-o"></i><span>Copy Link</span></button><div aria-live="polite" class="share-self__status"><p class="share-self__success"><i aria-hidden="true" class="icon-check_circle"></i><span>Copied!</span></p><p class="share-self__failed"><i aria-hidden="true" class="icon-x_btnclose"></i><span>Copying failed.</span></p></div></div></section><section data-location="share_tools_article"><h4>Share</h4><div class="share-buttons a2a a2a_kit" style="line-height: 16px;"><a href="/#facebook" aria-label="Share on Facebook" data-id="article-share-facebook" rel="nofollow noopener" role="link" target="_blank" title="Share on Facebook" class="btn btn--facebook a2a_button_facebook" data-interactiontype="social"><i aria-hidden="true" class="icon-facebook"></i><span>Facebook</span></a><a href="/#twitter" aria-label="Share on X (formerly Twitter)" data-id="article-share-twitter" rel="nofollow noopener" role="link" target="_blank" title="Share on X (formerly Twitter)" class="btn btn--twitter a2a_button_twitter" data-interactiontype="social"><i aria-hidden="true" class="icon-twitter"></i><span>X (formerly Twitter)</span></a><a href="/#linkedin" aria-label="Share on LinkedIn" data-id="article-share-linkedin" rel="nofollow noopener" role="link" target="_blank" title="Share on LinkedIn" class="btn btn--linkedin a2a_button_linkedin" data-interactiontype="social"><i aria-hidden="true" class="icon-linkedin"></i><span>LinkedIn</span></a><a href="/#email" aria-label="Share on email" data-id="article-share-email" rel="nofollow noopener" role="link" target="_blank" title="Share on email" class="btn btn--email a2a_button_email" data-interactiontype="content_email_click"><i aria-hidden="true" class="icon-mail"></i><span>email</span></a><a href="/#bluesky" aria-label="Share on Bluesky" data-id="article-share-bluesky" rel="nofollow noopener" role="link" target="_blank" title="Share on Bluesky" class="btn btn--bluesky a2a_button_bluesky" data-interactiontype="social"><i aria-hidden="true" class="icon-bluesky"></i><span>Bluesky</span></a></div></section></div></div><div data-location="references_article" id="core-collateral-references" role="tabpanel" aria-labelledby="pane-core-collateral-references" data-core-tabs="core-collateral-references" tabindex="-1"><header><h2 id="pane-core-collateral-references"><i aria-hidden="true" class="icon-references"></i>References</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><h3>References</h3><div role="list" class="section--wrapper"><div role="listitem" data-has="label"><div class="label">1.</div><div id="core-r1" class="citations"><div class="citation"><div class="citation-content">Global Initiative for Asthma. Global strategy for asthma management and prevention. 2022 (<a href="https://ginasthma.org/gina-reports/">https://ginasthma.org/gina-reports/</a>).</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r1-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Global+strategy+for+asthma+management+and+prevention&amp;publication_year=2022" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r1-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r1-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] yet fluctuating, airway inflammation. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r4-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] effect on underlying airway inflammation, </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r16" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>c [...] led the Global Initiative for Asthma (GINA) </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r1-4" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>d [...] -agonist combination, as defined by GINA, </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">2.</div><div id="core-r2" class="citations"><div class="citation"><div class="citation-content">O’Byrne PM, Jenkins C, Bateman ED. The paradoxes of asthma management: time for a new approach? <em>Eur Respir J</em> 2017;50:1701103-1701103.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r3"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1183/13993003.01103-2017" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/28889114/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000410089300024" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=The+paradoxes+of+asthma+management%3A+time+for+a+new+approach%3F&amp;publication_year=2017&amp;journal=Eur+Respir+J&amp;pages=1701103-1701103&amp;doi=10.1183%2F13993003.01103-2017&amp;pmid=28889114" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">3.</div><div id="core-r3" class="citations"><div class="citation"><div class="citation-content">Reddel HK, FitzGerald JM, Bateman ED, et al. GINA 2019: a fundamental change in asthma management: treatment of asthma with short-acting bronchodilators alone is no longer recommended for adults and adolescents. <em>Eur Respir J</em> 2019;53:1901046-1901046.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r3"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1183/13993003.01046-2019" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/31249014/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000474194800043" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=GINA+2019%3A+a+fundamental+change+in+asthma+management%3A+treatment+of+asthma+with+short-acting+bronchodilators+alone+is+no+longer+recommended+for+adults+and+adolescents.&amp;publication_year=2019&amp;journal=Eur+Respir+J&amp;pages=1901046-1901046&amp;doi=10.1183%2F13993003.01046-2019&amp;pmid=31249014" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">4.</div><div id="core-r4" class="citations"><div class="citation"><div class="citation-content">2020 focused updates to the asthma management guidelines: a report from the National Asthma Education and Prevention Program Coordinating Committee Expert Panel Working Group. 2020 (<a href="https://www.nhlbi.nih.gov/health-topics/all-publications-and-resources/2020-focused-updates-asthma-management-guidelines">https://www.nhlbi.nih.gov/health-topics/all-publications-and-resources/2020-focused-updates-asthma-management-guidelines</a>).</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r4-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=2020+focused+updates+to+the+asthma+management+guidelines%3A+a+report+from+the+National+Asthma+Education+and+Prevention+Program+Coordinating+Committee+Expert+Panel+Working+Group&amp;publication_year=2020" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r4-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r4-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] effect on underlying airway inflammation, </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r17" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] Asthma Education and Prevention Program </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r23" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>c [...] Drug Administration in the United States. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">5.</div><div id="core-r5" class="citations"><div class="citation"><div class="citation-content">Bloom CI, Cabrera C, Arnetorp S, et al. Asthma-related health outcomes associated with short-acting β<sub>2</sub>-agonist inhaler use: an observational UK study as part of the SABINA Global Program. <em>Adv Ther</em> 2020;37:4190-4208.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r10"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1007/s12325-020-01444-5" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32720299/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000552933100001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Asthma-related+health+outcomes+associated+with+short-acting+%CE%B22-agonist+inhaler+use%3A+an+observational+UK+study+as+part+of+the+SABINA+Global+Program.&amp;publication_year=2020&amp;journal=Adv+Ther&amp;pages=4190-4208&amp;doi=10.1007%2Fs12325-020-01444-5&amp;pmid=32720299" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">6.</div><div id="core-r6" class="citations"><div class="citation"><div class="citation-content">Lugogo N, Gilbert I, Tkacz J, Gandhi H, Goshi N, Lanz MJ. Real-world patterns and implications of short-acting β<sub>2</sub>-agonist use in patients with asthma in the United States. <em>Ann Allergy Asthma Immunol</em> 2021;126(6):681-689.e1.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r10"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.anai.2021.01.024" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/33515710/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000663638900012" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Real-world+patterns+and+implications+of+short-acting+%CE%B22-agonist+use+in+patients+with+asthma+in+the+United+States.&amp;publication_year=2021&amp;journal=Ann+Allergy+Asthma+Immunol&amp;pages=681-689.e1&amp;doi=10.1016%2Fj.anai.2021.01.024&amp;pmid=33515710" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">7.</div><div id="core-r7" class="citations"><div class="citation"><div class="citation-content">Nwaru BI, Ekström M, Hasvold P, Wiklund F, Telg G, Janson C. Overuse of short-acting β<sub>2</sub>-agonists in asthma is associated with increased risk of exacerbation and mortality: a nationwide cohort study of the global SABINA programme. <em>Eur Respir J</em> 2020;55:1901872-1901872.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r10"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1183/13993003.01872-2019" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/31949111/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000531099900018" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Overuse+of+short-acting+%CE%B22-agonists+in+asthma+is+associated+with+increased+risk+of+exacerbation+and+mortality%3A+a+nationwide+cohort+study+of+the+global+SABINA+programme.&amp;publication_year=2020&amp;journal=Eur+Respir+J&amp;pages=1901872-1901872&amp;doi=10.1183%2F13993003.01872-2019&amp;pmid=31949111" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">8.</div><div id="core-r8" class="citations"><div class="citation"><div class="citation-content">Bateman ED, Price DB, Wang HC, et al. Short-acting β<sub>2</sub>-agonist prescriptions are associated with poor clinical outcomes of asthma: the multi-country, cross-sectional SABINA III study. <em>Eur Respir J</em> 2021 September 24 (Epub ahead of print).</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r8-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/34561293/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000830088400010" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Short-acting+%CE%B22-agonist+prescriptions+are+associated+with+poor+clinical+outcomes+of+asthma%3A+the+multi-country%2C+cross-sectional+SABINA+III+study.&amp;publication_year=2021&amp;journal=Eur+Respir+J&amp;pmid=34561293" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r8-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r10" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] risk of severe asthma exacerbation. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r23" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] Drug Administration in the United States. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">9.</div><div id="core-r9" class="citations"><div class="citation"><div class="citation-content">Janson C, Menzies-Gow A, Nan C, et al. SABINA: an overview of short-acting β<sub>2</sub>-agonist use in asthma in European countries. <em>Adv Ther</em> 2020;37:1124-1135.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r10"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1007/s12325-020-01233-0" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/31981105/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000509236800004" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=SABINA%3A+an+overview+of+short-acting+%CE%B22-agonist+use+in+asthma+in+European+countries.&amp;publication_year=2020&amp;journal=Adv+Ther&amp;pages=1124-1135&amp;doi=10.1007%2Fs12325-020-01233-0&amp;pmid=31981105" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">10.</div><div id="core-r10" class="citations"><div class="citation"><div class="citation-content">Quint JK, Arnetorp S, Kocks JWH, et al. Short-acting β<sub>2</sub>-agonist exposure and severe asthma exacerbations: SABINA findings from Europe and North America. <em>J Allergy Clin Immunol Pract</em> 2022 March 29 (Epub ahead of print).</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r10"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.jaip.2022.02.047" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/35364341/" target="_blank">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Short-acting+%CE%B22-agonist+exposure+and+severe+asthma+exacerbations%3A+SABINA+findings+from+Europe+and+North+America.&amp;publication_year=2022&amp;journal=J+Allergy+Clin+Immunol+Pract&amp;doi=10.1016%2Fj.jaip.2022.02.047&amp;pmid=35364341" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">11.</div><div id="core-r11" class="citations"><div class="citation"><div class="citation-content">O’Byrne P, Fabbri LM, Pavord ID, Papi A, Petruzzelli S, Lange P. Asthma progression and mortality: the role of inhaled corticosteroids. <em>Eur Respir J</em> 2019;54:1900491-1900491.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r14-1"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1183/13993003.00491-2019" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/31048346/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000486537500034" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Asthma+progression+and+mortality%3A+the+role+of+inhaled+corticosteroids.&amp;publication_year=2019&amp;journal=Eur+Respir+J&amp;pages=1900491-1900491&amp;doi=10.1183%2F13993003.00491-2019&amp;pmid=31048346" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">12.</div><div id="core-r12" class="citations"><div class="citation"><div class="citation-content">Rabe KF, Atienza T, Magyar P, Larsson P, Jorup C, Lalloo UG. Effect of budesonide in combination with formoterol for reliever therapy in asthma exacerbations: a randomised controlled, double-blind study. <em>Lancet</em> 2006;368:744-753.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r12-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S0140-6736(06)69284-2" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/16935685/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000240240200026" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Effect+of+budesonide+in+combination+with+formoterol+for+reliever+therapy+in+asthma+exacerbations%3A+a+randomised+controlled%2C+double-blind+study.&amp;publication_year=2006&amp;journal=Lancet&amp;pages=744-753&amp;doi=10.1016%2FS0140-6736%2806%2969284-2&amp;pmid=16935685" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r12-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r14-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] patients with a range of asthma severity </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r35" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] in patients with moderate-to-severe asthma. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">13.</div><div id="core-r13" class="citations"><div class="citation"><div class="citation-content">Rogliani P, Ritondo BL, Ora J, Cazzola M, Calzetta L. SMART and as-needed therapies in mild-to-severe asthma: a network meta-analysis. <em>Eur Respir J</em> 2020;56:2000625-2000625.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r13-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1183/13993003.00625-2020" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32430423/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000571572000019" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=SMART+and+as-needed+therapies+in+mild-to-severe+asthma%3A+a+network+meta-analysis.&amp;publication_year=2020&amp;journal=Eur+Respir+J&amp;pages=2000625-2000625&amp;doi=10.1183%2F13993003.00625-2020&amp;pmid=32430423" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r13-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r14-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] patients with a range of asthma severity </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r22-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] had been using for maintenance therapy. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">14.</div><div id="core-r14" class="citations"><div class="citation"><div class="citation-content">Sobieraj DM, Weeda ER, Nguyen E, et al. Association of inhaled corticosteroids and long-acting β-agonists as controller and quick relief therapy with exacerbations and symptom control in persistent asthma: a systematic review and meta-analysis. <em>JAMA</em> 2018;319:1485-1496.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r14-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1001/jama.2018.2769" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/29554195/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000429590200017" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Association+of+inhaled+corticosteroids+and+long-acting+%CE%B2-agonists+as+controller+and+quick+relief+therapy+with+exacerbations+and+symptom+control+in+persistent+asthma%3A+a+systematic+review+and+meta-analysis.&amp;publication_year=2018&amp;journal=JAMA&amp;pages=1485-1496&amp;doi=10.1001%2Fjama.2018.2769&amp;pmid=29554195" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r14-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r14-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] patients with a range of asthma severity </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r22-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] had been using for maintenance therapy. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">15.</div><div id="core-r15" class="citations"><div class="citation"><div class="citation-content">Global Initiative for Asthma. Global strategy for asthma management and prevention. 2019 (<a href="https://ginasthma.org/wp-content/uploads/2019/06/GINA-2019-main-report-June-2019-wms.pdf">https://ginasthma.org/wp-content/uploads/2019/06/GINA-2019-main-report-June-2019-wms.pdf</a>).</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r16"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Global+strategy+for+asthma+management+and+prevention&amp;publication_year=2019" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">16.</div><div id="core-r16" class="citations"><div class="citation"><div class="citation-content">Reddel HK, Bacharier LB, Bateman ED, et al. Global Initiative for Asthma Strategy 2021: executive summary and rationale for key changes. <em>Am J Respir Crit Care Med</em> 2022;205:17-35.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r16"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1164/rccm.202109-2205PP" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/34658302/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000738848700011" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Global+Initiative+for+Asthma+Strategy+2021%3A+executive+summary+and+rationale+for+key+changes.&amp;publication_year=2022&amp;journal=Am+J+Respir+Crit+Care+Med&amp;pages=17-35&amp;doi=10.1164%2Frccm.202109-2205PP&amp;pmid=34658302" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">17.</div><div id="core-r17" class="citations"><div class="citation"><div class="citation-content">Cloutier MM, Baptist AP, Blake KV, et al. 2020 focused updates to the asthma management guidelines: a report from the National Asthma Education and Prevention Program Coordinating Committee Expert Panel Working Group. <em>J Allergy Clin Immunol</em> 2020;146:1217-1270.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r17"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.jaci.2020.10.003" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/33280709/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000596937900002" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=2020+focused+updates+to+the+asthma+management+guidelines%3A+a+report+from+the+National+Asthma+Education+and+Prevention+Program+Coordinating+Committee+Expert+Panel+Working+Group.&amp;publication_year=2020&amp;journal=J+Allergy+Clin+Immunol&amp;pages=1217-1270&amp;doi=10.1016%2Fj.jaci.2020.10.003&amp;pmid=33280709" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">18.</div><div id="core-r18" class="citations"><div class="citation"><div class="citation-content">Bodzenta-Lukaszyk A, Dymek A, McAulay K, Mansikka H. Fluticasone/formoterol combination therapy is as effective as fluticasone/salmeterol in the treatment of asthma, but has a more rapid onset of action: an open-label, randomized study. <em>BMC Pulm Med</em> 2011;11:28-28.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r18"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1186/1471-2466-11-28" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/21605396/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000208592800028" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Fluticasone%2Fformoterol+combination+therapy+is+as+effective+as+fluticasone%2Fsalmeterol+in+the+treatment+of+asthma%2C+but+has+a+more+rapid+onset+of+action%3A+an+open-label%2C+randomized+study.&amp;publication_year=2011&amp;journal=BMC+Pulm+Med&amp;pages=28-28&amp;doi=10.1186%2F1471-2466-11-28&amp;pmid=21605396" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">19.</div><div id="core-r19" class="citations"><div class="citation"><div class="citation-content">Bousquet J, Boulet LP, Peters MJ, et al. Budesonide/formoterol for maintenance and relief in uncontrolled asthma vs. high-dose salmeterol/fluticasone. <em>Respir Med</em> 2007;101:2437-2446.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r22-1"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.rmed.2007.07.014" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/17905575/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000251212700002" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Budesonide%2Fformoterol+for+maintenance+and+relief+in+uncontrolled+asthma+vs.+high-dose+salmeterol%2Ffluticasone.&amp;publication_year=2007&amp;journal=Respir+Med&amp;pages=2437-2446&amp;doi=10.1016%2Fj.rmed.2007.07.014&amp;pmid=17905575" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">20.</div><div id="core-r20" class="citations"><div class="citation"><div class="citation-content">Kuna P, Peters MJ, Manjra AI, et al. Effect of budesonide/formoterol maintenance and reliever therapy on asthma exacerbations. <em>Int J Clin Pract</em> 2007;61:725-736.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r22-1"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1111/j.1742-1241.2007.01338.x" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/17362472/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000245608700007" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Effect+of+budesonide%2Fformoterol+maintenance+and+reliever+therapy+on+asthma+exacerbations.&amp;publication_year=2007&amp;journal=Int+J+Clin+Pract&amp;pages=725-736&amp;doi=10.1111%2Fj.1742-1241.2007.01338.x&amp;pmid=17362472" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">21.</div><div id="core-r21" class="citations"><div class="citation"><div class="citation-content">O’Byrne PM, Bisgaard H, Godard PP, et al. Budesonide/formoterol combination therapy as both maintenance and reliever medication in asthma. <em>Am J Respir Crit Care Med</em> 2005;171:129-136.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r22-1"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1164/rccm.200407-884OC" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/15502112/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000226258400008" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Budesonide%2Fformoterol+combination+therapy+as+both+maintenance+and+reliever+medication+in+asthma.&amp;publication_year=2005&amp;journal=Am+J+Respir+Crit+Care+Med&amp;pages=129-136&amp;doi=10.1164%2Frccm.200407-884OC&amp;pmid=15502112" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">22.</div><div id="core-r22" class="citations"><div class="citation"><div class="citation-content">Scicchitano R, Aalbers R, Ukena D, et al. Efficacy and safety of budesonide/formoterol single inhaler therapy versus a higher dose of budesonide in moderate to severe asthma. <em>Curr Med Res Opin</em> 2004;20:1403-1418.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r22-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1185/030079904X2051" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/15383189/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000224343100010" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Efficacy+and+safety+of+budesonide%2Fformoterol+single+inhaler+therapy+versus+a+higher+dose+of+budesonide+in+moderate+to+severe+asthma.&amp;publication_year=2004&amp;journal=Curr+Med+Res+Opin&amp;pages=1403-1418&amp;doi=10.1185%2F030079904X2051&amp;pmid=15383189" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r22-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r22-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] had been using for maintenance therapy. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r35" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] in patients with moderate-to-severe asthma. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">23.</div><div id="core-r23" class="citations"><div class="citation"><div class="citation-content">Food and Drug Administration. Albuterol sulfate HFA (<a href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2005/021457s001lbl.pdf">https://www.accessdata.fda.gov/drugsatfda_docs/label/2005/021457s001lbl.pdf</a>).</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r23"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Albuterol+sulfate+HFA" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">24.</div><div id="core-r24" class="citations"><div class="citation"><div class="citation-content">Usmani OS, Roche N, Jenkins M, Stjepanovic N, Mack P, De Backer W. Consistent pulmonary drug delivery with whole lung deposition using the aerosphere inhaler: a review of the evidence. <em>Int J Chron Obstruct Pulmon Dis</em> 2021;16:113-124.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r25"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.2147/COPD.S274846" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/33500616/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000610875700001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Consistent+pulmonary+drug+delivery+with+whole+lung+deposition+using+the+aerosphere+inhaler%3A+a+review+of+the+evidence.&amp;publication_year=2021&amp;journal=Int+J+Chron+Obstruct+Pulmon+Dis&amp;pages=113-124&amp;doi=10.2147%2FCOPD.S274846&amp;pmid=33500616" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">25.</div><div id="core-r25" class="citations"><div class="citation"><div class="citation-content">Cappelletti C, Maes A, Rossman K, et al. Dose-ranging and cumulative dose studies of Albuterol Sulfate MDI in Co-Suspension Delivery technology (AS MDI; PT007) in patients with asthma: the ASPEN and ANTORA trials. <em>Clin Drug Investig</em> 2021;41:579-590.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r25"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1007/s40261-021-01040-7" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/34089147/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000658107800001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Dose-ranging+and+cumulative+dose+studies+of+Albuterol+Sulfate+MDI+in+Co-Suspension+Delivery+technology+%28AS+MDI%3B+PT007%29+in+patients+with+asthma%3A+the+ASPEN+and+ANTORA+trials.&amp;publication_year=2021&amp;journal=Clin+Drug+Investig&amp;pages=579-590&amp;doi=10.1007%2Fs40261-021-01040-7&amp;pmid=34089147" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">26.</div><div id="core-r26" class="citations"><div class="citation"><div class="citation-content">Juniper EF, Bousquet J, Abetz L, Bateman ED, GOAL Committee. Identifying ‘well-controlled’ and ‘not well-controlled’ asthma using the Asthma Control Questionnaire. <em>Respir Med</em> 2006;100:616-621.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r26"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.rmed.2005.08.012" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/16226443/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000236643300005" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Identifying+%E2%80%98well-controlled%E2%80%99+and+%E2%80%98not+well-controlled%E2%80%99+asthma+using+the+Asthma+Control+Questionnaire.&amp;publication_year=2006&amp;journal=Respir+Med&amp;pages=616-621&amp;doi=10.1016%2Fj.rmed.2005.08.012&amp;pmid=16226443" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">27.</div><div id="core-r27" class="citations"><div class="citation"><div class="citation-content">Chipps BE, Albers FC, Reilly L, Johnsson E, Cappelletti C, Papi A. Efficacy and safety of as-needed albuterol/budesonide versus albuterol in adults and children aged ≥4 years with moderate-to-severe asthma: rationale and design of the randomised, double-blind, active-controlled MANDALA study. <em>BMJ Open Respir Res</em> 2021;8(1):e001077-e001077.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r27-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1136/bmjresp-2021-001077" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/34887317/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000729565200001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Efficacy+and+safety+of+as-needed+albuterol%2Fbudesonide+versus+albuterol+in+adults+and+children+aged+%E2%89%A54+years+with+moderate-to-severe+asthma%3A+rationale+and+design+of+the+randomised%2C+double-blind%2C+active-controlled+MANDALA+study.&amp;publication_year=2021&amp;journal=BMJ+Open+Respir+Res&amp;pages=e001077-e001077&amp;doi=10.1136%2Fbmjresp-2021-001077&amp;pmid=34887317" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r27-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r27-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] South America, Europe, and South Africa </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r27-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] the full text of this article at NEJM.org). </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r27-3" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>c [...] procedures have been described previously. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r27-4" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>d [...] or a change in maintenance therapy. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r27-5" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>e [...] of 0.22 with the use of albuterol alone. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">28.</div><div id="core-r28" class="citations"><div class="citation"><div class="citation-content">Juniper EF, O’Byrne PM, Guyatt GH, Ferrie PJ, King DR. Development and validation of a questionnaire to measure asthma control. <em>Eur Respir J</em> 1999;14:902-907.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r28"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1034/j.1399-3003.1999.14d29.x" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/10573240/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000083614800029" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Development+and+validation+of+a+questionnaire+to+measure+asthma+control.&amp;publication_year=1999&amp;journal=Eur+Respir+J&amp;pages=902-907&amp;doi=10.1034%2Fj.1399-3003.1999.14d29.x&amp;pmid=10573240" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">29.</div><div id="core-r29" class="citations"><div class="citation"><div class="citation-content">Juniper EF, Buist AS, Cox FM, Ferrie PJ, King DR. Validation of a standardized version of the Asthma Quality of Life Questionnaire. <em>Chest</em> 1999;115:1265-1270.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r29"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1378/chest.115.5.1265" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/10334138/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000080299400013" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Validation+of+a+standardized+version+of+the+Asthma+Quality+of+Life+Questionnaire.&amp;publication_year=1999&amp;journal=Chest&amp;pages=1265-1270&amp;doi=10.1378%2Fchest.115.5.1265&amp;pmid=10334138" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">30.</div><div id="core-r30" class="citations"><div class="citation"><div class="citation-content">Bonini M, Di Paolo M, Bagnasco D, et al. Minimal clinically important difference for asthma endpoints: an expert consensus report. <em>Eur Respir Rev</em> 2020;29:190137-190137.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r30"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1183/16000617.0137-2019" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32499305/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000552492900007" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Minimal+clinically+important+difference+for+asthma+endpoints%3A+an+expert+consensus+report.&amp;publication_year=2020&amp;journal=Eur+Respir+Rev&amp;pages=190137-190137&amp;doi=10.1183%2F16000617.0137-2019&amp;pmid=32499305" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">31.</div><div id="core-r31" class="citations"><div class="citation"><div class="citation-content">Juniper EF, Guyatt GH, Feeny DH, Ferrie PJ, Griffith LE, Townsend M. Measuring quality of life in children with asthma. <em>Qual Life Res</em> 1996;5:35-46.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r32"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1007/BF00435967" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/8901365/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=A1996UB23400005" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Measuring+quality+of+life+in+children+with+asthma.&amp;publication_year=1996&amp;journal=Qual+Life+Res&amp;pages=35-46&amp;doi=10.1007%2FBF00435967&amp;pmid=8901365" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">32.</div><div id="core-r32" class="citations"><div class="citation"><div class="citation-content">Juniper EF, Guyatt GH, Willan A, Griffith LE. Determining a minimal important change in a disease-specific Quality of Life Questionnaire. <em>J Clin Epidemiol</em> 1994;47:81-87.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r32"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/0895-4356(94)90036-1" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/8283197/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=A1994MT27800009" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Determining+a+minimal+important+change+in+a+disease-specific+Quality+of+Life+Questionnaire.&amp;publication_year=1994&amp;journal=J+Clin+Epidemiol&amp;pages=81-87&amp;doi=10.1016%2F0895-4356%2894%2990036-1&amp;pmid=8283197" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">33.</div><div id="core-r33" class="citations"><div class="citation"><div class="citation-content">Papi A, Canonica GW, Maestrelli P, et al. Rescue use of beclomethasone and albuterol in a single inhaler for mild asthma. <em>N Engl J Med</em> 2007;356:2040-2052.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r33"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_5_34_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa2203163&amp;key=10.1056%2FNEJMoa063861&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/17507703/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000246490500005" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Rescue+use+of+beclomethasone+and+albuterol+in+a+single+inhaler+for+mild+asthma.&amp;publication_year=2007&amp;journal=N+Engl+J+Med&amp;pages=2040-2052&amp;doi=10.1056%2FNEJMoa063861&amp;pmid=17507703" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">34.</div><div id="core-r34" class="citations"><div class="citation"><div class="citation-content">Israel E, Cardet J-C, Carroll JK, et al. Reliever-triggered inhaled glucocorticoid in Black and Latinx adults with asthma. <em>N Engl J Med</em> 2022;386:1505-1518.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r34"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_5_35_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa2203163&amp;key=10.1056%2FNEJMoa2118813&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/35213105/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000761375000001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Reliever-triggered+inhaled+glucocorticoid+in+Black+and+Latinx+adults+with+asthma.&amp;publication_year=2022&amp;journal=N+Engl+J+Med&amp;pages=1505-1518&amp;doi=10.1056%2FNEJMoa2118813&amp;pmid=35213105" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">35.</div><div id="core-r35" class="citations"><div class="citation"><div class="citation-content">Jenkins CR, Bateman ED, Sears MR, O’Byrne PM. What have we learnt about asthma control from trials of budesonide/formoterol as maintenance and reliever? <em>Respirology</em> 2020;25:804-815.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r35"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1111/resp.13804" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32237004/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000522536700001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=What+have+we+learnt+about+asthma+control+from+trials+of+budesonide%2Fformoterol+as+maintenance+and+reliever%3F&amp;publication_year=2020&amp;journal=Respirology&amp;pages=804-815&amp;doi=10.1111%2Fresp.13804&amp;pmid=32237004" target="_blank">Google Scholar</a></div></div></div></div></div></div></div></div><aside data-core-aside="right-rail">



        
        <div id="DTM_Position_MedRectangle" class="ad">
 <!--emptycomment-->
</div>




        
        <div class="ng-page_layout-sidebarSpacing"></div>










    
    
        <div data-widget-def="relatedArticlesWidget" data-widget-id="8206d5cd-cb8c-4ff9-8c46-3d22e0dee215" data-location="recirc_curatedRelated_article">
        



        
        <div class="ng-related-articles"><h3 class="ng-subsection-title"><span class="ng-subsection-title_text">Related articles</span></h3><ul class="ng-related-articles_list"><li class="ng-related-articles_item"><div class="issue-item issue-item_sm"><div class="issue-item_meta"><ul class="issue-item_meta-list clearfix"><li class="issue-item_meta-item"><a href="/browse/nejm-article-type/editorial" class="issue-item_type">Editorial</a></li><li class="issue-item_meta-item"><span class="issue-item_date">Jun 01, 2022</span></li></ul></div><div class="issue-item_row"><div class="issue-item_left"><div class="issue-item_content clearfix"><h4 class="issue-item_title"><a href="/doi/full/10.1056/NEJMe2205717" data-interactiontype="article_recirculation_click" class="issue-item_title-link animation-underline">Another Rescue Therapy Option for Patients with Moderate-to-Severe Asthma</a></h4><div class="issue-item_authors-and-text"><span class="issue-item_authors">M. Schatz</span></div></div></div></div></div></li><li class="ng-related-articles_item"><div class="issue-item issue-item_sm"><div class="issue-item_meta"><ul class="issue-item_meta-list clearfix"><li class="issue-item_meta-item"><a href="/browse/nejm-article-type/correspondence" class="issue-item_type">Correspondence</a></li><li class="issue-item_meta-item"><span class="issue-item_date">Aug 17, 2022</span></li></ul></div><div class="issue-item_row"><div class="issue-item_left"><div class="issue-item_content clearfix"><h4 class="issue-item_title"><a href="/doi/full/10.1056/NEJMc2209189" data-interactiontype="article_recirculation_click" class="issue-item_title-link animation-underline">Albuterol–Budesonide Fixed-Dose Combination Rescue Inhaler for Asthma</a></h4><div class="issue-item_authors-and-text"></div></div></div></div></div></li></ul></div>

        </div>
    





        
        <div class="ng-page_layout-sidebarSpacing"></div>




        
        <div id="nejm_jobs" class="nejm_jobs"> <!-- top red rectangle --><div id="nejm-widget" class="nejm-widget" style="display: block;"><div class="nejm-widget_logo">	<a target="nejm-win" href="https://www.nejmcareercenter.org/?query=fjw">		<img alt="CareerCenter" src="https://apps1.nejmcareercenter.org/images/nejmCCID-JobsWidget.gif" width="140" height="36">	</a></div><div class="nejm-widget_cont"> <!-- content --><div class="nejm-widget_title">PHYSICIAN JOBS</div><div class="nejm-widget_date">June 10, 2025</div><div class="nejm-widget_item"><div><span> New York City, New York</span></div><div><span>Ambulatory Medicine</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/887329/primary-care-internal-medicine-physician-ambulatory-care/?query=fjwp&amp;rid=16388">PRIMARY CARE INTERNAL MEDICINE PHYSICIAN - AMBULATORY CARE</a></div></div><div class="nejm-widget_item"><div><span> Glendale, Arizona</span></div><div><span>Urology</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/882933/urology-opportunity-with-banner-medical-group-at-banner-thunderbird-medical-center/?query=fjwp&amp;rid=120">Urology Opportunity with Banner Medical Group at Banner Thunderbird Medical Center</a></div></div><div class="nejm-widget_item"><div><span> Texas</span></div><div><span>Gastroenterology</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/890352/gastroenterologist-academic-physician-led-large-growing-health-system-open-to-j1-h1b/?query=fjwf&amp;rid=346908">Gastroenterologist - Academic - physician led, large/growing health system! - Open to J1 / H1B</a></div></div><div class="nejm-widget_item"><div><span> Massachusetts</span></div><div><span>Internal Medicine</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/881673/internal-medicine-outpatient-physician-feeding-hills-ma/?query=fjwf&amp;rid=705">Internal Medicine - Outpatient Physician, Feeding Hills MA</a></div></div><div class="nejm-widget_item"><div><span> Bridgeport, Connecticut</span></div><div><span>Critical Care Medicine</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/890038/critical-care-intensivist-md-do/?query=fjwf&amp;rid=33464">Critical Care Intensivist MD/DO</a></div></div><div class="nejm-widget_item"><div><span> Morristown, Tennessee</span></div><div><span>Emergency Medicine</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/891116/emergency-medicine-physician-in-morristown-tn/?query=fjwf&amp;rid=4552">Emergency Medicine Physician in Morristown, TN</a></div></div></div> <!-- content --> <!-- footer --></div> <!-- nejm-widget --></div><script src="https://apps1.nejmcareercenter.org/?width=300&amp;sp=all"></script>




        
        <div class="ng-page_layout-sidebarSpacing"></div>










    
    
        <div data-widget-def="literatumAd" data-widget-id="001e4aa7-b6fe-4b21-9d5b-5bde81227c67" id="ad-article-right-rail-300x250-1">
        



        
        



    
        <div class="pb-house-message adplaceholder exists">
            <a href="/action/clickThrough?id=128743&amp;url=https%3A%2F%2Fstore.nejm.org%2Fsignup%2Fnejm%2Fregister%2Fnotablearticles2024%3Fpromo%3DONFQNAR4%26query%3Dcm-ra%26utm_source%3Dnejm%26utm_medium%3Dcm%26utm_campaign%3Dna24&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMoa2203163&amp;pubId=41283778&amp;placeholderId=101337&amp;productId=1007"><img src="/sda/128743/rightRail--notable24_001.jpg" width="300" height="250"></a>
            
        </div>
    

    

    



        </div>
    





        
        <div class="ng-page_layout-sidebarSpacing"></div>




        
        <script src="https://widgets.nejm.org/onepub-widgets/loader/webcomponents-loader.js" async="" nonce="94d6d44785b61aed-SJC">
<script src="https://widgets.nejm.org/onepub-widgets/loader/polyfill-support.js"  nonce="94d6d44785b61aed-SJC"></script>
<script src="https://widgets.nejm.org/onepub-widgets/more-like-this.js" type="module" nonce="94d6d44785b61aed-SJC"></script>

<more-like-this class="onepub-widget" dataid="onepub-more-like-this" collections="catalyst-article, clinician-article, evidence-article, nejm-ai-article, nejm-article" headertitle="More Like This" maxitems="5"><!----><div class="more-like-this onepub-more-like-this_"><!--?lit$075152854$--><onepub-fonts><wc-fetch></wc-fetch><!--?lit$075152854$--><div class="mlt-wrapper"><div class="mlt-header-container"><div class="mlt-header-content-left"><div class="mlt-header-title-container"><span class="mlt-header-title">More Like This</span></div><!--?lit$075152854$--></div></div><div class="mlt-body"><!--?lit$075152854$--><!----><div class="mlt-article-container"><div class="mlt-article-container-header"><a data-location="recirc_Semantic" class="mlt-article-type nejm" href="https://www.nejm.org/browse/nejm-article-type/original-article" target="_self"><!--?lit$075152854$-->Original Article</a> <span class="mlt-article-site-label"><!--?lit$075152854$-->NEJM</span> <span class="mlt-article-pubdate"><!--?lit$075152854$-->May 19, 2025</span></div><div class="mlt-article-title"><a data-location="recirc_Semantic" href="https://www.nejm.org/doi/full/10.1056/NEJMoa2504544?query=recirc_Semantic" target="_self">As-Needed Albuterol–Budesonide in Mild Asthma</a></div><div class="mlt-article-authors"><!--?lit$075152854$-->C. LaForce and Others</div></div><!----><!----><div class="mlt-article-container"><div class="mlt-article-container-header"><a data-location="recirc_Semantic" class="mlt-article-type nejm" href="https://www.nejm.org/browse/nejm-article-type/clinical-practice" target="_self"><!--?lit$075152854$-->Clinical Practice</a> <span class="mlt-article-site-label"><!--?lit$075152854$-->NEJM</span> <span class="mlt-article-pubdate"><!--?lit$075152854$-->Sep 14, 2023</span></div><div class="mlt-article-title"><a data-location="recirc_Semantic" href="https://www.nejm.org/doi/full/10.1056/NEJMcp2304871?query=recirc_Semantic" target="_self">Asthma in Adults</a></div><div class="mlt-article-authors"><!--?lit$075152854$-->G. Mosnaim</div></div><!----><!----><div class="mlt-article-container"><div class="mlt-article-container-header"><a data-location="recirc_Semantic" class="mlt-article-type nejm" href="https://www.nejm.org/browse/nejm-article-type/original-article" target="_self"><!--?lit$075152854$-->Original Article</a> <span class="mlt-article-site-label"><!--?lit$075152854$-->NEJM</span> <span class="mlt-article-pubdate"><!--?lit$075152854$-->Jul 02, 2020</span></div><div class="mlt-article-title"><a data-location="recirc_Semantic" href="https://www.nejm.org/doi/full/10.1056/NEJMoa1916046?query=recirc_Semantic" target="_self">Triple Inhaled Therapy at Two Glucocorticoid Doses in Moderate-to-Very-Severe COPD</a></div><div class="mlt-article-authors"><!--?lit$075152854$-->K.F. Rabe and Others</div></div><!----><!----><div class="mlt-article-container"><div class="mlt-article-container-header"><a data-location="recirc_Semantic" class="mlt-article-type nejm" href="https://www.nejm.org/browse/nejm-article-type/correspondence" target="_self"><!--?lit$075152854$-->Correspondence</a> <span class="mlt-article-site-label"><!--?lit$075152854$-->NEJM</span> <span class="mlt-article-pubdate"><!--?lit$075152854$-->Nov 30, 2023</span></div><div class="mlt-article-title"><a data-location="recirc_Semantic" href="https://www.nejm.org/doi/full/10.1056/NEJMc2312345?query=recirc_Semantic" target="_self">Asthma in Adults</a></div><div class="mlt-article-authors"><!--?lit$075152854$--></div></div><!----><!----><div class="mlt-article-container"><div class="mlt-article-container-header"><a data-location="recirc_Semantic" class="mlt-article-type nejm-evidence" href="https://evidence.nejm.org/browse/nejm-article-type/patient-platform?query=recirc_Semantic" target="_self"><!--?lit$075152854$-->Patient Platform</a> <span class="mlt-article-site-label"><!--?lit$075152854$-->NEJM Evidence</span> <span class="mlt-article-pubdate"><!--?lit$075152854$-->Dec 26, 2023</span></div><div class="mlt-article-title"><a data-location="recirc_Semantic" href="https://evidence.nejm.org/doi/full/10.1056/EVIDpp2300292?query=recirc_Semantic" target="_self">Living with Asthma in Low- and Middle-Income Countries in the Six WHO Regions</a></div><div class="mlt-article-authors"><!--?lit$075152854$-->K. Mortimer and Others</div></div><!----></div><div class="mlt-footer"></div></div></onepub-fonts><style>:host{display:block}@keyframes fadeIn{0%{opacity:0}100%{opacity:1}}.more-like-this{max-width:25rem}.more-like-this *{font-variant-numeric:lining-nums}.mlt-wrapper{animation:fadeIn 1s}.mlt-header-container{border-bottom:#4d4d4d solid .0625rem;border-top:#4d4d4d solid .125rem}.mlt-header-title{color:#1a1a1a;display:block;font-family:var(--sans-serif);font-size:1rem;font-weight:700;letter-spacing:.02rem;line-height:1.5rem;padding-bottom:.94rem;padding-top:.94rem;text-transform:uppercase}.mlt-header-description{color:#333;display:block;font-family:ff-scala-sans-pro;font-size:.75rem;letter-spacing:.05rem;margin-top:-.5rem;padding-bottom:1rem;text-transform:uppercase}.mlt-article-container{border-bottom:#e5e5e5 solid .0625rem;margin-top:1.38rem}.mlt-article-container-header{font-family:var(--sans-serif);font-size:.6875rem;letter-spacing:.04em;line-height:1.125rem;margin:0 0 1rem;text-transform:uppercase}.mlt-article-type{font-weight:700;line-height:1.25rem;letter-spacing:.04rem;text-decoration:none}.mlt-article-type:hover{text-decoration:underline}.nejm{color:#f30}.nejm-ai{color:#006197}.nejm-catalyst{color:#5708a6}.nejm-evidence{color:#69a323}.mlt-article-site-label::after,.mlt-article-type::after{border-right:1px solid #e5e5e5;content:'';display:inline;padding:.1875rem .375rem .125rem 0;margin:0 .375rem 0 0}.mlt-article-pubdate{color:#666;font-style:normal;font-weight:700;line-height:1.25rem;letter-spacing:.04em}.mlt-article-authors{color:#666;font-family:var(--sans-serif);font-size:1rem;font-style:normal;font-weight:400;letter-spacing:normal;line-height:1.5rem;margin-bottom:1.38rem}.mlt-article-site-label{color:#666;font-style:normal;font-weight:700;letter-spacing:.04em}.mlt-article-title{margin-bottom:.5rem}.mlt-article-title>a{background-image:linear-gradient(#f30,#f30);background-position:0 90%;background-repeat:no-repeat;background-size:0 0;color:#1a1a1a;font-family:var(--quadraat-web);font-size:1.25rem;font-style:normal;font-weight:700;letter-spacing:normal;line-height:1.8rem;margin:1.5rem 0 .35rem 0;text-decoration:none;transition:background .25s ease-in-out}.mlt-article-title>a:hover{background-position:0 98%;background-size:100% .125rem;text-decoration:none}.skeleton-card{box-shadow:0 0 4px 1px rgba(0,0,0,.1);margin:1rem 0;padding:1rem}</style></div></more-like-this>




        
        <div><div class="pb-dropzone" data-pb-dropzone="col-0" title="col-0"></div></div>










    
    
        <div data-widget-def="UX3HTMLWidget" data-widget-id="ad06db99-f228-4c92-9ad7-c4ae0fdbdbf1" id="bc-web-rec">
        



        
        <!-- BlueConic TEST empty HTML widget with DIV wrapper with id=bc-web-rec -->

        </div>
    

</aside></article><div data-extent="article-wrapper"><div class="core-container"></div><div class="after-credits"><div class="core-container"><a href="/doi/pdf/10.1056/NEJMoa2203163?download=true" id="downloadPdfUrl" data-doi="10.1056/NEJMoa2203163" data-behavior="trackDownloadEvent" data-interactiontype="article_tools_download_pdf" data-multimedia-type="Article PDF" data-multimedia-filename="nejmoa2203163.pdf"><span>Download PDF</span></a></div></div></div><script id="axel-publication-metadata" type="application/json">{"doi":"10.1056/NEJMoa2203163"}
</script><script type="text/javascript" data-ot-ignore="data-ot-ignore" defer="defer" src="https://static.addtoany.com/menu/page.js" class="optanon-category-C0004 ot-vscat-C0004"></script><div class="articles-nav"></div><template id="figure_nav_template"><nav><a href="#" title="Open in viewer" class="open-in-viewer"><i aria-hidden="true" class="icon-expand"></i></a></nav></template><template id="fv_panel_template" data-sharesocial="Share"><div class="fv__panel js--hidden"><div class="fv__panel__text"><div class="fv__panel__contentTitle"></div><div class="fv__panel__contentText"></div></div></div></template>
<template id="fv_directory_template" data-overlay="View figure"><div class="fv__directory"><div class="fv__header"><nav class="tab__nav"></nav><a href="#" title="Close figure viewer" class="fv__close"><i aria-hidden="true" class="icon-close"></i></a></div><div class="fv__content tab__content"></div></div></template><template id="fv_directory_tabItem_template" data-figures="Figures" data-others="Others" data-tables="Tables"><button role="tab" data-toggle="tab" class="tab__nav__item"></button></template>
<template id="fv_lightbox_template" data-sr-back="Go to figure location within the article" data-sr-closealt="Close" data-sr-download="Toggle download panel" data-sr-download-pptx="Download PPT" data-sr-info="Toggle information panel" data-sr-panel="Close panel" data-sr-share="Toggle share panel" data-sr-zoom="Zoom" data-text-close="Back to article" data-text-nav-figures="All figures" data-text-nav-others="All others" data-text-nav-tables="All tables" data-text-viewall="View all material" data-title-back="Back to article" data-title-closealt="Close" data-title-download="Download" data-title-download-pptx="Download PPT" data-title-info="Info" data-title-share="Share" data-title-zoom="Zoom"></template>
<template id="fv_toolbar_template"><div class="fv__toolbar__info"><strong class="fv__toolbar__contentTitle uppercase"></strong><p class="fv__toolbar__contentText"></p></div></template><template id="toCitationLink" data-citation="Citation" data-footnote="Footnote"><div class="to-citation__wrapper"><a class="to-citation"><i aria-hidden="true" class="icon-return"></i><span>Go to</span></a></div></template><template id="toCitationButton" data-citation="Citation" data-footnote="Footnote"><div class="to-citation__wrapper"><button class="to-citation"><i aria-hidden="true" class="icon-return"></i><span>Go to</span></button></div></template><template id="toCitationAccordion" data-collapse-citation="Hide Citations" data-expand-citation="Show Citations" data-collapse-footnote="Hide Footnotes" data-expand-footnote="Show Footnotes"><div class="to-citation__wrapper"><button aria-controls="aria-controls" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="data-expand-title" data-collapsed-title="data-collapsed-title" class="accordion__toggle__title"></span></button><div role="menu" aria-label="links" class="to-citation__accordion no-separator"><ul></ul></div></div></template><template id="toCitationAccordionItem"><li><a class="to-citation"><i aria-hidden="true" class="icon-return"></i><span></span></a></li></template><template id="citations_truncate_template"><div class="citations-truncation"><button data-label-expand="Show all references" data-label-collapse="Show fewer" data-label-remaining="references remaining" class="btn btn--secondary"><span>Show all references</span></button></div></template><template id="collateral_texts_template" data-references="References" data-figure="Go to Figure" data-media="Go to Media" data-more="More" data-original="Go to original" data-table="Go to Table" data-inviewer="Open in Viewer" data-allinviewer="Open all in viewer"><svg data-tags="copyright" viewBox="0 0 24 24"><path d="M12 20.016q3.281 0 5.648-2.368T20.016 12t-2.368-5.648T12 3.984 6.352 6.352 3.984 12t2.368 5.648T12 20.016zm0-18q4.125 0 7.055 2.93T21.985 12t-2.93 7.055T12 21.985t-7.055-2.93T2.015 12t2.93-7.055T12 2.015zm-.14 7.125q-1.876 0-1.876 2.718v.282q0 2.718 1.875 2.718.704 0 1.172-.398t.469-1.008h1.781q0 1.172-1.031 2.063-.984.843-2.39.843-1.876 0-2.86-1.125t-.984-3.093v-.282q0-1.921.937-3 1.125-1.265 2.906-1.265 1.547 0 2.438.89.984.985.984 2.297H13.5q0-.328-.14-.61-.235-.468-.329-.562-.469-.468-1.172-.468z"></path></svg><span>Request permissions</span><i aria-hidden="true" class="icon-open_in_new"></i></template><template id="collapsible_authors_template"><button aria-expanded="false" data-expandable="all" data-label-expand="Expand All" data-label-collapse="Collapse All" class="collateral-contributors-control"><span>Expand All</span></button></template>
<template id="collapsible_tables_collapse_template"><div class="collapsible-figure-btn__wrapper expanded"><button aria-expanded="true" class="btn collapsible-figure-btn btn--inverse"><i aria-hidden="true" class="icon-arrow-up"></i><span class="text-uppercase">Collapse</span></button></div></template>
<template id="collapsible_tables_expand_template"><div class="collapsible-figure-btn__wrapper collapsed"><button aria-expanded="false" class="btn collapsible-figure-btn btn--inverse"><i aria-hidden="true" class="icon-arrow-down"></i><span class="text-uppercase">Expand Table</span></button></div></template><template id="authorsAffiliationsLink"><a href="#tab-contributors" class="to-authors-affiliations">Authors Info &amp; Affiliations</a></template>

        <div role="navigation" aria-label="Sticky Navigation" class="st-header"><div class="st-header__content"><div class="st-header__item st-header__menu"></div><div class="st-header__current st-header__item"><div class="st-header__label">Now Reading:</div><div class="st-header__title">Albuterol–Budesonide Fixed-Dose Combination Rescue Inhaler for Asthma</div></div><div class="st-header__share st-header__item"><div class="share-dropblock dropdown"><a id="sticky-header-dropBlock" href="#" role="button" data-toggle="dropdown" aria-haspopup="true" aria-expanded="false" class="dropdown-toggle"><span title="" data-toggle="tooltip" data-trigger="hover" data-original-title="Share options"><span class="sr-only">Share</span><i aria-hidden="true" class="icon-share"></i></span></a><div aria-labelledby="sticky-header-dropBlock" data-location="share_tools_article" class="dropdown-menu"><ul class="rlist--inline a2a a2a_kit" style="line-height: 16px;"><li><a href="/#facebook" aria-label="Share on Facebook" data-id="article-share-facebook" rel="nofollow noopener" role="link" target="_blank" title="Share on Facebook" class="btn btn--facebook a2a_button_facebook" data-interactiontype="social"><i aria-hidden="true" class="icon-facebook"></i></a></li><li><a href="/#twitter" aria-label="Share on X (formerly Twitter)" data-id="article-share-twitter" rel="nofollow noopener" role="link" target="_blank" title="Share on X (formerly Twitter)" class="btn btn--twitter a2a_button_twitter" data-interactiontype="social"><i aria-hidden="true" class="icon-twitter"></i></a></li><li><a href="/#linkedin" aria-label="Share on LinkedIn" data-id="article-share-linkedin" rel="nofollow noopener" role="link" target="_blank" title="Share on LinkedIn" class="btn btn--linkedin a2a_button_linkedin" data-interactiontype="social"><i aria-hidden="true" class="icon-linkedin"></i></a></li><li><a href="/#email" aria-label="Share on email" data-id="article-share-email" rel="nofollow noopener" role="link" target="_blank" title="Share on email" class="btn btn--email a2a_button_email" data-interactiontype="content_email_click"><i aria-hidden="true" class="icon-mail"></i></a></li><li><a href="/#bluesky" aria-label="Share on Bluesky" data-id="article-share-bluesky" rel="nofollow noopener" role="link" target="_blank" title="Share on Bluesky" class="btn btn--bluesky a2a_button_bluesky" data-interactiontype="social"><i aria-hidden="true" class="icon-bluesky"></i></a></li></ul></div></div></div><div class="st-header__nav st-header__item"><div class="content-navigation"><a href="/doi/full/10.1056/NEJMp2201955" aria-label="Previous article" aria-disabled="false" class="content-navigation__prev"><div aria-hidden="true" class="content-navigation__hint"><div class="content-navigation__hint__content"><h6>PREVIOUS ARTICLE</h6><div>Daughters’ Keeper — The Care and Treatment of Black Girls in America</div></div></div><i aria-hidden="true" class="icon-arrow-left"></i><span>Previous</span></a><a href="/doi/full/10.1056/NEJMoa2201300" aria-label="Next article" aria-disabled="false" class="content-navigation__next"><div aria-hidden="true" class="content-navigation__hint"><div class="content-navigation__hint__content"><h6>NEXT ARTICLE</h6><div>Efficacy and Safety of a Recombinant Plant-Based Adjuvanted Covid-19 Vaccine</div></div></div><span>Next</span><i aria-hidden="true" class="icon-arrow-right"></i></a></div></div></div><div class="st-header__track"><div id="progress-tracker" class="st-header__tracker" style="width: 0px;"></div></div></div><div class="fv figureViewer js--has-focus-mode"><div class="fv__directory" data-core-tabs="default" style="display: flex;"><div class="fv__header"><nav class="tab__nav" role="tablist"><button role="tab" data-toggle="tab" class="tab__nav__item active" aria-controls="#tab-pane-figures" aria-selected="true">Figures</button><button role="tab" data-toggle="tab" class="tab__nav__item" aria-controls="#tab-pane-tables" tabindex="-1" aria-selected="false">Tables</button></nav><a href="#" title="Close figure viewer" class="fv__close"><i aria-hidden="true" class="icon-close"></i></a></div><div class="fv__content tab__content"><div class="tab__pane fv__list fv__list--figures" id="tab-pane-figures" aria-label="All figures" tabindex="0" role="tabpanel"><div class="fv__item"><a class="fv__open-item fv__item__view fv__fit" href="#fv-f0" data-type="figures" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2203163_f0.jpg"><img src="/cms/10.1056/NEJMoa2203163/asset/064d7417-8268-4305-aba1-5cd26a8cace9/assets/images/large/nejmoa2203163_f0.jpg" height="3416" width="2640" aria-labelledby="f0" loading="lazy"><span class="fv__fit--overlay"><span>View figure</span></span></a><div class="fv__item__title"></div><div class="fv__item__description"><figcaption>Download a PDF of the <a href="#ap0">Research Summary</a>.</figcaption></div></div><div class="fv__item"><a class="fv__open-item fv__item__view fv__fit" href="#fv-f1" data-type="figures" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2203163_f1.jpg"><img src="/cms/10.1056/NEJMoa2203163/asset/9aa4eec4-18e3-49aa-9cbc-666fcfd02336/assets/images/large/nejmoa2203163_f1.jpg" height="3119" width="2640" aria-labelledby="f1" loading="lazy"><span class="fv__fit--overlay"><span>View figure</span></span></a><div class="fv__item__title">Figure 1</div><div class="fv__item__description"><figcaption><div class="caption">Screening, Randomization, and Analyses.</div><div class="notes"><div role="doc-footnote">All 37 patients who remained in the treatment phase of the trial after the primary database lock to complete 24 weeks across the three trial groups were children or adolescents; the 1 patient in the lower-dose combination group who remained in the 2-week safety follow-up period after the primary database lock was an adolescent.</div></div></figcaption></div></div><div class="fv__item"><a class="fv__open-item fv__item__view fv__fit" href="#fv-f2" data-type="figures" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2203163_f2.jpg"><img src="/cms/10.1056/NEJMoa2203163/asset/351e096a-ce26-4ce4-867e-6b566ef5e868/assets/images/large/nejmoa2203163_f2.jpg" height="3142" width="2640" aria-labelledby="f2" loading="lazy"><span class="fv__fit--overlay"><span>View figure</span></span></a><div class="fv__item__title">Figure 2</div><div class="fv__item__description"><figcaption><div class="caption">Time-to-Event Analysis of the First Event of Severe Asthma Exacerbation (Primary End Point).</div><div class="notes"><div role="doc-footnote">Data are presented for all the patients. Children 4 to 11 years of age were excluded in the comparison between the higher-dose combination group and the albuterol-alone group; therefore, the number of patients in the albuterol-alone group in this comparison (1014 patients) was lower than that in the comparison with the lower-dose combination group, in which children 4 to 11 years of age were included. The anticipated probability of a first event of severe asthma exacerbation among the patients who received albuterol alone was 0.22.</div></div></figcaption></div></div></div><div class="tab__pane fv__list fv__list--tables" id="tab-pane-tables" aria-label="All tables" tabindex="-1" role="tabpanel"><div class="fv__item"><a class="fv__open-item fv__item__view" href="#fv-t1" data-type="tables" data-interactiontype="multimedia_click" data-multimedia-type="Table"><i class="icon-tables"></i></a><div class="fv__item__title">Table 1</div><div class="fv__item__description"><figcaption><div class="caption">Demographic and Clinical Characteristics of the Patients at Screening.<a href="#fv-t1fn1" role="doc-noteref">*</a></div></figcaption></div></div><div class="fv__item"><a class="fv__open-item fv__item__view" href="#fv-t2" data-type="tables" data-interactiontype="multimedia_click" data-multimedia-type="Table"><i class="icon-tables"></i></a><div class="fv__item__title">Table 2</div><div class="fv__item__description"><figcaption><div class="caption">Intention-to-Treat and Preplanned On-Treatment Efficacy Analyses of the Secondary End Points.<a href="#fv-t2fn1" role="doc-noteref">*</a></div></figcaption></div></div><div class="fv__item"><a class="fv__open-item fv__item__view" href="#fv-t3" data-type="tables" data-interactiontype="multimedia_click" data-multimedia-type="Table"><i class="icon-tables"></i></a><div class="fv__item__title">Table 3</div><div class="fv__item__description"><figcaption><div class="caption">Adverse Events Occurring in at Least 2% of Patients in Any Trial Group.<a href="#fv-t3fn1" role="doc-noteref">*</a></div></figcaption></div></div></div></div></div></div><div class="references-pop-up fade" aria-hidden="true"><div class="references-pop-up__heading text-dark d-flex align-items-center"><div class="references-pop-up__title flex-grow-1">Reference <span class="references-pop-up__heading-number">1</span></div><a class="references-pop-up__close text-dark" href="#" title="close pop-up" tabindex="-1" aria-hidden="true"><i class="icon-close" aria-hidden="true"></i></a></div><div class="references-pop-up__items citations to-citation__accordion external-links"></div></div></main>
    

</div>

                    
                        



        
        <div class="ng-page_layout ng-page_layout-fullWidth"><div class="container-fluid"><div class="row"><div class="col-12">



        
        




        
        <div class="ng-page_layout-contentSpacing"></div>










    
    
        <div data-widget-def="oneSearchMultiSearch" data-widget-id="778b3ad8-1a8d-43d8-8196-63b03df4a138" data-location="recirc_inIssue_bottom_article">
        



        
        <div class="os-ms os-ms-more-from-issue"><h3 class="ng-subsection-title"><a href="/toc/nejm/386/22" class="ng-subsection-title_link animation-icon-shift"><span class="ng-subsection-title_text">More from Vol. 386 No. 22</span><span class="ng-subsection-title_icon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-longArrowRight"></use></svg></span></span></a></h3><ul class="os-ms-more-from-issue_list"><li class="os-ms-more-from-issue_item"><div class="issue-item issue-item_sm"><div class="issue-item_meta"><ul class="issue-item_meta-list clearfix"><li class="issue-item_meta-item"><a href="/browse/nejm-article-type/original-article" class="issue-item_type">Original Article</a></li><li class="issue-item_meta-item"><span class="issue-item_date">Jun 02, 2022</span></li><li class="issue-item_meta-item"><span class="issue-item_free">FREE</span></li></ul></div><div class="issue-item_row"><div class="issue-item_left"><div class="issue-item_content clearfix"><h4 class="issue-item_title"><a href="/doi/full/10.1056/NEJMoa2202261" data-interactiontype="article_recirculation_click" class="issue-item_title-link animation-underline">Efficacy and Safety of the RBD-Dimer–Based Covid-19 Vaccine ZF2001 in Adults</a></h4><div class="issue-item_authors-and-text"><span class="issue-item_authors">L. Dai and Others</span></div></div></div></div></div></li><li class="os-ms-more-from-issue_item"><div class="issue-item issue-item_sm"><div class="issue-item_meta"><ul class="issue-item_meta-list clearfix"><li class="issue-item_meta-item"><a href="/browse/nejm-article-type/original-article" class="issue-item_type">Original Article</a></li><li class="issue-item_meta-item"><span class="issue-item_date">Jun 02, 2022</span></li><li class="issue-item_meta-item"><span class="issue-item_free">FREE</span></li></ul></div><div class="issue-item_row"><div class="issue-item_left"><div class="issue-item_content clearfix"><h4 class="issue-item_title"><a href="/doi/full/10.1056/NEJMoa2201300" data-interactiontype="article_recirculation_click" class="issue-item_title-link animation-underline">Efficacy and Safety of a Recombinant Plant-Based Adjuvanted Covid-19 Vaccine</a></h4><div class="issue-item_authors-and-text"><span class="issue-item_authors">K.J. Hager and Others</span></div></div></div></div></div></li><li class="os-ms-more-from-issue_item"><div class="issue-item issue-item_sm"><div class="issue-item_meta"><ul class="issue-item_meta-list clearfix"><li class="issue-item_meta-item"><a href="/browse/nejm-article-type/original-article" class="issue-item_type">Original Article</a></li><li class="issue-item_meta-item"><span class="issue-item_date">Jun 02, 2022</span></li><li data-toggle="tooltip" data-original-title="Video" class="issue-item_meta-item"><span role="img" aria-label="Video" tabindex="0" class="issue-item_video"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#tooltip-video"></use></svg></span></span></li><li class="issue-item_meta-item"><span class="issue-item_free">FREE</span></li></ul></div><div class="issue-item_row"><div class="issue-item_left"><div class="issue-item_content clearfix"><h4 class="issue-item_title"><a href="/doi/full/10.1056/NEJMoa2119662" data-interactiontype="article_recirculation_click" class="issue-item_title-link animation-underline">Brief Report: Neoantigen T-Cell Receptor Gene Therapy in Pancreatic Cancer</a></h4><div class="issue-item_authors-and-text"><span class="issue-item_authors">R. Leidner and Others</span></div></div></div></div></div></li></ul></div>

        </div>
    

</div></div></div></div>

                    
                        



        
        <div class="ng-page_layout-bottomAd"><div class="container-fluid"><div class="row"><div class="col-12">









    
    
        <div data-widget-def="literatumAd" data-widget-id="7e022d0d-4a48-44a7-af66-033cf5c13eb8" id="ad-article-bottom-FULLx320-1">
        



        
        



    
        <div class="pb-house-message adplaceholder exists">
            <!-- START: Circulation Footer 3 -->
<aside class="g-cta-subscribe">
	<style>
.bads_footer-banner24-ONJQNRF1{background:url(/pb-assets/contextual_messaging/footer-yel-background-2x-1513629627453.jpg) center center no-repeat;padding:20px;display:block;margin:0;min-height:inherit;background-size:cover;text-decoration:none!important;color:#1a1a1a;text-align:left}.bads_footer-banner24-ONJQNRF1 .g-cta-subscribe__title{font-size:42px;line-height:44px;letter-spacing:.2px;margin:0 0 20px;font-family:ff-quadraat-web-pro,sans-serif;font-weight:600}.bads_footer-banner24-ONJQNRF1-inner{max-width:1300px;margin:0 auto}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__actions .a-btn{width:130px;padding-left:12px}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__login{position:static;color:#000;font-size:18px;line-height:27px;border:0}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__actions{margin:20px 0 20px 0;list-style-type:none;padding:0}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__login a{color:#0a68ad}.bads_clearfix:after{visibility:hidden;display:block;font-size:0;content:" ";clear:both;height:0}.bads_clearfix{display:block}.bads_footer-banner24-ONJQNRF1-inner .bads_subs-btn{float:left;width:50%;padding:30px 0}.bads_footer-banner24-ONJQNRF1-inner .bads_device-img{float:left;padding-left:30px;width:50%}.bads_footer-banner24-ONJQNRF1 .bads_device-img>img{display:block;max-width:100%;height:auto}.bads_footer-banner24-ONJQNRF1 .bads_h5{font-size:18px;text-transform:uppercase;line-height:24px;font-weight:600;margin:-15px 0 0;letter-spacing:.2px}@media only screen and (max-width:480px){.bads_footer-banner24-ONJQNRF1-inner .bads_device-img,.bads_footer-banner24-ONJQNRF1-inner .bads_subs-btn{width:100%;float:none}.bads_footer-banner24-ONJQNRF1-inner .bads_device-img{padding-left:0}.bads_footer-banner24-ONJQNRF1 .g-cta-subscribe__title{font-size:20px;line-height:27px;margin-bottom:10px}.bads_footer-banner24-ONJQNRF1-inner .bads_subs-btn{padding-top:0;padding-bottom:0}.bads_footer-banner24-ONJQNRF1{height:auto}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__actions{margin:0 0 12px;list-style-type:none}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__login{line-height:25px;font-size:15px;margin-bottom:10px}.bads_footer-banner24-ONJQNRF1 .bads_device-img{width:280px!important;margin:0 auto}.bads_footer-banner24-ONJQNRF1 .bads_h5{margin:0 0 3px;font-size:14px}}@media only screen and (min-width:480px) and (max-width:1024px){.bads_footer-banner24-ONJQNRF1 .g-cta-subscribe__title{font-size:20px;line-height:30px;margin-bottom:15px}.bads_footer-banner24-ONJQNRF1-inner .bads_subs-btn{padding:0}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__login{font-size:14px}.bads_footer-banner24-ONJQNRF1 .bads_h5{font-size:13px;margin-top:0}}@media only screen and (min-width:1025px) and (max-width:1200px){.bads_footer-banner24-ONJQNRF1-inner .bads_subs-btn{padding:10px 0}.bads_footer-banner24-ONJQNRF1 .bads_h5{margin:0 0 5px}}@media only screen and (min-width:1401px){.bads_footer-banner24-ONJQNRF1 .bads_device-img>img{float:right}}
	</style>
	<div class="bads_footer-banner24-ONJQNRF1">
	  <div class="bads_footer-banner24-ONJQNRF1-inner bads_clearfix">
		 <div class="bads_subs-btn">
			<p class="g-cta-subscribe__title">Tap into groundbreaking research and clinically relevant insights</p>
			<ul class="g-cta-subscribe__actions">
				<li class="g-cta-subscribe__actions-primary">
				  <a href="/action/clickThrough?id=127716&amp;url=%2Faction%2FstoreProxy%3Faction%3Dsubscribe%26url%3Dhttps%253A%252F%252Fwww.nejm.org%252Fdoi%252Ffull%252F10.1056%252FNEJMoa2203163%26promo%3DONFQNRF1&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMoa2203163&amp;pubId=41283778&amp;placeholderId=101336&amp;productId=1035" class="ng-btn_primary ng-btn_iconRight"><span class="ng-btn_text">Subscribe </span><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#arrows-longArrowRight"></use></svg></span></a>
				</li>
			</ul>
			<p class="g-cta-subscribe__login">Already a subscriber? <a href="/action/clickThrough?id=127716&amp;url=%2Faction%2FstoreProxy%3Faction%3Dactivate%26url%3Dhttps%253A%252F%252Fwww.nejm.org%252Fdoi%252Ffull%252F10.1056%252FNEJMoa2203163%26promo%3DONFQANR4&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMoa2203163&amp;pubId=41283778&amp;placeholderId=101336&amp;productId=1035">Activate</a> your online access.</p>
		 </div>

		<div class="bads_device-img">
		   <img src="/sda/127716/footer-devices-2x.png" alt="Devices">
		</div>
	   </div>
	</div>
</aside>
<!--/END: Circulation Footer 3 -->
            
        </div>
    

    

    



        </div>
    

</div></div></div></div>

                    
                        



        
        <footer class="ng-footer footer__top" style="position: relative;"><div data-location="footer" class="ng-footer_columns"><div class="container-fluid"><div class="row"><div class="col-lg-4 col-md-6 col-sm-12 ng-footer_column"><div class="row"><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title">ARTICLE CATEGORIES</h4>
<ul class="ng-footer_column-list">
    <li class="ng-footer_column-list-item">
        <a href="/browse/nejm-article-category/research" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Research</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/browse/nejm-article-category/review" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Reviews</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/browse/nejm-article-category/clinical-cases" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Clinical Cases</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/browse/nejm-article-category/perspective" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Perspective</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/browse/nejm-article-category/commentary" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Commentary</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/browse/nejm-article-category/other" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Other</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/medical-article-index" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Browse all Articles</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/toc/nejm/current" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Current Issue</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/loi/nejm" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Issue Index</span></a></li>
</ul>
</div><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title">RESOURCES</h4>
<ul class="ng-footer_column-list">
    <li class="ng-footer_column-list-item"><a href="/author-center/home" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Authors &amp; Reviewers</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/author-center/home" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Submit a Manuscript</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/products-and-services" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Subscribers</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://tools.ovid.com/ovidtools/nejm.html" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Institutional Administrators</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/media" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Media</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/how-to-advertise" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Advertisers</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/information-for-subscription-agents" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Agents</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/permissions" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Permissions &amp; Licensing</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/reprints" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Reprints</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://www.nejmcareercenter.org" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">NEJM CareerCenter</span></a>
    </li>
</ul>
</div></div></div><div class="col-lg-4 col-md-6 col-sm-12 ng-footer_column"><div class="row"><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title" aria-label="About us">ABOUT US</h4>
<ul class="ng-footer_column-list">
    <li class="ng-footer_column-list-item"><a href="/about-nejm/about-nejm" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">About NEJM</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://www.nejmgroup.org/" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">NEJM Group</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/products-and-services" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Products &amp; Services</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/editors-and-publishers" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Editors &amp; Publishers</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/advertising-policies" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Advertising Policies</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/contact-nejm" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text" aria-label="Contact us">Contact Us</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/frequently-asked-questions?#Accessibility" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Accessibility</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/frequently-asked-questions" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">FAQs</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/help" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Help</span></a></li>
    <li class="ng-footer_column-list-item"><a href="mailto:sitefeedback@nejm.org" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Site Feedback</span></a></li>
</ul>
</div><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title">SUBSCRIPTIONS</h4>
<ul class="ng-footer_column-list">
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=subscribe&amp;promo=ONF4NRS3" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Subscribe</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=renew&amp;product=nejm&amp;promo=ONFLNRR3&amp;prc=ONFARN52" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Renew</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=activate&amp;promo=ONFLNAA1" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Activate Subscription</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=register&amp;promo=ONFLNRC4" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Create Account</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://myaccount.nejm.org" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Manage Account</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=paybill&amp;product=nejm&amp;promo=BNFLPBA1" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Pay Bill</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://www.wolterskluwer.com/en/solutions/ovid/nejm-complete-collection" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Institutional Sales</span></a></li>    
    <li class="ng-footer_column-list-item"><a href="https://myaccount.nejm.org/special-content" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Special Content</span></a></li>
</ul>
</div></div></div><div class="col-lg-4 col-md-12 ng-footer_column"><div class="row"><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title">STAY CONNECTED</h4>
<ul class="ng-footer_column-list">
    <li class="ng-footer_column-list-item"><a href="https://myaccount.nejm.org/emails?section=NEJM" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Email Alerts</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=register&amp;promo=ONFLNRC3" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Create Account</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/products-and-services" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Apps</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://www.nejmcareercenter.org" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">NEJM CareerCenter</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/rss-feed/" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Podcasts</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/rss-feed/" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">RSS Feed</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/institutional-access" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Remote Access</span></a></li>
</ul>
</div><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title" aria-label="Follow us">FOLLOW US</h4>
<ul class="ng-footer_column-list">
<li class="ng-footer_column-list-item"><a href="https://www.facebook.com/TheNewEnglandJournalofMedicine" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-facebook"></use></svg></span></span><span class="ng-footer_column-link-text">Facebook</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://twitter.com/nejm" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-twitter"></use></svg></span></span><span class="ng-footer_column-link-text">X (formerly Twitter)</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://www.instagram.com/nejm/" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-instagram"></use></svg></span></span><span class="ng-footer_column-link-text">Instagram</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://www.youtube.com/user/NEJMvideo" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-youtube"></use></svg></span></span><span class="ng-footer_column-link-text">Youtube</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://www.linkedin.com/company/nejm-group" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-linkedin"></use></svg></span></span><span class="ng-footer_column-link-text">LinkedIn</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://bsky.app/profile/nejm.org" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-bluesky"></use></svg></span></span><span class="ng-footer_column-link-text">Bluesky</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://www.tiktok.com/@nejm.org" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-tiktok"></use></svg></span></span><span class="ng-footer_column-link-text">TikTok</span></a></li>
</ul>
</div></div></div></div></div></div><div data-location="footer" class="ng-footer_journals"><div class="container-fluid"><div class="row"><div class="col-12">



        
        <h4 class="ng-footer_journals-label">JOURNALS</h4>
<ul class="ng-footer_journals-list">
<li class="ng-footer_journals-item"><a href="https://www.nejm.org/" target="_blank" rel="noopener" class="ng-footer_journals-link">The New England Journal of Medicine</a></li>
<li class="ng-footer_journals-item"><a href="https://catalyst.nejm.org/" target="_blank" rel="noopener" class="ng-footer_journals-link">NEJM Catalyst Innovations in Care Delivery</a></li>
<li class="ng-footer_journals-item"><a href="https://evidence.nejm.org/" target="_blank" rel="noopener" class="ng-footer_journals-link">NEJM Evidence</a></li>
<li class="ng-footer_journals-item"><a href="https://ai.nejm.org/" target="_blank" rel="noopener" class="ng-footer_journals-link">NEJM AI</a></li>
</ul>
</div></div></div></div><div data-location="legal" class="ng-footer_bottom"><div class="container-fluid"><div class="row"><div class="col-lg-7 col-md-6 ng-footer_bottom-left">



        
        <p>Copyright © 2025 <a href="https://www.massmed.org/" target="_blank" rel="noopener" class="ng-footer_bottom-link"><b>Massachusetts Medical Society</b></a>. All rights reserved, including those for text and data mining, AI training, and similar technologies. Electronic ISSN 1533-4406. Print ISSN 0028-4793.The content of this site is intended for health care professionals.</p>
</div><div class="col-lg-5 col-md-6 ng-footer_bottom-right">



        
        <style>
  #teconsent a {
    color: #666;
    text-decoration: none;
  }
  #teconsent a:hover {
    color: #666;
    text-decoration: underline;
  }
</style>
<ul class="ng-footer_bottom-list">
<li class="ng-footer_bottom-list-item"><a href="https://www.nejmgroup.org/legal/copyright-information.htm" target="_blank" rel="noopener" class="ng-footer_bottom-link">Copyright</a></li>
<li class="ng-footer_bottom-list-item"><a href="https://www.nejmgroup.org/legal/terms-of-use.htm" target="_blank" rel="noopener" class="ng-footer_bottom-link">Terms</a></li>
<li class="ng-footer_bottom-list-item"><a href="https://www.nejmgroup.org/legal/privacy-policy.htm" target="_blank" rel="noopener" class="ng-footer_bottom-link">Privacy Policy</a></li>
<li class="ng-footer_bottom-list-item"><span id="teconsent" consent="undefined" aria-label="Open Cookie Preferences Modal" role="complementary"><a role="link" id="icon-id024677161934005698" tabindex="0" lang="en" aria-haspopup="dialog" aria-label="Cookie Preferences, opens a dedicated popup modal window" class="truste_cursor_pointer">Cookie Preferences</a></span></li>
</ul>
<a href="https://www.nejmgroup.org/" title="NEJM Group" target="_blank" rel="noopener" class="ng-footer_logo-link"><img src="/specs/products/mms-nextgen/mms/releasedAssets/images/other-images/logo_group.svg" alt="NEJM Group logo" class="ng-footer_logo" loading="lazy" width="103" height="40"></a>
</div></div></div></div><div data-show-after="400" class="back-to-top back-to-top--align-right  "><button data-snap="footer__top" class="back-to-top__action position-relative p-0 m-0 border-0 d-flex flex-column align-items-center justify-content-center"><svg viewBox="0 0 36 36" class="position-relative"><path d="M18 2.0845 a 15.9155 15.9155 0 0 1 0 31.831 a 15.9155 15.9155 0 0 1 0 -31.831" class="back-to-top__action__ring-bg"></path><path d="M18 2.0845 a 15.9155 15.9155 0 0 1 0 31.831 a 15.9155 15.9155 0 0 1 0 -31.831" stroke-dasharray="0, 100" class="back-to-top__action__ring"></path></svg><span class="back-to-top__action-icon position-absolute d-flex"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-up"></use></svg></span></span><span class="sr-only">Back to top</span></button></div></footer>

                    
                        



        
        <!-- TrustArc: Banner -->
<div id="consent_blackbar"><style>  #consent_blackbar{    position:relative;    width:100%;    z-index: 999999;  }    #trustarc-banner-overlay {  background-color: rgb(0, 0, 0);   opacity: 0.3;   position: fixed;   z-index: 1000000;   width: 100%;  height: 100%;   top: 0px;   left: 0px;   overflow: hidden;}.truste-title {  /*font-family: "Source Sans Pro", sans-serif;  font-size: 23px;  font-style: normal;  font-stretch: normal;*/  color: #222;  margin-bottom: 20px;  text-align: center;/*  font-weight:bold;*/}.truste-footer {  margin: 0 auto;      }.truste-left {  margin: 0px 0px 15px 15px;/*font-family: "Source Sans Pro", sans-serif;  font-size: 14px;    */}.truste-banner { margin: 0 auto; }.truste-messageColumn {/*font-family: "Source Sans Pro", sans-serif;  font-size: 14px;*/  color: #666666;  margin: 0px;}#truste-consent-button, #truste-consent-required {    background-color: #FF1E00;    color: #F2F1F1;    padding: 5px 10px;    border: 1px solid #FF1E00;    border-radius: 0px;    cursor: pointer;    text-transform:uppercase;/*    font-family: "Source Sans Pro",sans-serif;    font-size: 15px;*/  }      #truste-show-consent {    background-color: #FF1E00;    color: #F2F1F1;    border: 1px solid #FF1E00;    padding: 5px 10px;    border-radius: 0px;    cursor: pointer;    text-transform:uppercase;/*    font-family: "Source Sans Pro",sans-serif;    font-size: 15px;*/  }div.truste-consent-track-class {  position: fixed;  z-index:9999999;   background: #666;   border: 1px solid #333;    /*padding: 10px 60px;*/    bottom:0px;    right:0px;    left:0px;    margin: 10px;}.truste-left {  margin: 0;}div.text-content {  display: flex;  flex-direction: column;  align-self: baseline;}#truste-consent-text {    /*font-family: "Source Sans Pro", sans-serif;    font-size: 16px;*/    color: #fff;    margin: 15px 0px;}.truste-footer {  padding-top: 15px;}#truste-consent-content {  margin: 0 auto;    padding: 0 10px;    max-width: 1366px;}.truste-consent-footer {  display: none;}.flex-container {  display: block;  align-items: center;  justify-content: space-between;}#truste-consent-buttons {  float: right;  margin: 10px 5px 10px 0px;}#truste-show-consent { background: #F30 !important;}#truste-consent-button, #truste-consent-required { background: #F30 !important; } /* MEDIA QUERIES */  @media screen and (max-width: 500px) {  #truste-consent-track {    padding: 5px 20px;  }  }@media screen and (max-width: 375px) {  .truste-buttonsColumn {    float: none;    margin: 0;  }  #truste-consent-button, #truste-consent-required, #truste-show-consent {    width: 100%;    margin-bottom: 5px;  }          #truste-consent-buttons {  float: none;  margin: 10px 0px 10px 0px;	}}</style><div id="truste-consent-track" style="display: block; opacity: 1;">  <div id="trustarc-banner-overlay"></div>  <div class="truste-consent-track-class">    <div id="truste-consent-content" class="truste-banner">        <div class="flex-container">          <div class="text-content">            <div id="truste-consent-text" class="truste-messageColumn">This site uses cookies and related technologies, as described in our privacy policy, for purposes that may include site operation, analytics, enhanced user experience, or advertising. You may choose to consent to our use of these technologies, or manage your own preferences.                       </div>          </div>          <div id="truste-consent-buttons" class="truste-buttonsColumn">            <button id="truste-show-consent" aria-haspopup="dialog">Manage Settings</button>      <button id="truste-consent-button">Accept</button>      <!-- <button id="truste-consent-required">Decline All</button> -->          </div>        </div>                <div style="clear:both;"></div>    </div>  </div></div><!--emptycomment--></div>
<!-- /TrustArc: Banner -->

                    
                        



        
        <link rel="stylesheet" href="https://cssjs.nejm.org/mmsWidgets.css"><script nonce="94d6d44785b61aed-SJC" type="text/javascript" src="https://cssjs.nejm.org/mmsWidgets.js"></script><script nonce="94d6d44785b61aed-SJC" type="text/javascript">var litSSO = {
    "ucid": null,
    "accessToken": null,
    "authState": null
};

var loginUri = '/action/doSsoLogin';
var logoutUri = '/action/doLogout';

displayAuthenticatedMessage();

mmsWidgets.init({
    clientId: 'qsra7g4d6jwdsgn3zbe6udp6r6278mr9',
    origin: 'NEJM',
    xdReceiver: 'http://www.nejm.org/pb-assets/sso/xd.html',
    isFullPageSignIn: isSignInPage(),
    debug: true,

    onReady: function (e) {
        console.log('<<<<<<<<<< client: received onReady event.');
        $("A.litSsoLogin").click(function (e) {
            if (!$(e.currentTarget).hasClass("noMd") || $(e.currentTarget).parents(".header_sm-login").length === 0) {
                mmsWidgets.signIn(e);
                return false;
            }
        });
        $("A.litSsoLogout").click(function (e) {
            mmsWidgets.signOut(e);
            return false;
        });
        $("A.litSsoCreate").click(function (e) {
            mmsWidgets.showRegModal(e);
            return false;
        });
        $("A.litSsoSubscribe").click(function (e) {
            if (!$(e.currentTarget).hasClass("noMd") || $(e.currentTarget).parents(".header_sm-login").length === 0)
                location.assign(e.currentTarget.href);
            return false;
        });
        if (window.doSSOLogin) {
            window.setTimeout(function () {
                mmsWidgets.signIn();
            }, 500);
        }
        ;
    },
    onLoginSuccess: function (e) {
        console.log('<<<<<<<<<< client: received onLoginSuccess event.' + JSON.stringify(e));

        const redirectUrl = getRedirectUri(window.location.search, location.href.replace(window.location.origin, ""));
        document.cookie = "skipSso=; expires=; path=/";
        if (!litSSO.ucid || e.ucid != litSSO.ucid || !litSSO.accessToken || e.accessToken != litSSO.accessToken) {
            location.assign(loginUri + "?ucid=" + e.profile.ucid
                + "&accessToken=" + e.accessToken
                + "&authState=" + e.authState
                + "&email=" + encodeURIComponent(e.profile.email)
                + "&givenNames=" + e.profile.givenName
                + "&surname=" + e.profile.familyName
                + "&redirectUri=" + redirectUrl
                + "&uccLastUpdatedDate=" + encodeURIComponent(e.profile.uccLastUpdatedDate)
                + "&rememberMe=" + e.rememberMe);
        }
    },
    onAuthStateReady: function (e) {
        console.log('<<<<<<<<<< client: received onAuthStateReady event.' + JSON.stringify(e))

        var isMmsSsoAuthenticated = (e.authState && e.authState !== "anonymous" && e.authState !== "lead" && e.ucid && e.accessToken) ? true : false;
        var isLitSsoAuthenticated = (litSSO.ucid && litSSO.accessToken && litSSO.authState) ? true : false;
        console.log('           isMmsSsoAuthenticated=' + isMmsSsoAuthenticated + ', isLitSsoAuthenticated=' + isLitSsoAuthenticated);

        if (isMmsSsoAuthenticated) {
            if (!isLitSsoAuthenticated || litSSO.ucid != e.ucid) {
                if (window.skipSso)
                    document.cookie = "skipSso=" + encodeURIComponent(e.ucid) + "; expires=; path=/";

                if (!window.skipSso && document.cookie.indexOf("skipSso=" + encodeURIComponent(e.ucid)) == -1) {
                    location.assign(loginUri + "?ucid=" + e.profile.ucid
                        + "&accessToken=" + e.accessToken
                        + "&authState=" + e.authState
                        + "&email=" + encodeURIComponent(e.profile.email)
                        + "&givenNames=" + e.profile.givenName
                        + "&surname=" + e.profile.familyName
                        + "&redirectUri=" + location.href.replace(window.location.origin, "")
                        + "&uccLastUpdatedDate=" + encodeURIComponent(e.profile.uccLastUpdatedDate)
                        + "&rememberMe=" + e.rememberMe);
                } else
                    console.log('**** client: Skip SSO ****');
            } else if (e.accessToken !== litSSO.accessToken)
                updateLitSession(e.ucid, e.accessToken);
        } else if (isLitSsoAuthenticated)
            location.assign(logoutUri + "?redirectUri=" + encodeURIComponent(location.href.replace(window.location.origin, "")));

        if (document.getElementById("ssoerr-ucid"))
            document.getElementById("ssoerr-ucid").innerHTML = e.ucid;

    },
    onRegistrationSuccess: function (e) {
        console.log('<<<<<<<<<< client: received onRegistrationSuccess event.' + JSON.stringify(e))
        document.cookie = "skipSso=; expires=; path=/";
        var uccLastUpdatedDate = '1812-01-01 00:00:00.1 +0000';
        location.assign(loginUri + "?ucid=" + e.profile.ucid
            + "&accessToken=" + e.accessToken
            + "&authState=" + e.authState
            + "&email=" + encodeURIComponent(e.profile.email)
            + "&givenNames=" + e.profile.givenName
            + "&surname=" + e.profile.familyName
            + "&redirectUri=" + location.href.replace(window.location.origin, "")
            + "&uccLastUpdatedDate=" + encodeURIComponent(uccLastUpdatedDate)
            + "&rememberMe=" + e.rememberMe);
    },
    onLogoutSuccess: function (e) {
        console.log('<<<<<<<<<< client: received onLogoutSuccess event.' + JSON.stringify(e))

        document.cookie = "skipSso=; expires=; path=/";
        location.assign(logoutUri);
    },
});

function updateLitSession(ucid, accessToken) {
    $.ajax({
        method: "GET",
        url: "/action/doSsoSessionUpdate",
        data: {ucid: ucid, accessToken: accessToken},
        success: function (callData, textStatus) {
            console.log("Session accessToken updated")
            litSSO.accessToken = accessToken
        },
        error: function (jqXHR, textStatus, errorThrown) {
            alert("Your website session has expired and will now be reset.")
            console.log("Session update failed: " + jqXHR.responseText)
            location.assign(logoutUri + "?redirectUri=" + encodeURIComponent(location.href.replace(window.location.origin, "")));
        }
    });
}

function getRedirectUri(location, fallback) {
    const urlParams = new URLSearchParams(location);
    const uriUrlParam = urlParams.get('uri');
    if (uriUrlParam)
        return encodeURIComponent(uriUrlParam);
    else
        return encodeURIComponent(fallback);
}

function isSignInPage() {
    return document.querySelector('meta[name="pbContext"]').content.indexOf("customPage:string:/sign-in") > -1;
}

function displayAuthenticatedMessage() {
    if (isSignInPage()) {
        var div = document.getElementById('authMsg');
        if ("" === "PersonUser") {
            div.innerHTML += "You are already signed in to " + window.location.origin.replace("https://", "").replace("www.", "") + ". If you would like to sign in with a different email address, please use the form below.";
        } else {
            div.innerHTML = '';
        }
    }
}</script>

                    
                
            </div>
        </div><iframe name="trustarc_notice" id="trustarcNoticeFrame" title="Trustarc Cross-Domain Consent Frame" src="https://consent.trustarc.com/get?name=crossdomain.html&amp;domain=nejm.com" style="display: none;"></iframe><script src="https://consent.trustarc.com/asset/notice.js/v/v1.7-1576" async="async" crossorigin="" importance="high" nonce="94d6d44785b61aed-SJC"></script>
        


        
        

            <script src="/products/mms-nextgen/mms/releasedAssets/js/build.lazyload.bundle-c8c4e7d20884f81951fb.js" nonce="94d6d44785b61aed-SJC"></script>

        <script src="/products/mms-nextgen/mms/releasedAssets/js/main.bundle-3819a02ec7bc2aca01ec.js" nonce="94d6d44785b61aed-SJC"></script>
        


<div id="adModal" tabindex="-1" aria-labelledby="exampleModalCenterTitle" class="ng-modal modal" style="display: none;" aria-hidden="true">
    <div role="document" class="ng-modal_dialog modal-dialog modal-dialog-centered ad-promoLayer">
        <div class="ng-modal_content modal-content p-0">
            <div class="ng-modal_body modal-body m-0">
                <div class="ng-modal_header modal-header">
                    <button type="button" data-dismiss="modal" aria-label="Close" class="ng-modal_close close"><span aria-hidden="true"><span class="icon-component "><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#close"></use></svg></span></span>
                    </button>
                </div>

            </div>
        </div>
    </div>
</div>
<script type="text/javascript" src="/wro/1125813~product.js" nonce="94d6d44785b61aed-SJC"></script>








<input id="showLayers" type="hidden" value="true">

    <!-- placeholder id=null, description=ad-layer-config -->
    <!-- placeholder id=null, description=ad-lauchLayer-1 -->
    <!-- placeholder id=null, description=ad-layer-promo-1 -->

    <input id="firstAd" type="hidden" value="">
    <input id="secondAd" type="hidden" value="">

    
    
    

    
    
    <input id="IsInstitution" type="hidden" value="false">
    <input id="IsSubscriber" type="hidden" value="true">
    <input id="CustomerId" type="hidden" value="">


<script type="text/javascript" nonce="94d6d44785b61aed-SJC">
  jQuery.extend(jQuery.mmsLayers.config, {
    rules: [{
      "name": "Launch Layer Ad",
      "frequency": 30,
      "showOnPage": 5,
      "enabled": false,
      "cookieName": "MarketingLaunchLayer",
      "styleClass": "launchLayer"
    },
    {
      "name": "Promo Layer Ad",
      "frequency": 14,
      "enabled": true,
      "cookieName": "PromoLayer",
      "styleClass": "promoLayer"
    },
    {
      "name": "Interstitial Ad",
      "frequency": 7,
      "enabled": false,
      "cookieName": "InterstitialAd"
    },
    {
      "name": "Iperceptions - Ion Layer Ad",
      "showOnPage": 1,
      "enabled": false,
      "test": false,
      "cookieName":"Iperceptions"
    }]
 });
</script>

















    <script type="text/javascript" nonce="94d6d44785b61aed-SJC">
        $(document).ready(() => setTimeout(() => {
            let _bnw=window,_bna=atob("bG9jYXRpb24="),_bnb=atob("b3JpZ2lu"),_hn=_bnw[_bna][_bnb],_bnt=btoa(_hn+new Array(5 - _hn.length % 4).join(" "));
            $.get("/resource/lodash?t="+_bnt);
        },4000));
    </script>












    

    
    

    
    
    
    
        
            
                <script type="text/javascript" src="/wro/1125813~article-metrics.js" nonce="94d6d44785b61aed-SJC"></script>
            
            
            
        
    




<script type="text/javascript" src="/wro/1125813~full-text-analytics.js" nonce="94d6d44785b61aed-SJC"></script>


    


            <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'94d6d4476ec51aed',t:'MTc0OTUzNzEyMi4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script><iframe height="1" width="1" style="position: absolute; top: 0px; left: 0px; border: none; visibility: hidden;"></iframe><script defer="" src="https://static.cloudflareinsights.com/beacon.min.js/vcd15cbe7772f49c399c6a5babf22c1241717689176015" integrity="sha512-ZpsOmlRQV6y907TI0dKBHq9Md29nnaEIPlkf84rnaERnq6zvWvPUqr2ft8M1aS28oN72PdrCzSjY4U6VaAw1EQ==" data-cf-beacon="{&quot;rayId&quot;:&quot;94d6d4476ec51aed&quot;,&quot;serverTiming&quot;:{&quot;name&quot;:{&quot;cfExtPri&quot;:true,&quot;cfEdge&quot;:true,&quot;cfOrigin&quot;:true,&quot;cfL4&quot;:true,&quot;cfSpeedBrain&quot;:true,&quot;cfCacheStatus&quot;:true}},&quot;version&quot;:&quot;2025.5.0&quot;,&quot;token&quot;:&quot;f55e150c7a5f4a4ab9ef82f4a1c9c43c&quot;}" crossorigin="anonymous"></script><div style="display:none;" id="signInEmbedded" class="ucc-fullpage-signin ucc-widgets-nejm-next">
  <div class="capture_header">
    <h1>Sign In</h1>
  </div>    
  <div class="capture_signin">
    {* #signInForm *}
    <div class="ucc-form-inner-wrapper">
      {* signInEmailAddress *}
      {* currentPassword *}
      <div style="padding-top:10px;">
          <div class="capture_form_item capture_form_rememberme">
          <label class="ucc-form-checkbox">                
            <input checked="checked" id="ucc-remember-me-cb-embedded" name="ucc-remember-me-cb-embedded" type="checkbox" value="true">
            <span>Remember Me</span>
          </label>                           
          </div>
          <div class="capture_form_item capture_form_forgotpwd">
            <a role="button" class="ucc-anchor-button" data-capturescreen="forgotPassword">Forgot your password?</a>
          </div>
      </div>
      <div class="capture_form_item">      
        <button id="ucc-sign-in-submit-embedded" class="capture_primary capture-full-width-btn" type="submit">Sign In</button>
      </div>
      <div class="capture_form_item capture_form_footer">
        <div class="ucc-no-acct-msg">Don't have an account?</div>
        <div class="ucc-no-acct-msg-2">
          <a role="button" class="ucc-anchor-button" onclick="mmsWidgets.closeSignIn(event); mmsWidgets.showRegAuto(event);">Create Account</a>
          <span></span><a href="https://store.nejm.org/nejm?promo=ONF4NRS1">Subscribe</a>
        </div>
      </div>
      <div class="capture_form_item capture_form_submit">
        
      </div>      
    </div>
    {* /signInForm *}
  </div>
</div><div style="display:none;" id="forgotPassword" class="ucc-widgets-nejm-next">
  <div class="capture_header">
    <h1>Forgot Password</h1>
  </div>   
  <div class="ucc-form-inner-wrapper">
  <p style="color:black">Enter the email address associated with your account then click Continue. We will email you a link to a page where you can easily create a new password.</p>
  </div> 
  <div class="capture_forgotpassword">
    {* #forgotPasswordForm *}      
      <div class="ucc-form-inner-wrapper">
        {* forgotPasswordEmailAddress *}
        {* captcha *}
        <div class="capture_form_item" style="padding-top: 20px;">        
          <input id="ucc-widget-forgotpwd-submit" value="Continue" type="submit" class="capture_btn capture_primary capture-full-width-btn">
        </div>
      </div>
    {* /forgotPasswordForm *}
  </div>
  </div><div style="display:none;" id="forgotPasswordSuccess" class="ucc-widgets-nejm-next">
  <div class="capture_header">
    <h1>Create New Password</h1>
  </div>    
  <div class="capture_forgotpassword">
      <div class="ucc-form-inner-wrapper">
        <p style="padding-top: 30px; padding-bottom: 30px;">We've sent an email with instructions to create a new password. Your existing password has not been changed.</p>        
        <div class="capture_form_item">      
          <button class="capture_btn capture_primary capture-full-width-btn" onclick="janrain.capture.ui.modal.close()">CLOSE</button>
        </div>
      </div>
  </div>
  </div><div style="display:none;" id="resetPassword" class="ucc-widgets-nejm-next">
      <div class="row">      
        <div class="col-md-8 col-md-offset-2 reset-pwd-info"><p>To reset your password, enter a new password twice and click the 'Reset Password' button.</p></div>
      </div>
      <div class="col-md-4 col-md-offset-4">
        {* #changePasswordFormNoAuth *}
          {* newPassword *}
          {* newPasswordConfirm *}     
          <div class="capture_form_item">
            <input value="RESET PASSWORD" type="submit" class="capture_btn capture_primary capture-full-width-btn">
          </div>
          {* /changePasswordFormNoAuth *}
      </div>
    </div><div style="display:none;" id="resetPasswordSuccess">
        <div class="reset-pwd-info">
          <div class="reset-pwd-success-welcome"></div>
          <p class="reset-pwd-success-msg">Your password has been reset. You will need to <a href="/signin" onclick="mmsWidgets.signIn(event)">sign in</a> again using your new password to access site content and features.</p>
          <p class="reset-pwd-success-nav"></p>
        </div>      
    </div><div style="display:none;" id="resetPasswordRequestCode" class="ucc-widgets-nejm-next">
        {* #resetPasswordForm *}
        <div class="capture_form_error">The link that you followed to reset your password has expired.</div>
          <div class="col-md-8 col-md-offset-2">
            <p class="reset-pwd-info">Enter the email address associated with your account then click Continue. We will email you a link to a page where you can easily create a new password.</p>
          </div>
          <div class="col-md-4 col-md-offset-4">
            {* signInEmailAddress *}
            <div class="capture_form_item">
              <input value="continue" type="submit" class="capture_btn capture_primary capture-full-width-btn">
            </div>
          </div>
        {* /resetPasswordForm *}
    </div><div style="display:none;" id="resetPasswordRequestCodeSuccess">
      <div class="reset-pwd-info">
        <p>If the address matches an existing account, you will receive an email with instructions to reset your password.</p>
        <p class="reset-pwd-success-nav"></p>
      </div>
  </div>

        
        
    

<div id="addtoany" style="position: static;"><div class="a2a_overlay" id="a2a_overlay"></div><div id="a2a_modal" class="a2a_modal a2a_hide" role="dialog" tabindex="-1" aria-label=""><div class="a2a_modal_body a2a_menu a2a_hide" id="a2a_copy_link"><label for="a2a_copy_link_text" id="a2a_copy_link_icon" class="a2a_svg a2a_s_link a2a_logo_color"><svg focusable="false" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 32 32"><title>Copy link</title><path fill="#FFF" d="M7.591 21.177c0-.36.126-.665.377-.917l2.804-2.804a1.235 1.235 0 0 1 .913-.378c.377 0 .7.144.97.43-.026.028-.11.11-.255.25-.144.14-.24.236-.29.29a2.82 2.82 0 0 0-.2.256 1.056 1.056 0 0 0-.177.344 1.43 1.43 0 0 0-.046.37c0 .36.126.666.377.918a1.25 1.25 0 0 0 .918.377c.126.001.251-.015.373-.047.125-.037.242-.096.345-.175.09-.06.176-.127.256-.2.1-.094.196-.19.29-.29.14-.142.223-.23.25-.254.297.28.445.607.445.984 0 .36-.126.664-.377.916l-2.778 2.79a1.242 1.242 0 0 1-.917.364c-.36 0-.665-.118-.917-.35l-1.982-1.97a1.223 1.223 0 0 1-.378-.9l-.001-.004Zm9.477-9.504c0-.36.126-.665.377-.917l2.777-2.79a1.235 1.235 0 0 1 .913-.378c.35 0 .656.12.917.364l1.984 1.968c.254.252.38.553.38.903 0 .36-.126.665-.38.917l-2.802 2.804a1.238 1.238 0 0 1-.916.364c-.377 0-.7-.14-.97-.418.026-.027.11-.11.255-.25a7.5 7.5 0 0 0 .29-.29c.072-.08.139-.166.2-.255.08-.103.14-.22.176-.344.032-.12.048-.245.047-.37 0-.36-.126-.662-.377-.914a1.247 1.247 0 0 0-.917-.377c-.136 0-.26.015-.37.046-.114.03-.23.09-.346.175a3.868 3.868 0 0 0-.256.2c-.054.05-.15.148-.29.29-.14.146-.222.23-.25.258-.294-.278-.442-.606-.442-.983v-.003ZM5.003 21.177c0 1.078.382 1.99 1.146 2.736l1.982 1.968c.745.75 1.658 1.12 2.736 1.12 1.087 0 2.004-.38 2.75-1.143l2.777-2.79c.75-.747 1.12-1.66 1.12-2.737 0-1.106-.392-2.046-1.183-2.818l1.186-1.185c.774.79 1.708 1.186 2.805 1.186 1.078 0 1.995-.376 2.75-1.13l2.803-2.81c.751-.754 1.128-1.671 1.128-2.748 0-1.08-.382-1.993-1.146-2.738L23.875 6.12C23.13 5.372 22.218 5 21.139 5c-1.087 0-2.004.382-2.75 1.146l-2.777 2.79c-.75.747-1.12 1.66-1.12 2.737 0 1.105.392 2.045 1.183 2.817l-1.186 1.186c-.774-.79-1.708-1.186-2.805-1.186-1.078 0-1.995.377-2.75 1.132L6.13 18.426c-.754.755-1.13 1.672-1.13 2.75l.003.001Z"></path></svg></label><input id="a2a_copy_link_text" type="text" title="Copy link" readonly=""><div id="a2a_copy_link_copied">✓</div></div><div class="a2a_modal_body a2a_menu a2a_thanks a2a_hide" id="a2a_thanks"><div class="a2a_localize" data-a2a-localize="inner,ThanksForSharing">Thanks for sharing!</div></div></div><div class="a2a_menu a2a_full a2a_localize" id="a2apage_full" role="dialog" tabindex="-1" aria-label="Share" data-a2a-localize="title,Share"><div class="a2a_full_header"><div id="a2apage_find_container" class="a2a_menu_find_container"><label for="a2apage_find" id="a2apage_find_icon" class="a2a_svg a2a_s_find"><svg focusable="false" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24" aria-hidden="true"><title>Find any service</title><path fill="#CCC" d="M19.7 18.2l-4.5-4.5c.7-1.1 1.2-2.3 1.2-3.6 0-3.5-2.8-6.3-6.3-6.3s-6.3 2.8-6.3 6.3 2.8 6.3 6.3 6.3c1.4 0 2.6-.4 3.6-1.2l4.5 4.5c.6.6 1.3.7 1.7.2.5-.4.4-1.1-.2-1.7zm-9.6-3.6c-2.5 0-4.5-2.1-4.5-4.5 0-2.5 2.1-4.5 4.5-4.5 2.5 0 4.5 2.1 4.5 4.5s-2 4.5-4.5 4.5z"></path></svg></label><input id="a2apage_find" class="a2a_menu_find a2a_localize" type="text" autocomplete="off" title="Find any service" data-a2a-localize="title,FindAnyServiceToAddTo"></div></div><div class="a2a_full_services" id="a2apage_full_services" role="presentation"></div><div class="a2a_full_footer"><a href="https://www.addtoany.com" title="Share Buttons" rel="noopener" target="_blank"><span class="a2a_svg a2a_s__default a2a_s_a2a a2a_logo_color"><svg focusable="false" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 32 32"><g fill="#FFF"><path d="M14 7h4v18h-4z"></path><path d="M7 14h18v4H7z"></path></g></svg></span>AddToAny</a></div></div><div id="a2apage_dropdown" class="a2a_menu a2a_mini a2a_localize a2a_hide" tabindex="-1" aria-label="Share" data-a2a-localize="label,Share"><div class="a2a_mini_services" id="a2apage_mini_services"></div><div id="a2apage_cols_container" class="a2a_cols_container"><div class="a2a_col1" id="a2apage_col1"></div><div id="a2apage_2_col1" class="a2a_hide"></div><div class="a2a_clear"></div></div><div class="a2apage_wide a2a_wide"><a href="#addtoany" id="a2apage_show_more_less" class="a2a_more a2a_localize" title="Show all" data-a2a-localize="title,ShowAll"><span class="a2a_svg a2a_s__default a2a_s_a2a a2a_logo_color"><svg focusable="false" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 32 32"><g fill="#FFF"><path d="M14 7h4v18h-4z"></path><path d="M7 14h18v4H7z"></path></g></svg></span><span class="a2a_localize" data-a2a-localize="inner,More">More…</span></a></div></div><div style="height: 1px; width: 1px; position: absolute; z-index: 100000; top: 0px; visibility: hidden;"><iframe id="a2a_sm_ifr" title="AddToAny Utility Frame" aria-hidden="true" src="https://static.addtoany.com/menu/sm.25.html#type=core&amp;event=load" style="height: 1px; width: 1px; border: 0px; left: 0px; top: 0px; position: absolute; z-index: 100000; display: none;"></iframe></div></div><div id="janrainEngageEmbed" style="display: none;"><div class="janrainContent" style="width: 380px !important; height: 156px !important; padding-left: 5px !important; padding-right: 5px !important; box-sizing: content-box !important; background-color: rgb(255, 255, 255) !important; border: 1px solid rgb(192, 192, 192) !important; border-radius: 10px !important; overflow: hidden !important; position: relative !important;"><div id="janrainView"><div class="janrainHeader" style="background-color: rgb(255, 255, 255) !important; font-size: 14px !important; color: rgb(102, 102, 102) !important; position: relative !important; height: 20px !important; left: -5px !important; padding: 5px 5px 0px !important; white-space: nowrap !important; width: 380px !important; z-index: 100 !important; border-radius: 10px 10px 0px 0px !important; text-align: left !important;"><div style="padding-left: 1px !important; font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important;">Sign in using your account with</div></div><div id="janrainProviderPages" style="padding-top: 5px; left: 5px; position: absolute;"><div class="janrainPage" pageindex="0"><ul class="providers" id="janrainProviders_0" style="float: left !important; list-style-type: none !important; margin: 0px !important; padding: 0px !important;"><li id="janrain-aol" role="button" style="list-style: none !important; height: 30px !important; width: 185px !important; margin-top: 0px !important; margin-right: 5px !important; margin-bottom: 5px !important; position: relative !important; border: 1px solid rgb(204, 204, 204) !important; border-radius: 5px !important; cursor: pointer !important; white-space: nowrap !important; overflow: hidden !important; background-image: -webkit-linear-gradient(bottom, rgb(238, 238, 238), rgb(255, 255, 255)) !important;"><a tabindex="1" href="javascript:void(0);" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; font-size: 12px !important; line-height: 14px !important; margin-left: auto !important; margin-right: auto !important; text-decoration: none !important; display: block !important; padding-left: 5px !important; padding-right: 5px !important; text-align: left !important; width: auto !important;"><span class="janrain-provider-icon-24 janrain-provider-icon-aol" style="margin-top: 3px !important; background-color: transparent !important;"></span><span class="janrain-provider-text-color-aol" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; cursor: pointer !important; margin-left: 7px !important; text-align: left !important; margin-top: 9px !important; vertical-align: top !important; display: inline-block !important;">AOL</span></a></li><li id="janrain-openid" role="button" style="list-style: none !important; height: 30px !important; width: 185px !important; margin-top: 0px !important; margin-right: 5px !important; margin-bottom: 5px !important; position: relative !important; border: 1px solid rgb(204, 204, 204) !important; border-radius: 5px !important; cursor: pointer !important; white-space: nowrap !important; overflow: hidden !important; background-image: -webkit-linear-gradient(bottom, rgb(238, 238, 238), rgb(255, 255, 255)) !important;"><a tabindex="3" href="javascript:void(0);" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; font-size: 12px !important; line-height: 14px !important; margin-left: auto !important; margin-right: auto !important; text-decoration: none !important; display: block !important; padding-left: 5px !important; padding-right: 5px !important; text-align: left !important; width: auto !important;"><span class="janrain-provider-icon-24 janrain-provider-icon-openid" style="margin-top: 3px !important; background-color: transparent !important;"></span><span class="janrain-provider-text-color-openid" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; cursor: pointer !important; margin-left: 7px !important; text-align: left !important; margin-top: 9px !important; vertical-align: top !important; display: inline-block !important;">OpenID</span></a></li></ul><ul class="providers" id="janrainProviders_1" style="float: left !important; list-style-type: none !important; margin: 0px !important; padding: 0px !important;"><li id="janrain-yahoo" role="button" style="list-style: none !important; height: 30px !important; width: 185px !important; margin-top: 0px !important; margin-right: 5px !important; margin-bottom: 5px !important; position: relative !important; border: 1px solid rgb(204, 204, 204) !important; border-radius: 5px !important; cursor: pointer !important; white-space: nowrap !important; overflow: hidden !important; background-image: -webkit-linear-gradient(bottom, rgb(238, 238, 238), rgb(255, 255, 255)) !important;"><a tabindex="2" href="javascript:void(0);" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; font-size: 12px !important; line-height: 14px !important; margin-left: auto !important; margin-right: auto !important; text-decoration: none !important; display: block !important; padding-left: 5px !important; padding-right: 5px !important; text-align: left !important; width: auto !important;"><span class="janrain-provider-icon-24 janrain-provider-icon-yahoo" style="margin-top: 3px !important; background-color: transparent !important;"></span><span class="janrain-provider-text-color-yahoo" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; cursor: pointer !important; margin-left: 7px !important; text-align: left !important; margin-top: 9px !important; vertical-align: top !important; display: inline-block !important;">Yahoo!</span></a></li></ul></div></div><div style="background-color: rgb(255, 255, 255) !important; width: 380px !important; height: 10px !important; position: absolute !important; left: 0px !important; padding-left: 5px !important; padding-right: 5px !important; padding-bottom: 5px !important; bottom: 0px !important; font-size: 10px !important; text-align: left !important; color: rgb(102, 102, 102) !important; font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; border-radius: 0px 0px 10px 10px !important;"><div style="padding-left: 1px !important;"><a href="http://janrain.com/products/engage/social-login?utm_source=mms.rpxnow.com&amp;utm_medium=Partner&amp;utm_campaign=attribution" target="_blank">Social Login by Janrain</a></div></div></div></div></div><yql-dikctmwxbgps></yql-dikctmwxbgps><script type="text/javascript" src="https://api.altmetric.com/v1/internal-556fdf0f/doi/10.1056/nejmoa2203163?callback=_altmetric.embed_callback&amp;domain=www.nejm.org&amp;cache_until=3-10"></script><div role="status" aria-live="assertive" aria-relevant="additions" class="ui-helper-hidden-accessible"></div><iframe name="captureIFrame_7qb2gi10ubbikkp0nic3gsvlpha3pcvukmlpxtx8" data-transactionid="7qb2gi10ubbikkp0nic3gsvlpha3pcvukmlpxtx8" id="captureIFrame_7qb2gi10ubbikkp0nic3gsvlpha3pcvukmlpxtx8" src="about:blank" class="" data-captureiframeloadeventbound="yes" style="display: none;"></iframe><div id="janrainModalOverlay" style="inset: 0px; position: fixed; background-color: rgb(0, 0, 0); opacity: 0.4; display: none; z-index: 1000;"></div><div id="janrainModal" style="width: 380px; height: 131px; position: absolute; z-index: 1000; display: none;"><a href="#" class="janrain_modal_closebutton" style="position: absolute; cursor: pointer; z-index: 1000;">X</a><div style="display: block;" id="signIn" class="ucc-widgets-nejm-next janrain-capture-ui capture-ui-content capture_screen_container" data-capturescreenname="signIn" data-captureventadded="true">
    <div class="capture_header">
      <h1>Sign In</h1>
    </div>    
    <div class="capture_signin">
      <form id="capture_signIn_signInForm" name="signInForm" data-capturefield="signInForm" action="https://mms.us.janraincapture.com/widget/traditional_signin.jsonp" class="capture_form capture_signInForm" method="POST" novalidate="novalidate" data-transactionid="7qb2gi10ubbikkp0nic3gsvlpha3pcvukmlpxtx8" target="captureIFrame_7qb2gi10ubbikkp0nic3gsvlpha3pcvukmlpxtx8" accept-charset="UTF-8" next="{&quot;noop&quot;:&quot;&quot;}"><div id="capture_signIn_signInForm_defaultSavedProfileMessage"></div><div id="capture_signIn_signInForm_errorMessages"></div><input id="capture_signIn_utf8" data-capturefield="undefined" value="✓" type="hidden" class="capture_utf8" name="utf8"><input id="capture_signIn_screen_7qb2gi10ubbikkp0nic3gsvlpha3pcvukmlpxtx8" data-capturefield="undefined" value="signIn" type="hidden" class="capture_screen_7qb2gi10ubbikkp0nic3gsvlpha3pcvukmlpxtx8" name="capture_screen"><input id="capture_signIn_js_version_7qb2gi10ubbikkp0nic3gsvlpha3pcvukmlpxtx8" data-capturefield="undefined" value="d445bf4" type="hidden" class="capture_js_version_7qb2gi10ubbikkp0nic3gsvlpha3pcvukmlpxtx8" name="js_version"><input id="capture_signIn_transactionId_7qb2gi10ubbikkp0nic3gsvlpha3pcvukmlpxtx8" data-capturefield="undefined" value="7qb2gi10ubbikkp0nic3gsvlpha3pcvukmlpxtx8" type="hidden" class="capture_transactionId_7qb2gi10ubbikkp0nic3gsvlpha3pcvukmlpxtx8" name="capture_transactionId"><input id="capture_signIn_form_7qb2gi10ubbikkp0nic3gsvlpha3pcvukmlpxtx8" data-capturefield="undefined" value="signInForm" type="hidden" class="capture_form_7qb2gi10ubbikkp0nic3gsvlpha3pcvukmlpxtx8" name="form"><input id="capture_signIn_flow_7qb2gi10ubbikkp0nic3gsvlpha3pcvukmlpxtx8" data-capturefield="undefined" value="standard" type="hidden" class="capture_flow_7qb2gi10ubbikkp0nic3gsvlpha3pcvukmlpxtx8" name="flow"><input id="capture_signIn_client_id_7qb2gi10ubbikkp0nic3gsvlpha3pcvukmlpxtx8" data-capturefield="undefined" value="qsra7g4d6jwdsgn3zbe6udp6r6278mr9" type="hidden" class="capture_client_id_7qb2gi10ubbikkp0nic3gsvlpha3pcvukmlpxtx8" name="client_id"><input id="capture_signIn_redirect_uri_7qb2gi10ubbikkp0nic3gsvlpha3pcvukmlpxtx8" data-capturefield="undefined" value="https://www.nejm.org" type="hidden" class="capture_redirect_uri_7qb2gi10ubbikkp0nic3gsvlpha3pcvukmlpxtx8" name="redirect_uri"><input id="capture_signIn_response_type_7qb2gi10ubbikkp0nic3gsvlpha3pcvukmlpxtx8" data-capturefield="undefined" value="code" type="hidden" class="capture_response_type_7qb2gi10ubbikkp0nic3gsvlpha3pcvukmlpxtx8" name="response_type"><input id="capture_signIn_flow_version_7qb2gi10ubbikkp0nic3gsvlpha3pcvukmlpxtx8" data-capturefield="undefined" value="20240514181256512029" type="hidden" class="capture_flow_version_7qb2gi10ubbikkp0nic3gsvlpha3pcvukmlpxtx8" name="flow_version"><input id="capture_signIn_settings_version_7qb2gi10ubbikkp0nic3gsvlpha3pcvukmlpxtx8" data-capturefield="undefined" value="" type="hidden" class="capture_settings_version_7qb2gi10ubbikkp0nic3gsvlpha3pcvukmlpxtx8" name="settings_version"><input id="capture_signIn_locale_7qb2gi10ubbikkp0nic3gsvlpha3pcvukmlpxtx8" data-capturefield="undefined" value="en-US" type="hidden" class="capture_locale_7qb2gi10ubbikkp0nic3gsvlpha3pcvukmlpxtx8" name="locale"><input id="capture_signIn_recaptcha_version_7qb2gi10ubbikkp0nic3gsvlpha3pcvukmlpxtx8" data-capturefield="undefined" value="2" type="hidden" class="capture_recaptcha_version_7qb2gi10ubbikkp0nic3gsvlpha3pcvukmlpxtx8" name="recaptchaVersion">
      <div class="ucc-form-inner-wrapper">
        <div id="capture_signIn_form_item_signInEmailAddress" class="capture_form_item capture_email capture_form_item_signInEmailAddress" data-capturefield="undefined"><label for="capture_signIn_signInEmailAddress">Email Address</label><input id="capture_signIn_signInEmailAddress" data-capturefield="signInEmailAddress" value="" type="email" class="capture_signInEmailAddress capture_required capture_text_input" placeholder="Email Address" name="signInEmailAddress"><div class="capture_tip" style="display:none;"></div><div class="capture_tip_validating" data-elementname="signInEmailAddress">Validating</div><div class="capture_tip_error" data-elementname="signInEmailAddress"></div></div>
        <div id="capture_signIn_form_item_currentPassword" class="capture_form_item capture_password capture_form_item_currentPassword" data-capturefield="undefined"><label for="capture_signIn_currentPassword">Password</label><input id="capture_signIn_currentPassword" data-capturefield="currentPassword" value="" type="password" class="capture_currentPassword capture_required capture_text_input" placeholder="Password" name="currentPassword"><div class="capture_tip" style="display:none;"></div><div class="capture_tip_validating" data-elementname="currentPassword">Validating</div><div class="capture_tip_error" data-elementname="currentPassword"></div></div>
        <div style="padding-top:10px;">
            <div class="capture_form_item capture_form_rememberme">
                <label class="ucc-form-checkbox">                
                    <input checked="checked" id="ucc-remember-me-cb" name="ucc-remember-me-cb" type="checkbox" value="true">
                    <span>Remember Me</span>
                </label>          
            </div>
            <div class="capture_form_item capture_form_forgotpwd">
              <a role="button" class="ucc-anchor-button" data-capturescreen="forgotPassword">Forgot your password?</a>
            </div>
        </div>
        <div class="capture_form_item">
          <button id="ucc-sign-in-submit" class="capture_primary capture-full-width-btn" type="submit">Sign In</button>
        </div>
       
        <div class="capture_form_item">
          <div class="ucc-no-acct-msg">Don't have an account?</div>
          <div class="ucc-no-acct-msg-2" id="signInModalCreateAccountLink">
          <a role="button" class="ucc-anchor-button" onclick="mmsWidgets.closeSignIn(event); mmsWidgets.showRegAuto(event);">Create Account</a>
            <span></span><a href="https://store.nejm.org/nejm?promo=ONF4NRS1">Subscribe</a>
          </div>

          <div class="ucc-no-acct-msg-2" id="signInModalCloseLink" style="display:none">
          <a role="button" class="ucc-anchor-button" onclick="mmsWidgets.closeSignIn(event);">Create Account</a>
            <span></span><a href="https://store.nejm.org/nejm?promo=ONF4NRS1">Subscribe</a>
          </div>

        </div>
     
        <div class="capture_form_item capture_form_submit">
          
        </div>      
      </div>
      </form>
    </div>
  </div></div></body></html>